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ABSTRACT 
 
 
Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver 
disease among youth in the United States. This recent rise of NAFLD may be partially due to 
perinatal programming, where in utero exposures alter the lifelong health trajectory of offspring. 
Maternal pregnancy diet and endocrine disrupting chemical exposure have been identified as 
drivers of perinatal programming. However, the potential for maternal diet to modify the impact 
of perinatal chemical exposure is not well understood. This dissertation examined whether 
perinatal exposure to two common environmental toxicants, bisphenol A (BPA) and high fat 
diets (HFDs), would affect NAFLD incidence in offspring. A longitudinal mouse exposure study 
and a human birth cohort were used to investigate this hypothesis and to evaluate the translation 
of findings across species.  
Oral exposure to one of six diets: Control, Western HFD, Mediterranean HFD or each 
diet with 50g BPA/kg added, occurred pre-gestation through lactation. All mice were weaned 
onto the Control diet, thus isolating exposure to the perinatal period. Offspring NAFLD was 
assessed via hepatic steatosis and hepatic oxidative response at postnatal day 10 (PND10) and 
10-months. Hepatic triglyceride (TG) levels were altered by perinatal HFD in dams, but in 
offspring perinatal exposures affected metabolic outcomes not hepatic TGs. Hepatic histology 
from 10-month offspring highly correlated with hepatic TG levels, validating the TG findings. 
Hepatic 8-isoprostane (8-iso) levels differed by perinatal exposure in PND10 and 10-month 
offspring, but alterations were age and sex-specific. Perinatal HFD and BPA minimally impacted 
 xv 
offspring redox parameters (EhGSH, EhCys, S-glut), suggestive of greater homeostatic control 
of these parameters compared to lipid oxidation. Dam metabolic phenotype significantly altered 
offspring hepatic steatosis and oxidative response, even when perinatal HFD and BPA did not, 
emphasizing the critical role of the maternal environment on offspring health.  
The impact of maternal BPA exposure and gestational Mediterranean diet adherence 
(MDS) on the metabolic health of peripubertal youth was examined in a well-established human 
birth cohort. Youth metabolic and oxidative health was assessed via metabolic risk score (MRS) 
and serum 8-iso. Maternal pregnancy average and Trimester 2 BPA were associated with a 
suggestive decrease in youth MRS driven by boys, but a suggestive increase in 8-iso levels 
driven by girls. Maternal MDS did not affect youth MRS, but altered youth serum 8-iso in 
opposite directions based on sex. Additional youth characteristics (peripubertal BPA, MDS, 
vigorous activity, and pubertal status) contributed to predictive models of MRS and 8-iso, 
underscoring the impact healthy lifestyle behaviors may have, potentially even modifying 
perinatal programming.  
The unexpected lack of protection exerted by the Mediterranean diet in both mouse and 
human studies, suggests the beneficial effect observed in adults may not apply to perinatal 
exposure. Greater impact of HFDs in mice but BPA in humans highlights the need to carefully 
scrutinize findings before translating across species. Despite this difference, sex-specific effects 
occurred in both species, emphasizing the importance of investigating perinatal programming in 
all offspring. This research suggests that perinatal BPA and HFD exposure may be insufficient to 
induce perinatal programming of NAFLD. The significant impact of dam metabolic phenotype in 
mice and peripubertal behaviors in humans on metabolic and oxidative outcomes suggest 
NAFLD risk can be altered and potentially prevented at multiple life stages.
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CHAPTER 1 
 
Introduction 
 
Rationale & Significance 
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease 
among children and adolescents in the U.S. [1–3]. NAFLD prevalence has increased with the 
concomitant rise in worldwide obesity and insulin resistance (IR); it is now regarded to be the 
hepatic precursor of metabolic syndrome [4]. Rising rates of childhood obesity are concerning 
due to the 2-6 fold increased risk of obese children becoming obese adults [5,6]. An estimated 
9% of U.S. children have NAFLD, but prevalence rises to 38% among obese children [7–9]. 
NAFLD describes a continuum of liver diseases, beginning with simple hepatic steatosis and 
steatohepatitis, advancing to fibrosis, cirrhosis and in some cases hepatocellular carcinoma [10–
12]. Of concern, hepatocellular carcinoma incidence has increased, now occurring in the absence 
of cirrhosis in up to 50% of cases [13,14].  
Simple steatosis and steatohepatitis are reversible with intensive lifestyle change, similar 
to current recommendations for pre-diabetes and early type 2 diabetes (T2DM): regular exercise 
and a healthy diet [15,16]. NAFLD prevalence is higher among: males than females, individuals 
of Mexican-American descent compared to those of non-Hispanic African and Caucasian 
descent, and individuals with concomitant metabolic disease (e.g. obesity, dyslipidemia, T2DM 
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and IR in the absence of overt T2DM) [17]. Improved understanding of contributors to NAFLD 
could help identify early biomarkers of disease. Early detection, while hepatic damage is still 
reversible, could reduce morbidity and improve quality of life for the 75-100 million individuals 
estimated to have NAFLD in the U.S. [18]. 
 
NAFLD: Pathogenesis, Diagnosis, and Treatment 
Pathogenesis of NAFLD 
 The liver plays a central role in energy homeostasis and nutrient metabolism. These 
functions are so energy-intensive, the liver accounts for almost 25% of the body’s total metabolic 
rate under basal conditions [19]. In healthy, fasted individuals, the liver relies on -oxidation of 
free fatty acids (FFAs) as it’s primary fuel source, while releasing glucose into circulation to 
supply metabolic fuel to peripheral, glucose-dependent tissues [19]. In healthy livers, uptake of 
circulating non-esterified fatty acids is mediated by fatty acid transport proteins (FATPs) and 
CD36; in the hepatocyte cytosol, the fatty acids are converted to acyl-CoAs, facilitated by fatty 
acylCoA synthetases (ACSs). Acyl-CoAs are also formed via de novo lipogenesis (DNL), the 
conversion of glucose to palmitic acid, catalyzed by acetyl-CoA carboxylase (ACC) and fatty 
acid synthase (FAS). ACS activates palmitic acid to palmitoyl-CoA. Acyl-CoAs are 
progressively esterified to a glycerol backbone resulting in triglyceride (TG) synthesis. These 
TGs can be packaged with apolipoproteinB 100 (apoB 100) to form very low density 
lipoproteins (VLDLs), which are secreted into circulation thus transporting TGs to peripheral 
tissues [20].   
 NAFLD begins as simple steatosis, lipid accumulation in hepatocytes. This hepatic lipid 
accumulation can result from increased FFA uptake from peripheral tissue and a higher rate of 
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DNL, both resulting in increased hepatic triglyceride levels. Elevated rates of -oxidation and 
higher VLDL production are not capable of compensating for the increased TG synthesis, which 
results in hepatic TG accumulation [20–23]. Hepatic alterations associated with NAFLD, such as 
increased FFAs, ceramide, JNK1, SOCS, TNF, and NF-B levels, interfere with intracellular 
insulin signaling cascades [24–26].  In healthy individuals, insulin binding to the insulin receptor 
triggers an intracellular phosphorylation cascade (e.g. PI3K, AKT/PKB). Insulin signaling 
cascades induce GLUT4 translocation to the cellular membrane of skeletal muscle, facilitating 
glucose uptake, they also increase lipogenic gene expression and decrease gluconeogenic gene 
expression. In adipose tissue, insulin has a potent inhibitory affect on lipolysis, but this inhibitory 
effect is suppressed in NAFLD patients, resulting in greater efflux of FFA out of adipose tissue 
[27]. Thus, NAFLD and IR appear to be mutually exacerbating conditions. 
Although NAFLD is known to run in families, it appears that heritability accounts for 
only 0.26-0.27 variance in disease prevalence in people of African, Caucasian, and Hispanic 
descent [28]. The gene locus, PNPLA3, is associated with a 3.24 increased in odds of NAFLD; 
single nucleotide polymorphisms (SNPs) vary by racial-ethnic background and likely impacts the 
difference in prevalence rates [29,30]. More than 10 SNPs have now been associated with 
increased incidence of NAFLD, but combined they only account for ~5% variance [29,31]. This 
leaves a large potential role for environmental influences, gene x environment interactions and 
epigenetic programming in NAFLD.  
Animal models have been used to investigate the molecular, tissue-specific changes that 
occur during NAFLD development and progression. Although rodents develop hepatic steatosis, 
the full range of human NAFLD phenotypes are not replicated in murine models [32,33], which 
has complicated the translation of findings from animal models to relevant clinical outcomes. 
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Many genetically modified mouse models mimic the histologic appearance of steatosis; for 
example, ob/ob and db/db mice exhibit steatosis resulting from obesity [32,34], increased levels 
of long-chain fatty acids and TGs occur in CD36-/- mice leading to steatosis and unchecked 
hepatic gluconeogenesis [35], additional mouse knock outs promote steatosis by promoting 
hepatic de novo lipogenesis. HFD-feeding of adult C57BL6/J mice induces hepatic steatosis, 
insulin resistance, and induction of multiple lipogenic transcription factors: SREBP-1c, PPAR, 
and LXR [33,36].  
 
Diagnosis of NAFLD 
 Clinical diagnosis of NAFLD is often challenging, since many patients are asymptomatic 
or have generic symptoms, like fatigue or mild abdominal discomfort in the upper right quadrant 
[18,37–40]. NAFLD is often discovered during clinical treatment for other metabolic diseases, 
such as diabetes mellitus, hyperlipidemia, hypertension or as an incidental finding during 
abdominal imaging for an unrelated condition [18,38–40]. Liver biopsy is the current, gold 
standard diagnostic measure of NAFLD [41]. Less invasive methods of diagnosis like radiologic 
procedures (e.g. ultrasound, CT, MRI) and common serum metabolite measures (e.g. ALT, AST, 
ALP, ferritin) have been investigated. Unfortunately, current serum metabolite panels are only 
predictive of NAFLD in 50% of patients [41–46], so are unable to predict early steatosis better 
than the odds of chance alone.  
Following a clinical diagnosis of NAFLD in human patients, staging of the disease is 
performed based on three main criteria: (1) the amount of hepatocyte ballooning, a measure of 
lipid accumulation per cell, (2) the level of hepatic inflammation, and (3) the extent of fibrosis 
that has occurred in the liver [41]. Simple steatosis, the early stage of NAFLD, is characterized 
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by macrovesicular triglyceride accumulation localized to the perivenular region in more than 5% 
of hepatocytes [47–51]. Progression of NAFLD from simple steatosis to steatohepatitis (NASH) 
occurs in about 1/3 of cases, and is characterized by scattered intralobular and mild portal 
inflammation, hepatocellular ballooning, increased steatosis in up to 66% of hepatocytes, and 
mitochondrial abnormalities. As NASH progresses, steatosis becomes panacinar, portal and 
intralobular inflammation increase, cellular disarray and early fibrosis become apparent [47,51–
53]. NASH can lead to hepatic cirrhosis and hepatocellular carcinoma (HCC). Over a 10 year 
period, hepatic cirrhosis develops in 5-20% of NASH cases [51]. At these more advanced stages 
of NAFLD, steatosis and inflammatory markers often become less apparent [54–56]. 
Interestingly, pediatric NAFLD can have a different histological presentation than the 
disease in adults. Although simple steatosis presents similarly in people of all ages, pediatric 
NASH occurs in two distinct patterns. Type I NASH mimics adult histopathology with 
increasing steatosis, hepatocellular ballooning, and perisinusoidal fibrosis, without portal 
involvement. In contrast, Type 2 NASH presents as steatosis accompanied by portal 
inflammation and fibrosis in the absence of hepatocellular ballooning and perisinusoidal fibrosis. 
Type 2 NASH is unique among children, with one study of pediatric NAFLD, reporting 16% of 
cases as simple steatosis, 17% as Type 1 NASH, but 51% as Type 2 NASH [57]. Compared to 
Type 1 NASH, cases of Type 2 NASH were more common among children who were younger, 
had more severe obesity, were male, or were of Asian, Hispanic, or Native American descent 
[51].  
 
Treatment of NAFLD 
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Pharmaceutical efforts to create a therapy for NAFLD, including pioglitazone, 
pentoxifylline, and vitamin E, have been less than 50% effective [31,37]. A confluence of 
multiple lipogenic, inflammatory, and fibrogenic pathways in the development and progression 
of NAFLD may explain the difficulty in diagnosis and treatment of NAFLD [58]. While efforts 
to find a pharmaceutical therapy for NAFLD continues, lifestyle intervention studies have 
reported some success. A systematic review of exercise intervention studies (8-48 week long) in 
NAFLD patients reported reduction of intrahepatic triglyceride levels in exercising participants 
independent of weight loss. The effect on fat mobilization was 30.2% in exercise interventions, 
but increased to 49.8% in participants assigned to diet and exercise interventions, suggesting an 
additional benefit from the combined intervention [59].  
 
Prevalence of NAFLD 
Many chronic diseases, including NAFLD, may result from fetal epigenetic 
reprogramming [60–62]. The Developmental Origins of Health and Disease (DOHaD) paradigm 
states that the fetal environment impacts gene regulation via epigenetic mechanisms, to optimally 
prepare the fetus for life in the environment into which it will be born [63,64]. Despite evidence 
that even healthy pregnancies produce an oxidizing state [65], early life programming as a driver 
of oxidative stress (OS) response and later chronic disease development has not been studied. 
One murine study found maternal malnutrition during pregnancy resulted in increased lipid 
oxidation in prostate tissue of young adult male offspring [14], but few studies have examined 
the impact on offspring hepatic function or the potential for prenatal exposures to reprogram 
redox-regulated IR gene expression. In utero diet and chemical exposures have been implicated 
as modifiers of fetal epigenetic programming [66–68]. Exposure to endocrine disrupting 
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chemicals (EDCs) is especially concerning since reprogramming can impact enzyme expression 
levels, hormone regulation, and homeostatic processes across the lifespan. 
 
Perinatal Programming of NAFLD 
 Metabolic diseases, including NAFLD, can be developmentally programmed. Maternal 
pre-gestational obesity is associated with increased hepatic lipid storage in infants [69,70]. 
Elevated placental transfer of fatty acids and glucose, early in pregnancy before subcutaneous 
adipose tissue develops to store excess nutrients, has been proposed as a potential rationale for 
the intrahepatic storage of excess lipids in infants of obese mothers [71]. In non-human primates 
perinatally exposed to a HFD, third trimester fetuses have 3-fold greater hepatic TGs and 
elevated levels of nuclear (8-OH—dG) and cytosolic (4-hydroxy-2-nonenal, HNE) oxidative 
stress, without increased body adiposity [72]. Fetal hepatic steatosis not only poses a health 
threat to young offspring, it also increases NAFLD risk into adulthood, with reports of worsened 
NAFLD phenotypes in adult mice [73,74].  Some researchers have proposed that the alterations 
in fetal liver function may be central to metabolic programming [74–76] 
Originally proposed in the mid-1990s, the Barker Hypothesis posits that offspring health 
can be altered by the in utero environment [67,77,78]. A mismatch between the fetal and 
postnatal environments increases the risk of chronic disease later in life; this paradigm is now 
known as prenatal programming. Although Barker’s original hypothesis focused on the effect of 
maternal diet during pregnancy on offspring’s cardiovascular health, the hypothesis has been 
expanded to include exposure to chemicals [79]. As the field of Environmental Health Sciences 
incorporated the concept of prenatal programming into its list of potential exposure-disease 
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relationships, the Barker Hypothesis became more widely known as the Developmental Origins 
of Health and Disease (DOHaD) hypothesis [80]. 
Epigenetics, heritable alterations in gene regulation without changing the genetic code, 
has been proposed as the underlying mechanism, by which these altered phenotypes may occur 
on a molecular basis. Epigenetics includes multiple types of gene regulatory mechanisms, 
including DNA methylation, histone modification, and non-coding RNA [81,82], all of which 
can be affected by the intrauterine environment [83]. DNA methylation is the most thoroughly 
studied mechanisms and refers to the bonding of a methyl group to a cytosine followed by a 
guanine (CpG) residue in the DNA code [82,84]. Methylation of CpG sites is generally 
associated with decreased gene expression; thus, DNA methylation is a method of regulating 
gene transcription via repression of RNA transcripts [84]. 
This epigenetic regulation of gene expression is especially sensitive to external exposures 
(e.g. diet, chemicals, stress) during periods of reprogramming. There are two waves of extensive 
epigenetic reprogramming that occur during early fetal development. Shortly after fertilization 
the first wave of global demethylation begins with active demethylation of the paternal genome 
begins, followed by the slower, passive demethylation of the maternal genome [63,85]. 
Repetitive elements and some specific gene loci do not completely demethylate during this first 
wave [86]; imprinted genes retain their parent-of-origin methylation marks, while transposons 
only partially demethylate on both parental genomes [63]. The second wave of epigenetic 
reprogramming only occurs in the primordial germ cells of the fetus, so will impact the next 
generation, if the fetus has offspring of its own. This reprogramming occurs while the primordial 
germ cells migrate to the genital ridge, occurring between gestational days 11.5-12.5 in mice. All 
parental, imprinted marks are erased; de novo methylation is established according to fetal sex 
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[87,88]. In mice, male de novo methylation occurs between gestational days 16.0-18.5. In 
females, germ cell development is halted following meiosis I; re-methylation occurs after birth in 
the mature oocyte [89]. Tissue-specific DNA methylation, which drives the specialized structure 
and function of different tissues, occurs later in development, during organogenesis [85]. These 
tissue-specific marks are relatively stable, however, fluctuation of DNA methylation in somatic 
tissues happens during sensitive periods of rapid growth and development, including pregnancy 
and puberty [63].  
Recently, a few new concepts have been posited to advance the understanding of 
epigenetics as a mechanism underlying environmental exposures and subsequent health effects. 
One such paradigm is the ‘Seed and Soil Model’ where ‘soil’ represents the potential epigenetic 
modifications in a genomic region, that will impact gene expression via alteration of basal gene 
expression or modification of the magnitude of response of the gene to an acute stimulus. The 
‘seed’ signifies a cellular signal, which could be homeostatic, toxicant-, pathogen-, pathology-
induced [90]. This paradigm emphasizes the importance of considering the cumulative effects of 
epigenetic changes at a particular genic locus to elucidate the impact of environmental exposures 
on exposure-triggered disease states. For instance, environmental exposures could lead to 
changes in basal gene expression via epigenetic reprogramming of the gene’s response to a 
normal, homeostatic stimulus. Or environmental exposures could reprogram a genic locus’ 
magnitude of response to a toxicant or other acute stimulus. In this paradigm, a receptive 
epigenetic soil will produce a more robust response following stimulus activation, due to the 
cumulative effect of epigenetic modifications favoring gene expression; non-receptive soil will 
produce a more moderate response [91]. 
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A second, recently proposed conceptual framework suggests that non-genomic signaling, 
acting as ‘readers, writers, and erasers’ of epigenomic signals can alter developmental 
reprogramming. These processes are controlled by proteins: histone methyltransferase (HMT, 
‘writers’), histone demethylases (HDM, ‘erasers’), and effector proteins (‘readers’). Intracellular 
phosphorylation cascades can regulate several HMTs; post-translational phosphorylation of 
HDMs alters their function, often triggering their dissociation from chromatin. Finally, 
phosphorylation of effector proteins alters their intracellular localization. This non-genomic 
regulation of enzymes that control epigenetic modifications is posited as a mechanism by which 
endocrine disrupting chemicals may alter epigenetic marks [92]. Non-genomic activity of the 
estrogen receptor, for instance, includes rapid kinase activation, triggering intracellular 
phosphorylation cascades [93]. These signals begin by ER activation on the extracellular 
membrane, thus triggering signaling pathways that are independent of ER localization to the 
nucleus. This type of non-genomic ER signaling has a demonstrated role in hormone-mediated 
gene transcription [29], and has been linked to alterations in health of the reproductive tract and 
mammary gland development.  
 
Bisphenol A Impacts Perinatal Programming  
  Over 70,000 new synthetic chemicals have been introduced to the market since 1970, less 
than 10% of which have undergone rigorous, unbiased analysis of their potential impacts on 
human health [94]. Considered a high production volume chemical by the U.S. EPA, produced in 
excess of 1 million pounds per year in the U.S., bisphenol A (BPA) [95] is now classified as an 
endocrine disrupting chemical (EDCs) [68,96–98]. Exposure to EDCs, exogenous chemicals that 
alter normal hormonal function, is especially concerning due to the potential for developmental 
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endocrine dysregulation with metabolic repercussions later in life. More than 95% of U.S. adults 
and children have detectable levels of BPA in their urine [99], suggesting exposure is widespread 
and likely chronic in the general population.  
 BPA has been associated with increased risk of obesity and associated metabolic diseases 
in both animal and human studies. In adults, urinary BPA levels are associated with increased 1.5 
odds of obesity, 1.28 odds of abdominal obesity, and 1.37 odds of IR [100]. Among pre-
menopausal women, urinary BPA levels were linked to increased fat mass and serum leptin 
levels [101]. In NHANES analyses from 2003-2006, adults with higher urinary BPA were more 
likely to be obese and have more abdominal adiposity compared to those with the lowest quartile 
of BPA levels [102]. Independent of risk factors, such as age, gender, race-ethnicity, BMI, 
diabetes, and smoking status, urinary BPA was also positively associated with hypertension 
[103]. The same trend was observed in U.S. children, with odds of obesity 2.5 times higher 
amongst youth in the top quartile of urinary BPA level compared to the lowest quartile [104]. 
Higher quartiles of urinary BPA in 6-18 year old children were associated with 1.64-2.01 greater 
odds of obesity, and 1.37-1.55 greater odds of increased waist circumference to height ratio, 
without impacting circulating glucose, insulin, or cholesterol levels [105]. These studies were all 
conducted with cross-sectional data, so causality cannot be determined; it is possible that 
individuals with greater adiposity are exposed to higher BPA levels.  
 Prenatal BPA exposure in human birth cohorts has been associated with decreased BMI 
early in life. In 2-5 year old children, maternal urinary BPA from pregnancy was associated with 
a non-significant lower BMI, especially in girls, but urinary BPA at 2 years was linked to a more 
rapid increase in BMI from 2-5 years [106]. Another cohort confirmed these findings, with 
prenatal urinary BPA from mothers was inversely associated with BMI in girls at 9 years; 
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urinary BPA in 9 year olds was associated with waist circumference, overall fat mass, and 
overweight-obesity status in youth of both sexes [107]. Trimester 2 maternal urinary BPA has 
also been linked to a 7.9 mmHg increase in diastolic blood pressure (DBP) in children at 4 years 
[108]. Sex-specific impacts of perinatal BPA exposure have been observed in murine studies 
also. Adult male mice perinatally exposed to human-relevant doses of BPA resulted in dose 
dependent increases in body and liver weights; however, in adult female mice BPA exposure was 
associated with decreased body and liver weights, serum leptin and lipids [109]. Male mice 
prenatally exposed to BPA from gestational days 9-16 had increased IR, reduced glucose 
tolerance, and altered calcium signaling in the pancreatic islets of Langerhans at 6 months [110]. 
In 30-day old male offspring, pancreatic -cell mass and proliferation were greater and apoptosis 
lower if perinatally exposed to BPA; these pancreatic alterations were accompanied by increased 
circulating insulin, c-peptide, and leptin levels in these fasted, PND30 offspring. By PND120, 
pancreatic -cell mass was decreased in BPA-exposed male offspring [111], suggestive of 
pancreatic burnout early in life, which may explain diabesogenic outcomes observed following 
prenatal BPA exposure [112]. 
 BPA exposure has been shown to alter epigenetic marks, suggesting that 
developmental epigenetic programming may underlie the increased metabolic risks observed in 
perinatally exposed offspring. In viable yellow agouti (Avy) mice, hypomethylation was observed 
at the Avy locus the [113], and later global hypomethylation was reported in PND22 offspring, 
perinatally exposed to 50ng, 50g, or 50mg BPA/kg diet [114]. Female 10-month offspring from 
this same perinatal mouse exposure study, had altered DNA methylation at Jak-2, Rxr, Rfxap, 
and Tmem238; methylation at all of these loci mediated the connection between perinatal BPA 
and metabolic outcomes, including body weight, body fat phenotype, and energy expenditure 
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[115]. Investigation of differential DNA methylation following perinatal BPA reported 
hypomethylation in neuronal pathways associated with metabolic function and energy regulation 
[116], further supporting the potential mechanistic role of epigenetic modification in offspring 
altered metabolic function. Genome-wide analyses have also reported altered DNA methylation 
by perinatal BPA in both mice and humans [117,118]. BPA exposure has been linked to 
epigenetic modifications in other mouse and human cohorts [119–124], suggesting widespread 
physiologic impacts may result from epigenetic alterations during development.   
 
High Fat Diets and Perinatal Programming 
Increasing evidence shows that maternal nutrition impacts the intrauterine metabolic 
environment and successive fetal epigenetic programming [66,125–127]. For example, studies in 
animal models demonstrate that maternal diet modulation, including caloric [128,129] and 
protein restriction [130,131], over-nutrition [132,133], and micronutrient supplementation [134], 
alters DNA methylation at candidate gene loci and globally at cytosine-guanine (CpG) 
dinucleotides and repetitive elements.  
Maternal high fat diet (HFD), in murine and non-human primate models, is associated 
with offspring adult obesity due to hyperphagia and a preference for high fat, high sugar foods 
[133,135]. Further work in rodents found that offspring prenatally exposed to HFD had increased 
hepatic steatosis in adulthood [136]. Thus, intrauterine exposure to a maternal HFD is known to 
increase risk of metabolic disease and NAFLD development in offspring. It then follows that 
maternal diet could modify the metabolic health effects of perinatal EDC exposures (like BPA). 
Interest in this synergy led to the nutrient-toxicant study design of this thesis research. All HFDs 
used in murine models examining diet-induced-obesity, NAFLD, and other metabolic outcomes 
  
14  
mimic a human Western diet, with a fat content of 45-65% total calories, composed largely of 
saturated fatty acids (SFA).  
 Epidemiologic studies suggest that Western and Mediterranean HFDs are both associated 
with altered risk of NAFLD. A prospective study of adolescents found a Western diet to be 
associated with NAFLD [137]. Conversely, consumption of a Mediterranean diet among adults 
with biopsy-confirmed NAFLD reduced hepatic steatosis and improved insulin sensitivity even 
without weight loss [138]. These findings suggest that composition of the HFD may be a critical 
component of disease risk. This was the basis for my hypothesis that Western HFD would 
exacerbate hepatic steatosis and lipid peroxidation resulting from perinatal BPA exposure, while 
Mediterranean HFD would have a mitigating effect.  
 
Study Overview 
Research Objectives 
The early stage of NAFLD, ‘simple steatosis’, is characterized by hepatic lipid 
accumulation and increased hepatocellular oxidation [58]. Thus, this dissertation was designed to 
examine the hypothesis that perinatal BPA exposure, modified by maternal diet, would 
increase hepatic lipid accumulation and hepatic oxidative response in offspring, thereby 
raising lifetime risk of NAFLD (Figure 1.1). Further, it was hypothesized that maternal 
consumption of a Western-style HFD concurrent with the perinatal BPA exposure would 
increase offspring NAFLD incidence, via either greater magnitude of response or earlier onset of 
morbidity. On the other hand, maternal Mediterranean HFD intake during perinatal BPA 
exposure was hypothesized to protect offspring against hepatic lipid accumulation and oxidative 
responses (Figure 1.2).  
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These hypotheses were examined in both a perinatal mouse exposure study and an 
established human birth cohort study, providing an opportunity to compare results across species 
and to determine if mouse study findings would translate to a human population. This 
dissertation aimed to examine (1) whether perinatal BPA and HFD exposures would increase 
hepatic lipid accumulation in mouse offspring, (2) if the exposures would alter hepatic oxidative 
response in these mouse offspring, and (3) whether maternal BPA levels and Mediterranean diet 
adherence during pregnancy would impact metabolic health and serum lipid oxidation in 
peripubertal human youths (Figure 1.3).  
 
Mouse Experimental Design 
 The perinatal mouse exposure study was conducted using a well-established viable 
yellow agouti (Avy) mouse colony, in which 250 generations of sibling mating, with forced 
heterozygosity for the Avy allele, have produced a genetically invariant background. At 8-10 
weeks of age, wild-type (a/a), virgin dams were randomized to one of six experimental diets: 
Control, Control + 50 g BPA/kg diet, Western HFD, Western + 50 g BPA/kg diet, 
Mediterranean HFD, or Mediterranean + 50 g BPA/kg diet. BPA, supplied by the National 
Toxicology Program (NTP, Durham, NC), was mixed into sucrose, creating a 0.1% BPA/sucrose 
mixture, which was mailed to Harlan Teklad for incorporation into the pellets of the three BPA-
containing experimental diets. After two weeks on their respective diets, dams (n=122) were 
mate-paired with virgin Avy/a colony males (average: 7.5 weeks old). Dams remained on their 
assigned diets through pregnancy and lactation.  
On postnatal day 21 (PND21), all offspring were weaned onto the Control diet, which 
they remained on for the duration of the study. In each litter, one male and one female a/a 
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offspring was randomly selected for longitudinal follow-up to 10 months. All remaining a/a 
offspring were sacrificed at postnatal day 10 (PND10). Outcome measurements, hepatic lipid 
accumulation and oxidative response, were assessed in offspring at both PND10 and 10-months 
(Figure 1.4). 
 
Mouse Design Decisions 
 The selection of a representative model species for physiologic research is imperative, to 
facilitate data interpretation and translation to human health outcomes. Agouti mice are 93% 
homologous with C57BL/6J and 7% homologous with C3H/HeJ mouse strains [139,140]. 
C57BL/6J are prone to aging associated obesity, glucose intolerance, insulin resistance, and 
readily develop diet-induced hepatic steatosis [32,141,142]. Additionally, reactive oxygen 
species (ROS) and gene expression of oxidative stress loci in liver and retroperitoneal adipose 
tissues have been observed to increase in HFD-fed male C57BL/6J mice prior to the 
development of insulin resistance or obesity [143]. Thus, it is reasonable to expect that diet-
induced hepatic steatosis and an early hepatic oxidative response could occur in the a/a offspring 
followed in this study. This viable yellow agouti mouse model has been extensively used to 
examine the epigenetic and phenotypic effects of perinatal BPA exposure [113,114,117,140,144–
146], including a BPA dose-range finding study to determine which mouse perinatal exposure 
level would result in human-relevant levels in mouse offspring liver samples [114]. Further, 
concurrent nutrient exposure has been shown to modify the impact of perinatal BPA exposure in 
these mice [113]. So agouti mice are not only expected to develop the physiologic outcomes of 
interest, but responsiveness to perinatal BPA and dietary exposures have previously been 
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demonstrated in this strain. This suggests the viable yellow agouti mouse model is a good choice 
for examining the potential for perinatal programming of NAFLD. 
 Toxicology studies often examine chemicals at doses levels of magnitude above than 
common human exposure dose. While this is helpful for determining overt toxicity, studies have 
suggested that endocrine disrupting chemicals, like BPA, often follow non-monotonic dose 
response curves; low dose exposures can exert hormone-like effects, triggering physiological 
cascades of response [147–149]. The BPA dose in this study was chosen based on offspring 
hepatic BPA levels in a previous perinatal exposure study in this agouti mouse colony [114]. 
This previous study used the same experimental design, with oral BPA introduced pre-gestation 
through lactation via the maternal diet. In 10-month mouse offspring, hepatic BPA levels 
averaged 2.0 ng/g, which is within the range of human fetal liver tissue (mean: 10.8 ng/g) and 
human maternal serum at delivery (mean: 5.9 ng/mL) (Table 1.1). Ingestion is a major route of 
BPA exposure in humans [147,150,151], and since this study examined potential modification of 
BPA-related health effects by diet, BPA was incorporated into the mouse food pellets. Many 
murine models of BPA exposure introduce the chemical via intraperitoneal (IP) injection or 
gavage a bolus dose directly into the stomach; these methods ensure exposure dose is identical 
across animals and consistent daily in each individual animal. Unlike carefully quantified 
injected doses, ingestion inherently introduces variation into animal dosing due to inter-
individual differences in intestinal absorption, uptake, and hepatic processing, but this more 
realistically mimics human BPA exposure. This study was designed to ensure BPA introduction 
in the mouse study was relevant to human exposure in route as well as dose.  
 When animal models are used to examine the impact of diet on a particular health 
outcome, traditionally one aspect of the diet is altered at a time. For instance, if comparing the 
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contribution of various lipid species in a diet, two diets composed of 45% calories from fat 
would be designed with one diet composed entirely of saturated fatty acids (SFA) and the second 
composed of monounsaturated fatty acids (MUFA); this allows direct comparison of the health 
effects of SFA vs. MUFA. This type of dietary comparison, altering only lipid composition, was 
considered for this dissertation research. However, since the perinatal mouse exposure study was 
designed to mimic human exposure (already discussed regarding BPA), it was determined that 
designing diets representative of human consumption patterns would provide more translatable 
results. Protein source and relative amount within the diet (20g/100g food) were held constant 
between the Control, Western HFD, and Mediterranean HFD. Lipid composition, carbohydrate 
content, vitamin and mineral levels were altered to reflect the differences observed in traditional 
Western and Mediterranean-style diets among free-living human populations. These diets are 
described in depth in Chapter 2. A challenge and common criticism of using human-relevant, 
experimental diets like this is that if differences are observed between dietary groups, it will be 
difficult to determine which aspect of the diet is driving the effect. However, the aim of this 
study was to examine if a common dietary pattern as a whole affected metabolic health outcomes 
in offspring, which component of the diet drove the effect was not part of the question. Humans 
eat complex diets with nutrients coming from many distinct food sources, so studies that use high 
levels of supplementation of a specific dietary nutrient are not able to determine if a complete 
human diet would result in a similar health effect. For example, a mouse consuming standard 
chow (e.g. AIN93-G) with omega-3 fatty acids added is not equivalent to a mouse consuming a 
complete Mediterranean-style diet.  
 
Human Birth Cohort Study 
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 This dissertation was built upon an existing, well-established human birth cohort study, 
which initially recruited mothers in 1997-2005 at hospitals serving low-to-moderate income 
areas. The Early Life Exposures in Mexico to ENvironmental Toxicants (ELEMENT), a more 
than 20 year collaboration with the Instituto Nacional de Salud Publica (INSP) in Mexico, 
recruited 236 mothers during a Trimester 1 (T1) clinic visit and an additional 14 mothers at 
delivery. Trimester-specific maternal BMI, urine samples, and dietary intake data were collected 
for the 236 mothers. Urinary BPA levels were quantified in spot urine samples from all three 
trimesters. Mediterranean diet scores (MDS) were computed from self-reported food frequency 
questionnaire data also collected in all three trimesters. A pregnancy average value was 
calculated for each mother’s urinary BPA and MDS in order to make data comparisons between 
this human birth cohort and the mouse exposure study, which provided experimentally constant 
exposures across pregnancy.  
 The 250 children followed from birth, in this study, were re-recruited for peripubertal 
clinic visits in 2010-2012, when they were 8-14 years old. Although research data was collected 
on these children at multiple clinic visits from birth through early childhood, this study only 
focused on the impact of prenatal exposures on peripubertal outcomes. Metabolic health in 
peripubertal youth was assessed via Metabolic Risk Score (MRS) and serum 8-isoprostane. The 
use of 8-isoprostane as a measure of lipid oxidation in this human cohort was a key determinant 
in the decision to include an 8-isoprostane outcome measure in the perinatal mouse exposure 
study, to improve data interpretation and translation from the mouse to human study in this 
dissertation (Figure 1.4).  
 
Species Specificity & Translation 
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Mouse studies can provide insight into mechanisms and pathways that are not easily 
accessible via bioavailable and ethical testing in humans. However, consideration of the 
translatability of animal results to human studies is critical for improvements in clinical and 
public health measures. Understanding human health is the main goal of biomedical research. 
Animal models are used to access tissues, time points, and to undergo exposures that would be 
unethical to conduct in people. This thesis aimed to make experimental study design between the 
longitudinal mouse exposure study and human birth cohort as comparable as possible, in order to 
provide clinically relevant, translatable results. This dissertation included multiple efforts to 
enhance data translation between the mouse and human findings. Design decisions in the 
perinatal mouse exposure study that were planned to mimic the ELEMENT birth cohort, include: 
(1) using an oral route of BPA exposure, (2) creating humanized HFDs for the mice, (3) using a 
Mediterranean diet score (MDS) to quantify human diet adherence, and (4) measuring the same 
marker of lipid peroxidation, 8-isoprostane, in both species.  
Another benefit of simultaneously investigating a scientific question across multiple 
species is the ability to compare the effect genetics may play on the exposure-health outcome 
relationship. The mice used for this study are genetically identical [153], so the genetic 
variability observed in humans is automatically controlled for in the mouse study. On the other 
hand, translating the mouse findings to an actual human birth cohort is instructive, because it 
allows findings to be investigated within the inherent genetic heterogeneity of human 
populations. The insights gained from examining mice and humans in a similar experimental 
design can provide a more complete picture of the exposure-health outcome relationship from 
the molecular level of physiologic mechanisms in the mice to biomarker trends that can be 
applied in human epidemiologic studies.   
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Figure 1.1 Conceptual Framework of this Dissertation  
 
 
This dissertation aimed to investigate if perinatal BPA exposure would be associated with 
increased incidence of NAFLD among offspring later in life, and whether this association could 
be modified by maternal diet during pregnancy. 
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Figure 1.2 Original Dissertation Hypothesis 
 
 
 
The original hypothesis of this dissertation research was that perinatal BPA exposure, modified 
by maternal diet, would increase hepatic lipid accumulation and hepatic oxidative response in 
offspring, thereby raising lifetime risk of NAFLD. Perinatal Western HFD exposure was 
expected to increase the steatotic and oxidative effects of BPA, while Mediterranean HFD 
exposure was predicted to prevent the NAFLD-inducing impact of perinatal BPA.  
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Figure 1.3 Conceptual Diagram of Dissertation Aims 
 
 Parallel	investigation	of	a	mouse	model	and	human	birth	cohort	study	provides	the	opportunity	to	examine	perinatal	programming	of	NAFLD	across	species.	Invasive,	tissue-specific	measurements	were	possible	in	the	mouse	offspring,	while	only	minimally	invasive	techniques	were	used	in	the	human	study.	However,	examining	the	same	type	and	timing	of	exposures	between	species	allowed	a	comparison	of	findings,	to	determine	if	mouse	study	results	would	translate	to	a	human	population.			
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Figure 1.4 Comparison of Mouse and Human Experimental Designs and Study Measurement 
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• 118	total		
• 60	females	
• 58	males	
10-month	Offspring	
• 138	total	
• 69	females	
• 69	males	
Mating	Pairs	
	
§ 122	original	pairs	
§ 101	litters	(3	all	pups	died)	
§ 98	viable	mating	pairs	
Offspring	at	Birth	
	
§ 705	total	pups	
§ 115	died	by	Day	3	(16.3%)	
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Offspring	that	Died		
	
§ 5	died	before	10-months	
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Figure	1.2	Mouse	Tracking	Across	Generations		
Measure	Category	
Mice	by	Age	
Dams	 PND10	 10-month	
Reproductive	
Outcomes	
(Chapter	2)	
• Time	to	Delivery	
• Litter	Size	
• %	Live	Pups	
• %	Female	Pups	
• %	Avy/a	Pups	
Same	as	Dams	 Same	as	Dams	
Metabolic		
Phenotype	
(Chapter	2	&	3)	
	
• Exposure	Weight	
• Mate-Pair	Weight	
• Exposure	Weight	Change	
• Gestational	Weight	Gain	
• Sacrifice	Body	Weight	
• Relative	Liver	Weight	
• Relative	mWAT	Weight	
• Serum	Leptin	
• Serum	Insulin	
• Body	Weight	
• Relative	Liver	Weight	
• Serum	Leptin	
• Body	Weight		
• Relative	Liver	Weight	
• Relative	mWAT	Weight	
• Serum	Leptin	
• Serum	Insulin	
• Serum	Resistin	
• Serum	PAI-1	
Hepatic	Lipid	
Outcomes	
(Chapter	2)	
• Liver	Triglycerides	 • Liver	Triglycerides	
• Liver	Triglycerides	
• Histologic	Analysis	
Hepatic	Oxidative	
Outcomes	
(Chapter	3)	
• Liver	8-isoprostane	
• EhGSH	(GSH	&	GSSG)	
• EhCys	(Cys	&	CysS)	
• S-glutathionylation	
• Liver	8-isoprostane	
• EhGSH	(GSH	&	GSSG)	
• EhCys	(Cys	&	CysS)	
• S-glutathionylation	
	
• Liver	8-isoprostane	
• EhGSH	(GSH	&	GSSG)	
• EhCys	(Cys	&	CysS)	
• S-glutathionylation	
	
F1:	Children	
Early	Childhood	
	
§ Clinic	Visits:	birth	to	5	years	
§ Data	NOT	included	in	this	analysis	
F0:	Mothers	 Maternal	Recruitment	
	
§ Trimester	1:	recruitment	(n=236)																																						
													&	data	collection	
§ Trimester	2:	data	collection	
§ Trimester	3:	data	collection	
§ Birth:	recruitment	(n=14)		
												&	data	collection	
Peripubertal	Re-Recruitment	
	
§ Youth:	8-14	years	old	(n=250)	
§ Data	Collection	
Girls	
(52.8%)	
Boys	
(47.2%)	
Measure	
Category	
Maternal-Child	Dyads	
Mothers	 Peripubertal	Youth	
Environmental	
Exposures	
(Chapter	4)	
• Urinary	BPA	(specific-gravity	adjusted)		
											T1,	T2,	T3,	pregnancy	average	
• Mediterranean	Diet	Score	
											T1,	T2,	T3,	pregnancy	average	
• Urinary	BPA	(specific-gravity	adjusted)		
													pubertal	clinic	visit	
• Mediterranean	Diet	Score	
													pubertal	clinic	visit	
Demographic	&	
Metabolic	
Characteristics	
(Chapter	4)	
	
• Maternal	Age	
• Educational	Attainment	
• Trimester	1	BMI	
• Gestational	Weight	Gain	
• Youth	Age	
• Pubertal	status	
• BMI	
• Skinfold	thicknesses	
• Physical	Activity:	vigorous	&	non	
Metabolic	
Outcome	
(Chapter	4)	
Not	Applicable	 • Metabolic	Risk	Score	
Oxidative	
Outcome	
(Chapter	4)	
Not	Applicable	 • Serum	8-isoprostane	
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Table 1.1 Comparison of Mouse Hepatic BPA Levels with Human BPA Exposure Levels 
 
Subjects Tissue Age 
Range 
Total BPA 
Conjugated BPA 
Mean (SD) 
Total BPA 
Mean (SD) 
Reference 
Mice (50μg BPA) Liver 10 mos. <LOQ – 11.3 ng/g 0.3 (0.3) ng/g 2.0 (3.5) ng/g Anderson et al, 2012 
Human: M&F Liver Fetal <LOQ – 96.8 ng/g 3.2 (8.0) ng/g 10.8 (18.5) ng/g Nahar et al, 2013 
Human: maternal Serum Delivery 0.5 – 22.3 ng/mL n/a 5.9 (0.94) ng/mL Padmanabhan et al, 2008 
Human: M&F Urine 40-59 yr <LOQ – 28.0 ng/mL n/a 3.5 (1.3) ng/mL LaKind & Naiman, 2015 
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CHAPTER 2 
 
Perinatal Exposure to Experimental Diets and Bisphenol A Alters  
Metabolic Outcomes in Dams and Offspring, but Increases Hepatic Steatosis Only in Dams 
 
 
ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) prevalence is increasing worldwide. Perinatal 
development has been identified as a critical window for altered lifelong health trajectory, and 
evidence supports a role for perinatal programming in chronic metabolic diseases, including 
obesity, type 2 diabetes, and metabolic syndrome. To examine the role two common exposures, 
diet and bisphenol A (BPA), play on perinatal programming of NAFLD across the life course, 
we developed a longitudinal mouse model that uses a human-relevant dose of oral BPA coupled 
with intake of Western or Mediterranean style diets in dams, from pre-gestation through 
lactation. We assessed hepatic steatosis via quantification of hepatic triglycerides (TGs) and 
metabolic health via body weight, relative organ weights, and serum hormone levels in dams and 
offspring, at postnatal day 10 (PND10) and 10-months. In dams, consumption of the Western or 
Mediterranean diets increased hepatic TGs 1.7-2.4 fold (p < 0.005), independent of BPA intake. 
However, among offspring, perinatal exposures had a greater impact on metabolic outcomes than 
on hepatic steatosis. At PND10, serum leptin levels were elevated (2.6-4.8 fold, p < 0.03) in pups 
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exposed to the Mediterranean diet, with sex-specific effects on body and organ weights (p < 
0.10). Similarly, at 10-months sex-specific increases in body (p < 0.10), organ weight (p < 0.02), 
and hormone levels (p < 0.005) were observed; however, they occurred mainly in mice 
perinatally exposed to the combination diets, Western+BPA or Mediterranean+BPA. These 
findings suggest that perinatal exposure to experimental diets and low-dose BPA may not be 
sufficient to program NAFLD later in life. Further, the impact of perinatal exposures on 
offspring metabolic health may differ by offspring life stage. Finally, alterations in dam 
phenotype by exposure appear to impact offspring health trajectory, suggestive of a need to 
better characterize mothers in future perinatal exposure studies. 
 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease 
among U.S. children and adults [1–3]. NAFLD prevalence has increased coincident with the rise 
in global obesity and insulin resistance (IR) and is likely a metabolic precursor to type 2 diabetes 
(T2DM) and metabolic syndrome (MetSyn) [4]. An estimated 9% of U.S. children have NALFD, 
but prevalence estimates rise to 38% among obese children [5], who will suffer a prolonged 
morbidity from these early-life alterations in hepatic function. NAFLD describes a range of 
pathologic states, beginning with simple hepatic steatosis and steatohepatitis, advancing to 
fibrosis, cirrhosis and in some cases hepatocellular carcinoma. If detected early at the simple 
steatosis stage, the condition is reversible [6], making steatosis a prime target for public health 
intervention. Thus, improved understanding of early life factors that contribute to hepatic 
steatosis is critical for slowing the incidence of youth NAFLD. 
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Many perinatal conditions alter fetal developmental trajectory and culminate in adult 
metabolic pathologies. Maternal disease states, nutritional deficit or excess, lifestyle choices, 
substance abuse, and environmental exposure to endocrine disrupting chemicals (EDCs) have all 
been associated with increased risk of offspring metabolic disease [7]. For instance, maternal 
pre-gestational weight/obesity and gestational weight gain are associated with increased risk of 
metabolic syndrome, insulin resistance, and obesity in offspring, in animal models and 
epidemiologic studies [8–11]. Perinatal diet, a contributing factor in maternal obesity, plays a 
major role in organizing the fetal developmental trajectory and offspring metabolism and health 
later in life [12,13]. In particular, in utero overnutrition has been associated with increased 
hepatic steatosis in offspring, suggestive of a prenatal programming component to NAFLD [14–
16]. However, based on these studies, it is unclear if all hypercaloric diets would have the same 
steatotic effect. 
Perinatal exposure to a Western-style high fat diet (HFD) is associated with a well-
documented increase in offspring hepatic steatosis and metabolic alterations, in animal models 
[17–21]. Similarly, in human adolescents consumption of a Western HFD is associated with 
increased risk of steatosis [22,23]. On the other hand, adherence to a Mediterranean HFD in 
human adults is associated with reversal of biopsy-confirmed NAFLD, significantly reducing 
hepatic steatosis and improving insulin sensitivity, even without weight loss [24–26]. A recent 
article even proposed the Mediterranean diet as the “diet of choice” for NAFLD patients [27]. 
However, perinatal exposure to a Mediterranean-style HFD has never been conducted in a 
murine model. The potential ability of a maternal Mediterranean HFD to protect against hepatic 
steatosis in offspring is appealing as a low-cost, high-gain public health intervention.  
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In addition to diet, perinatal exposure to the EDC bisphenol A (BPA) has been associated 
with fetal programming of metabolic diseases [28], including NAFLD [29–31]. BPA, a high 
production volume synthetic chemical found predominantly in polycarbonate plastics and epoxy 
resins [32], has been shown to cross the placenta in both humans and murine models [33–35]. 
We previously reported reduced expression of BPA-specific biotransformation enzymes (e.g. 
UGT2B15, SULT1A1, and STS) in human fetal tissue [35], suggestive of impaired fetal ability to 
metabolize BPA, making even low-dose exposures concerning. Perinatal exposure to low-dose 
BPA via either dam drinking water or subcutaneous pump is associated with greater body weight 
and hepatic lipid accumulation in offspring [36,37]. In both of these studies, dam BPA exposure 
began after conception, but a wave of fetal reprogramming occurs in the first few hours to days 
post-fertilization [38,39]; the later BPA exposures miss this critical window.    
Recognizing that human BPA exposure does not occur in a sterile environment, recent 
studies have begun to investigate the potential interaction between BPA and diet. Two murine 
models of perinatal oral BPA exposure with a post-weaning HFD challenge have reported 
greater hepatic damage in offspring exposed to both [40,41].  We built on these experiments by 
providing simultaneous perinatal exposure to diet and BPA, thus mimicking the concurrent 
exposure human mothers experience. Furthermore, to assess the potential impact of a diet-BPA 
interaction when background diet varied, we added low-dose BPA to a control diet and to 
Western and Mediterranean experimental diets. 
We examined the impact of perinatal experimental diets, with and without BPA, on 
hepatic steatosis and metabolic outcomes in dams and in offspring across the life-course (PND10 
and 10-months). Hepatic steatosis was assessed via hepatic triglyceride (TG) quantification in 
dams, PND10 and 10-month offspring; liver histology (OilRedO and H&E vacuolation) was 
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used to validate hepatic TG levels in 10-month offspring. Metabolic outcomes included body 
weight, relative organ weights, and serum hormone levels, for all mice. We hypothesized that 
perinatal Western diet would increase hepatic TGs and trigger metabolic alterations, while 
Mediterranean diet would minimize these changes. We also evaluated whether adding BPA to 
experimental diets would exacerbate hepatic steatosis. This study advances our understanding of 
factors that contribute to developmental programming of hepatic steatosis and related metabolic 
alterations in five ways, investigating: timing of exposure, comparison of two different 
experimental diets, effects of concurrent diet and BPA intake, impact of these exposures and 
interactions at two offspring life stages, and importance of maternal phenotype in offspring 
health trajectory. 
 
METHODS 
Experimental Design 
Mice used for this study originated in the Dolinoy Lab viable yellow agouti (Avy) mouse 
colony. The colony has been maintained by sibling mating for over 250 generations with forced 
heterozygosity for the Avy allele, producing a genetically invariant background with 93% 
homology to C57BL/6J and 7% homology to C3H/HeJ [42,43]. Mice were housed in 
polycarbonate-free cages with enrichment, in a climate-controlled room with a 12hr light-dark 
cycle, in accordance with the Institute for Laboratory Animal Research (ILAR) guidelines [44]. 
Mice were treated humanely and provided ad libitum access to food and water 24-hours a day, in 
accordance with the University of Michigan’s University Committee on Use and Care of 
Animals (UCUCA) policies on cage enrichment, cleaning, maintenance, and daily mouse health 
checks [45]. This study protocol (PRO00004797) was approved by UCUCA. 
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To reduce the effect of parity and age, virgin, 8-10 week old, wild-type (a/a) dams were 
randomly assigned to one of six exposure groups: Control, Control + 50 g BPA/kg diet, 
Western, or Western + 50 g BPA/kg diet, Mediterranean, or Mediterranean + 50 g BPA/kg 
diet. After two weeks on their respective diets, virgin a/a dams (10-12 weeks of age) were mated 
with young, virile Avy/a males (7.5 weeks old on average).  Dams remained on their assigned 
diets from pre-gestation through lactation (Figure 2.1), such that dams were directly exposed to 
their assigned diet for an average of 8-9 weeks. All offspring were weaned onto the Control diet 
at postnatal day 21 (PND21). 
Mating a/a females with Avy/a males generates litters of approximately 50% a/a and 50% 
Avy/a pups. Mice with the Avy allele have a range of coat colors from yellow to pseudoagouti 
(brown), that phenotypically display differences in epigenetic marks in the Agouti gene promoter 
[46–48]; wild type a/a mice have black coats and are thus easily distinguishable by eight days of 
age. To avoid confounding from the obesity and metabolic abnormalities observed in the Avy/a 
mice [49–51], only a/a pups were followed in this study. Offspring coat color was recorded at 
postnatal day 8 to determine which pups would be followed longitudinally. One male and one 
female a/a pup per litter were maintained for longitudinal testing to 10 months of age (10-
month). All other a/a pups were sacrificed at postnatal day 10 (PND10). Offspring sacrifices 
were conducted in the afternoon (2-5pm) to normalize diurnal hormone fluctuations. To further 
standardize measurements, 10-month females were only sacrificed when in estrus, confirmed by 
vaginal cytology [52]. Sacrificing offspring at 10 months approximates human middle age, prior 
to aging-related health decline [53]. 
 
Composition of Experimental Diets 
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Experimental diets were modifications of the standard AIN93G mouse diet [54,55]. Like 
AIN93G, the Control diet contains casein as the sole protein source, but the soybean oil was 
replaced with corn oil to remove the potential epigenetic programming effect of phytoestrogens 
in the soybean oil [56,57]. The Mediterranean and Western diets differed from the Control diet in 
their lipid ratio, carbohydrate profile, vitamin and mineral content; protein content was kept 
constant between all three diets.  
Mouse diets were formulated on a per weight basis at the University of Michigan and 
manufactured by Harlan Teklad (Madison, WI). The Mediterranean diet was based on a 
traditional Cretan diet which included high nut, fruit and vegetable content [58–60]. The Western 
diet was based on U.S. dietary intake as recorded in NHANES II [61,62]. This resulted in a 
Western diet composed of more saturated fats (butter and palm oil), lower fiber / higher sugar 
carbohydrates, higher salt, and lower antioxidant content [61,62] (Table S2.1, Figure 2.2). Both 
experimental diets were formulated by nutrient content (grams) per kilogram diet.  
 
Bisphenol A (BPA) Exposure 
The choice of 50 ug BPA/kg dose was based on a previous BPA dose range finding study 
[63], which found an intake of 50 g BPA/kg diet produced on average 2.02 ng BPA/g liver. 
This is within the human exposure levels measured in in human fetal liver samples (range: below 
limit of quantification to 96.8 ng BPA/g liver) [63]. BPA was supplied by the National 
Toxicology Program (NTP, Durham, NC). To create a 0.1% BPA/sucrose mixture, BPA (0.01 g) 
was mixed into sucrose (9.99 g) in glass containers. Harlan Teklad incorporated this mixture at 
0.05 g/kg into three of the six experimental diets: Control+BPA, Western+BPA, and 
Mediterranean+BPA.  
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Body and Tissue Weights 
To decrease variation and reduce human error, a strict protocol was followed for all 
sacrifices, necropsies, animal and tissue weighing [45]. The liver was dissected and separated by 
lobe; all analyses were run on the left lobe. Dam body weight was recorded three times 
throughout the study: (1) pre-gestation, at initial exposure to the study diets, (2) at mate-pairing, 
two weeks later, and (3) at sacrifice, four days post-weaning. Two weight change periods were 
calculated: dam pre-pregnancy weight change (pre-gestation to mate-pairing), and gestational 
weight gain (mate-pairing to sacrifice). Organ weights were measured for dam liver and 
mesenteric white adipose tissue (mWAT). mWAT, a component of visceral WAT that does not 
include gonadal fat, was separated from abdominal organs (stomach, pancreas, spleen, intestines) 
prior to weighing. 
Total body and liver weights were also recorded for PND10 offspring. Mice at PND10 
have negligible mWAT, so no adipose weights were recorded for the pups. 10-month offspring 
body, liver, and mWAT weights were measured during necropsy. Relative liver and mWAT 
weights were calculated as a ratio of: absolute organ weight / total body weight. All weights 
were measured on a SLF103 balance (Fisher Scientific) to the hundredths digit.  
 
Hepatic Triglycerides (TG) 
TG levels were quantified via the previously published TG extraction protocol [64], using 
the Sigma Triglyceride Determination Kit (TRO100). Samples were analyzed in triplicate 
(sensitivity 0.0625 mg/mL, 10.5% CV).  
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Liver Histology 
 Two histologic staining methods were used to validate hepatic TG quantification and to 
independently analyze hepatic lipid accumulation and lesions in 10-month offspring liver tissue: 
(1) OilRedO, and (2) hematoxylin and eosin (H&E). Tissue samples were frozen or fixed 
(respectively) during necropsy, then transferred to the University of Michigan In-Vivo Animal 
Core (IVAC) for histologic staining and analysis. Slides were read by a board-certified 
veterinary pathologist. 
Tissue reserved for OilRedO staining was embedded in optimal cutting temperature 
(OCT) compound, flash frozen in liquid nitrogen, and stored at -80oC. Frozen, OCT-embedded 
tissue was thinly sliced by microtome. The standard AbCam OilRedO kit (ab150678) protocol 
was followed to stain lipids on each slide. OilRedO staining was scored from 1-4 based on the 
amount of micro- and/or macro-vesicular vacuolation, multifocal or diffuse: 1 = minimal, 2 = 
mild, 3 = moderate, 4 = severe. 
To prepare liver samples for H&E staining, thin sections of liver were fixed in 10% 
neutral-buffered formalin during necropsy. In livers with visible gross masses, the boundary 
between mass and normal-appearing tissue was included in the fixed sections, to analyze the 
potential invasive properties of the mass. Once at the IVAC, samples were transferred to 70% 
ethanol, routinely processed and stained with H&E for histopathology. Lipid vacuolation was the 
primary outcome of interest, but additional morphologic changes were observed by the 
veterinary pathologist, including: hepatocyte hypertrophy, multinucleated hepatocytes, 
proliferative alterations (hepatocellular adenoma, nodular hyperplasia, mixed cell, clear cell, and 
eosinophillic foci), and non-proliferative alterations (cell infiltrates, oval cell and Kupffer cell 
hyperplasia, and inflammation). Morphologic changes were also scored on a 4-point scale based 
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on the percent of tissue affected: 1 = minimal (0-9%), 2 = mild (10-19%), 3 = moderate (20-
49%), 4 = marked (>50%).  
 
Serum Hormone Analyses 
Hormone levels were measured in blood samples collected via closed chest cardiac 
exsanguination [65], on semi-fasted mice. Whole blood was allowed to clot, serum separated, 
and stored at -80oC. On average, more than 650 L of whole blood was collected from dams, 
100 L from PND10 pups, and 1565 L from 10-month offspring. For dams and PND10 
offspring, Millipore Mouse ELISA kits were used to quantify serum leptin (EZML-82K, 
sensitivity 0.05 ng/mL, 3.0% CV) and insulin (EZRMI-13K, sensitivity 0.2 ng/mL, 6.0% CV) 
levels. Due to low serum volume from PND10 offspring, only leptin was analyzed. 
Serum from 10-month offspring was analyzed on a Luminex xMAP (ThermoFischer), at 
the MDRC Chemistry Lab. Six serum hormones were simultaneously measured via the 
Multiplex Mouse Adipokine Magnetic Bead Panel (MADKMAG-71K), with intra-assay %CV 
<10% and inter-assay %CV <20%. Assay sensitivity varied by hormone: leptin (4.2 pg/mL), 
insulin (13.0 pg/mL), resistin (1.1 pg/mL), IL-6 (2.3 pg/mL), PAI-1 (4.0 pg/mL), and TNF (5.3 
pg/mL). All hormone levels reported in this paper are the average of duplicate measures for each 
mouse.  
 
Statistical Analyses 
Values for all variables were inspected; values outside of a biologically plausible range 
were discarded. A probability plot of residuals was used to test the normality of each variable’s 
distribution. Right-skewed variables were ln-transformed. The effects of diet and BPA on liver 
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TG levels, serum hormones, body and organ weights were analyzed by ANOVA, followed by 
Tukey’s post-hoc analyses; this allowed comparison across all six perinatal exposure groups. 
Significance was pre-set at p < 0.05. 
Previous studies have reported sexually dimorphic metabolic responses to prenatal 
exposures [66,67], so cross-sectional PND10 and 10-month offspring comparisons were sex-
stratified. Results from the initial independent t-tests and ANOVAs suggested that experimental 
diets might have a larger effect than BPA on both dams and offspring. One-way ANOVAs were 
also run to compare all six perinatal exposure groups among dams, PND10 and 10-month 
offspring (Tables 2.2, S2.2, S2.3, S2.4, S2.5). We ran linear mixed models (LMM) to determine 
predictors of hepatic TGs, with perinatal diet and BPA exposure included as separate variables. 
This allowed us to examine the independent effects of experimental diets and BPA, and to 
examine the interaction of diet*BPA on metabolic outcomes. 
‘Cohort’ was significantly correlated to many dam and 10-month offspring variables, so 
was added to these models as a random intercept. However, ‘Cohort’ did not improve effect sizes 
or model fit (by AIC) in PND10 models, and since no PND10 variable means differed by cohort, 
we decided to remove it from those models. Some PND10 mice had littermates included in the 
models, so ‘Litter ID’ was included as a random effect in PND10 models. The range in litter size 
(3-11pups) was large in this study. ‘Litter size’ was included in all PND10 and 10-month 
models, as an a priori factor that could influence offspring metabolic health. Other variables 
previously identified as covariates for offspring metabolic changes were tested in regression 
models. Final models were selected based on the model with the largest effect size on perinatal 
exposure variables: experimental diets and BPA. All analyses were conducted in SAS 9.4 (Cary, 
NC, USA). 
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RESULTS 
Reproductive Outcomes 
Days to delivery averaged 27.7 days across all dams (n=97), with no difference by 
perinatal exposure group. On average, seven pups were born per litter across all exposure groups; 
however, 2.7-fold more Control+BPA pups died than Control (p = 0.0149) (Table 2.2). Pup 
deaths within the first three days of life is not unusual, especially in large litters, so the number 
of surviving pups per litter on postnatal day 4 (PND4) was also assessed. Initial litter size 
impacts in utero nutrient availability, while the number of living pups per litter can affect 
lactation nutrient availability and maternal care. Living pup litter size was 1.5-fold greater in 
Control compared to Control+BPA litters (p = 0.0075), consistent with the higher death rate 
among Control+BPA pups. The proportion of male and female pups did not differ by perinatal 
exposure group, with 51% male pups on average. Although Control+BPA (58.4%) and 
Mediterranean (57.8%) litters contained a greater percent of Avy/a offspring than Control (48.4%) 
litters, the differences were not significant. Pup deaths prior to PND4 may have occurred 
disproportionately in a particular sex or genotype group, but it was not possible to determine, 
since some dead offspring were not retrievable. 
 
Metabolic Outcomes 
Dams’ Response to Experimental Diets 
Dam body weight did not differ at initial exposure (Table S2.2). But pre-pregnancy 
weight change, during the first two weeks on the experimental diets, was greater in Western and 
Mediterranean diet groups (Figure S2.1). Dams on the Control and Control+BPA diets lost 
weight (-0.22 to -0.55g), while the other four groups gained weight (0.15 to 0.79g), especially 
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dams on Western (p = 0.0006), Western+BPA (p = 0.0001), and Mediterranean (p = 0.0062) 
diets. This exposure-derived weight gain led to greater mean pre-gestation body weights in 
Western (19.63g), Western+BPA (19.42g), and Mediterranean (19.66g) dams compared to 
Controls (18.55g), but the differences were not significant. Gestational weight gain did not differ 
between the six exposure groups, and although Western, Western+BPA, and Mediterranean 
dams remained heavier, on average (27.42g), than Control dams (25.72g), the differences were 
not significant at sacrifice, four days after pup weaning (Figure S2.2).  
Relative liver weight in dams did not differ by diet nor BPA exposure; on average, dam 
livers composed 5.0-5.5% of their overall body weight. However, greater relative mWAT (3.2-
3.3%) was collected from Western (p = 0.0035), and Western+BPA (p = 0.0078), compared to 
Control dams (2.4%). Exposure groups associated with greater pre-gestational body weight gain 
were the same as the groups that had higher relative mWAT at sacrifice.  
Post-partum, semi-fasting serum insulin levels in dams on Mediterranean and Western 
diet trended lower (~1.5ng/mL) than Control and Control+BPA (~2.5ng/mL) serum insulin 
levels, but the differences were not significant. Serum leptin levels were consistent in dams 
across all dietary exposure groups, ranging from about 4.5-5.9 ng/mL.  
Hepatic TGs did not differ by BPA exposure in dams. However, hepatic TGs were 
significantly higher in dams exposed to the Western (p = 0.0077), Western+BPA (p = 0.0410), 
Mediterranean (p = 0.0001), or Mediterranean+BPA (p = 0.0365) diets, compared to Control 
(Figure 2.3, Table S2.2). Control+BPA hepatic TGs trended higher than Control TGs, but 
hepatic TGs in Mediterranean+BPA and Western+BPA groups trended lower than their 
respective diets without BPA, suggestive of a potential interaction between these experimental 
diets and BPA. 
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PND10 Offspring’s Response to Experimental Diets  
PND10 offspring (n = 118) were exposed to experimental diets and BPA via maternal in 
utero transfer for at least three weeks and via mother’s milk for 10 days. The experimental diets 
did not impact body weight or relative liver weight in PND10 females (n = 60) or males (n = 58). 
Control+BPA males had lower average body weight (4.74g) compared to Control males (5.78g, 
p = 0.0434) at PND10; addition of BPA to the Mediterranean and Western diets did not result in 
decreased body weight (Table S2.3). Body weight did not differ among PND10 females based on 
perinatal exposure group. At this early age, average body weight did not differ by offspring sex, 
with males averaging 5.53g and females averaging 5.68g (p = 0.4130). Despite the lower body 
weight in Control+BPA males, relative liver weight did not differ between Control+BPA and 
Control males, comprising 3% total body weight in both groups. There were no differences in 
relative liver weight among other male or any female perinatal exposure groups either (Table 
S2.3).  
 Serum leptin levels were consistently highest among both female and male PND10 
offspring exposed to the Mediterranean diet. Female Mediterranean diet pups had average serum 
leptin levels 2.6-fold higher than Control females (p = 0.0011), while males exposed to the 
Mediterranean had levels 4.8-fold greater than Control males (p = 0.0284) (Table S2.3). 
Variation of leptin levels was greatest among Mediterranean offspring of both sexes, suggestive 
of inconsistency in hormonal response between individual Mediterranean mice. Serum leptin 
levels did not differ by Western diet or BPA exposure in female or male PND10 offspring.  
Hepatic TG levels were highest among Mediterranean PND10 offspring of both sexes. 
Mediterranean males had 7.3-fold greater hepatic TG levels compared to Control males (p < 
0.0001) (Table S2.3).  Although not significant, hepatic TGs were 1.6-fold higher among 
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Mediterranean females compared to Controls. As observed in the PND10 serum leptin levels, 
variation in hepatic TG levels was largest among Mediterranean pups of both sexes at PND10, 
suggestive of considerable inconsistency in hepatic TG storage between individual 
Mediterranean mice (Figure 2.4A & B). Neither perinatal Western diet nor BPA exposure altered 
hepatic TG levels in either sex. 
  
10-Month Offspring’s Response to Experimental Diets 
 By 10-months of age (n = 138), offspring had not been exposed to the experimental diets 
or BPA for more than nine months, since weaning. Body weight at 10-months did not differ by 
perinatal exposure. As expected, male offspring (44.87g) weighed more than females (34.63g), 
on average, at 10-months (Table S2.4). Females perinatally exposed to Western (3.8%), 
Western+BPA (3.7%) and Mediterranean (3.8%) diets, had greater relative liver weights 
compared to Control females (3.1%, p < 0.02). Relative liver weight did not differ by perinatal 
exposure in 10-month males. However, males perinatally exposed to the Western+BPA diet had 
greater relative mWAT (4.1%) compared to Control males (3.4%, p = 0.0235). Relative mWAT 
weight did not differ by perinatal exposure in 10-month females.  
Perinatal diet impacted serum leptin levels among 10-month males; Western+BPA serum 
leptin was 1.6-fold higher and Mediterranean was 1.5-fold higher than Control levels (p < 0.02) 
(Table S2.4). Western+BPA males also had 1.6-fold higher serum resistin levels compared to 
Control males (p = 0.0046). Among 10-month males, serum insulin and PAI-1 levels did not 
differ by perinatal exposure group.  However, in 10-month females, serum PAI-1 levels were 
1.6-fold greater in Mediterranean+BPA than Controls (p = 0.0043). No other serum hormones 
differed by perinatal exposure, among female offspring at 10-months. 
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Hepatic TGs were 2.4-fold higher in females perinatally exposed to the 
Mediterranean+BPA diet compared to Control females (p = 0.0118) (Table S2.4). Although all 
female experimental diet groups had hepatic TGs greater than Control, no other group 
differences were significant. Hepatic TGs did not differ by perinatal exposure group among male 
offspring at 10-months (Figure S2.4). 
 
Comparison of Hepatic Steatosis Measures in 10-month Offspring 
 H&E vacuolation and OilRedO staining were highly correlated to hepatic TG levels, in 
10-month offspring of both sexes (Table 2.3), indicating that hepatic TG quantification is an 
accurate proxy measure of hepatic lipid accumulation. The full range of scores, from 0 
(negligible) to 4 (severe lipid accumulation), was observed in both male and female 10-month 
offspring (Figure 2.5). 
 Hepatocellular response to perinatal exposures was sexually dimorphic, with multiple 
morphologic lesions differing significantly among experimental diets in female 10-month 
offspring, but not males (Table S2.5). Hepatocellular vacuolation was 1.7-fold greater in 
Mediterranean+BPA females compared to Controls (p = 0.0258), consistent with the observed 
hepatic TG difference. Surprisingly, OilRedO score was 2.3-fold higher among Control females 
than Western+BPA females (p = 0.0124), suggestive of less lipid accumulation in Western+BPA 
exposed offspring. Perinatal exposure did not impact hepatic steatosis, as measured by 
vacuolation or OilRedO score, in male offspring at 10-month (Table S2.5).  
 Hepatic adenomas were observed in 11 male mice, spread across five of the experimental 
exposure groups, including Control (Table S2.5). No adenomas were found in any female mice, 
but proliferative lesions differed by perinatal exposure groups. Proliferative lesions were only 
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observed in Control+BPA and Mediterranean+BPA females. Non-proliferative lesions also 
differed by perinatal exposure group in 10-month females; Control females had more non-
proliferative responses than Western, Western+BPA, and Mediterranean (p < 0.02). 
 
Predictive Modeling of Liver Triglycerides 
Dam Liver Triglycerides 
 Linear mixed models (LMM) were used to explore the contribution of perinatal 
experimental diets, perinatal BPA, and the interaction of these two concurrent exposures (Table 
2.4). Both experimental diets were associated with increased dam hepatic TG levels; Western 
dams had 11.24 mg/g (p = 0.0009) and Mediterranean dams had 18.02 mg/g (p = 0.0518) higher 
TGs than Control dams. BPA did not affect dam hepatic TG levels (p = 0.2279), but the 
Mediterranean*BPA interaction term had 13.24 mg/g (p = 0.0634) lower TG levels than 
Mediterranean dams. Every one gram increase in dam body weight at sacrifice was associated 
with 1.43 mg/g (p = 0.0116) greater hepatic TGs. Other potential covariates did not contribute 
significantly to the model, including: dam gestational weight gain, dam serum leptin, or insulin 
levels. 
 
PND10 Offspring Liver Triglycerides  
 Sex-stratified LMMs predicting Ln-transformed hepatic TGs in PND10 offspring 
included litter size as a covariate (Table 2.5). Neither perinatal experimental diets, BPA, nor their 
interaction terms significantly contributed to hepatic TG levels in female PND10 offspring. 
Western PND10 males had 5.9% (p = 0.0543) and Mediterranean males had 18.2% (p < 0.0001) 
greater TGs than Control males. Perinatal BPA exposure did not affect male PND10 hepatic TG 
levels, but the Mediterranean*BPA interaction term decreased TG levels by 12.7% (p = 0.0150) 
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compared to Mediterranean males.  Of note, the same two maternal factors associated with dam 
hepatic TGs, pre-gestational weight change and post-partum body weight, impacted hepatic TGs 
in PND10 males. PND10 male hepatic TGs increased by 4.8% (p = 0.0761) for every one-gram 
increase in dam body weight at sacrifice, but decreased by 4.6% (n.s.) for every one-gram 
change in pre-gestational weight. Although not significant, dam post-partum weight and pre-
gestational weight change improved model fit for PND10 females also (5.3% and -10.7%, 
respectively). Other potential covariates did not contribute significantly to the models, including 
all of the other PND10 variables (body weight, relative liver weight, and serum leptin levels) and 
dam variables (relative liver and mWAT weights, gestational weight gain, serum leptin, and 
insulin levels). 
 
10-month Offspring Liver Triglycerides  
 Similar to PND10 models, sex-stratified LMMs predicting Ln-transformed hepatic TGs 
in 10-month offspring included litter size as a covariate (Table 2.6). Perinatal exposure to neither 
experimental diet nor BPA alone significantly contributed to female 10-month offspring hepatic 
TG levels. However, the Mediterranean*BPA interaction term had 15.2% (p = 0.0309) higher 
TG levels than Mediterranean females. Also in females, hepatic TGs were associated with a 
24.6% (p = 0.0547) increase for every 1% increase in 10-month female relative mWAT weight. 
Although it did not contribute significantly to the model (p = 0.4143), presence of hepatic 
nodular hyperplasia improved model fit for 10-month female hepatic TGs. In 10-month males, 
neither perinatal diet nor BPA were significant predictors of Ln-transformed hepatic TGs. 
However, the best-fit model included the same covariates as the 10-month female model: 10-
month relative mWAT (25.4% increase, p = 0.1418) and nodular hyperplasia (6.3% increase, p = 
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0.0265). No other factors measured in 10-month offspring or their mothers (dams) were 
predictive of hepatic TGs in 10-month offspring of either sex. 
 
DISCUSSION 
 This longitudinal exposure study aimed to determine the life-course impact of perinatal 
experimental diets and BPA on offspring hepatic steatosis and metabolic health. Although dam 
hepatic TG levels differed by diet, alterations in metabolic outcomes were more pronounced than 
the effect on hepatic steatosis in offspring at PND10 and 10-months. Of note, the perinatal 
exposure that impacted offspring health outcomes differed by offspring age. At PND10, only the 
Mediterranean diet was associated with increased serum leptin (all offspring) and elevated 
hepatic TGs (males only); however, the large variation of these measures suggested considerable 
inter-individual differences in mouse response to the Mediterranean diet. In 10-month offspring, 
perinatal exposure to experimental diets+BPA was associated with sex-specific alterations in 
relative organ weights and serum hormone levels; this lasting impact of perinatal exposures, after 
>9 months on a Control diet supports the theory that offspring metabolic health can be 
developmentally programmed. Although not the original subjects of interest in this study, dam 
hepatic and metabolic responses to both experimental diets were marked and also predicted 
hepatic TG levels in PND10 offspring. Thus, dams may be an important group to phenotype in 
future murine models and epidemiological studies of perinatal exposures.  
 
Reproductive Outcomes 
We found no effect of perinatal diet on reproductive outcomes, including time to 
delivery, litter size, and percentage of male pups or Avy/a pups per litter. A 2009 systematic 
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review of perinatal HFD exposure outcomes also reported no difference in litter size or offspring 
birth weight between HFD and Control groups [68]. However, a recent study in C57BL/6J mice 
reported that HFD (60% fat, mostly lard) consumption, independent of dam obesity, was 
associated with decreased ovarian function due to depleted primordial follicles, and impaired 
fertility with fewer litters and smaller litter sizes [69]. The discrepancy may result from 
differences in fat content of the HFDs. The experimental diets in our study contained 42% of 
calories from fat, mimicking human HFDs, which rarely contain more than 45% kcal from fat 
[70]. The 60% fat diet used in the recent C57BL/6J study [69] is common in murine models of 
diet-induced metabolic disease, but it may not be directly applicable to human health.  
Perinatal BPA exposure is associated with decreases in uterine receptivity, implantation 
[71], and increases in offspring mortality [72]. Consistent with these findings, we observed 
greater Day 3 pup mortality in the Control+BPA offspring. However, the increased mortality did 
not occur in Western+BPA or Mediterranean+BPA groups, suggestive of a diet*BPA interaction. 
A potential mechanism for and implications of this interaction are examined later in this 
Discussion. 
 
Dam Metabolic & Hepatic Outcomes 
Irrespective of BPA content, dams consuming the Western or Mediterranean 
experimental diets had increased hepatic TGs compared to Control dams. Adult C57BL/6J mice 
are known to develop hepatocellular ballooning and hepatic simple steatosis after 7-8 weeks on a 
high fat diet [73–75]. However, the impact of HFDs on hepatic steatosis has not been reported in 
pregnant dams. While many studies use perinatal HFD exposure to investigate effects on 
offspring health [76], potential alterations in maternal health and physiology are rarely published. 
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In this study, dams were exposed to the experimental diets for an average of 8-9 weeks, so the 
observed hepatic steatosis aligned with the previously reported time to develop steatosis in non-
pregnant adult mice.   
Dams exposed to the Western, Western+BPA, or Mediterranean diets had greater pre-
gestational weight gain and relative mWAT weight. Weight gain on HFDs has previously been 
attributed to gains in adiposity, not lean mass [74]. The increased relative mWAT weight, 
without increases in relative liver weight, among dams on the experimental diets suggests that 
increased adiposity contributed to the greater pre-gestational weight gain compared to Control 
dams. Gestational weight gain is associated with an increased risk of overweight in children (2-
18 years) in many human birth cohort studies [77]. However, a large prospective cohort study in 
the Netherlands reported maternal pre-gestational obesity increased odds of childhood obesity, 
but excessive gestational weight gain had a more limited impact on children’s outcomes [78]. 
This distinction may explain the lack of effect the differential pre-gestational weight gain had on 
mouse offspring; none of the study dams were obese prior to mate-pairing. The clarification that 
some, not all, dam weight measures may impact offspring health trajectory supports the need to 
better characterize the maternal environment and metabolism when studying the potential 
perinatal programming of offspring metabolic disease.  
 
PND10 Metabolic & Hepatic Outcomes 
 Perinatal exposure to experimental diets in this study impacted hepatic TGs only in male 
PND10 offspring. This sexually dimorphic response has been previously observed in mice and 
rats [79,80], with male offspring consistently more likely to develop hepatic steatosis following 
perinatal HFD exposure than females. Among youth (2-19 years) accidental deaths in San Diego 
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County, males were also more likely to have hepatic steatosis (15%) than females (9%) [81], 
suggesting the sex-specific difference in rates of hepatic steatosis may translate to human 
populations.   
Metabolic outcomes at PND10 were most pronounced in offspring perinatally exposed to 
the Mediterranean diet. Although maternal HFD during pregnancy has been associated with 
increased serum leptin in 12-week old offspring [82], we only observed this elevated leptin 
response among Mediterranean diet offspring; the Western diet had no effect. The difference in 
offspring age, 12-weeks vs. PND10, may contribute to the dissimilar effect of perinatal exposure 
on offspring leptin levels. Breast milk contains leptin and is thought to contribute to regulation of 
food intake in offspring prior to weaning [83–85], so the serum leptin levels in our PND10 
offspring likely reflected variations in leptin from mother’s milk, not endogenously produced 
leptin as seen in 12-week old offspring. Among adults, elevated leptin may be indicative of 
leptin resistance, failure to regulate food intake despite high circulating leptin levels, often 
observed in metabolic conditions (obesity, MetSyn, T2DM) [86]. However, the postnatal leptin 
surge that occurs in the first two weeks of life in rodents is necessary for establishing 
hypothalamic pathways that will control food intake [87] and for the maturation of other organs 
involved in energy homeostasis, including the kidney, pancreas, ovary, and thymus [88]. Thus, 
elevated leptin levels in PND10 offspring exposed to the Mediterranean diet likely have a greater 
impact on organ development than on life long metabolic health.  
 
10-month Metabolic & Hepatic Outcomes 
 This study was designed to investigate the perinatal programming of hepatic steatosis. To 
strengthen potential findings, three measures of steatosis were included, quantification of hepatic 
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TGs, OilRedO staining of hepatic lipids, and analysis of hepatocellular vacuolation via 
histopathology. We observed hepatic steatosis among 10-month offspring, but it did not differ 
strongly by perinatal exposure group, suggesting it may have been normal, age-related steatosis. 
C57BL/6J mice are known to develop hepatic cysts and adenomas [89,90]; this age-related 
pathology has been previously observed in our viable yellow agouti colony, with 10.5% of non-
agouti, a/a 10-month male Controls displaying neoplastic lesions and over 50% of 10-month 
females and males exhibiting simple steatosis [42]. The presence of hepatic adenomas in only 
10-month males, not females, in our study is consistent with the higher background incidence of 
hepatic tumors in male C57BL/6J mice [91] .  
Strikingly, histopathologic evaluation of hepatic tissue found Control offspring had more 
non-proliferative changes than offspring perinatally exposed to the experimental diets. This may 
suggest Control mice retained the ability to regenerate and repair injured tissue more at 10-
months than did other groups. Thus, although age-related damage may be occurring, Control 
livers may still be able to respond to environmental stressors, returning to a healthier state, 
whereas livers perinatally exposed to experimental diets may not be able to repair as easily, and 
thus amass more tissue damage. 
Perinatal exposure to diet+BPA combinations (Western+BPA and Mediterranean+BPA) 
had the greatest effect on 10-month offspring metabolic outcomes. This response differed from 
both dams and PND10 offspring, suggesting that various perinatal exposures may impact 
offspring health at different ages. HFD consumption has been associated with increased relative 
liver weight in adult animals [92], we observed this effect in 10-month female offspring. 
However, in our mice, they had not been exposed to the experimental diets since weaning, 
suggesting that perinatal HFD exposure can also impact relative liver weight across the life 
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course. Interestingly, the increased liver weight did not translate to greater hepatic TGs, so mass 
was not necessarily due to increased lipid accumulation. The borderline increase in body weight 
and significant increase in relative mWAT weight among Western+BPA males at 10-months 
suggests that these males accumulated more visceral adipose across their life, due to the 
combined exposure in early life. These Western+BPA males also had the highest serum leptin 
and resistin levels and the lowest serum PAI-1, suggesting that the greater mWAT mass was 
metabolically active. 
 
Multifaceted Effects of the Experimental Diets & BPA 
Effects of the six perinatal exposures were much more complex than our original 
hypotheses. The Western diet had the expected, adipogenic effect [17–19] in dams, but barely 
impacted offspring. Conversely, we expected our Mediterranean diet would protect against 
metabolic and hepatic alterations, but in dams it was generally indistinguishable from the 
adipogenic effect of the Western diet, and was the only diet to increase PND10 hepatic TGs. 
Individual components of the Mediterranean diet (fish oil, olive oil, and polyphenols) have been 
investigated, but a complete Mediterranean diet has never been created for mice. A previous 
comparison of two purified perinatal diets found that maternal diets high in saturated fat 
promoted offspring hyperphagia, but equivalent consumption of a fish oil diet did not [93]. 
Further, a recent study in rats, reported that adding fish oil to a HFD in dams during pregnancy, 
prevented insulin resistance in adult male offspring, independent of body weight [94]. In adult 
mice predisposed to hepatic steatosis, daily 2% DHA/EPA supplementation reduced hepatic TGs 
by almost 40% [95], further supporting the health benefits of a fish-oil enriched diet.  
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On the other hand, consumption of olive oil, the primary fat component in the 
Mediterranean diet, is associated with increased steatosis in mice [96,97]. In mice, olive oil 
decreases activity of carnitine palmitoyltransferase I (CPT1), the rate limiting step for 
mitochondrial fatty acid -oxidation. This depression of CPT1 activity does not occur in humans 
consuming olive oil, thus may partially explain the differential outcome of the diet between the 
two species. In human studies, Mediterranean diet is associated with reversal of biopsy-
confirmed NAFLD in adults, significantly reducing hepatic steatosis and improving insulin 
sensitivity, even without weight loss [26,98]. A proteomics analysis reported that tissue 
oxidation and atherosclerotic plaque formation was delayed in mice consuming olive oil, despite 
increased hepatic steatosis and insulin resistance; the authors attributed this paradoxical response 
to the differential regulation of 80 hepatic antioxidant enzymes, including heat shock proteins, 
superoxide dismutase, glutathione peroxidase 1, thioredoxin peroxidase 2, fatty acid binding 
protein, carboxylesterase, and apolipoprotein A1 [97]. Thus, the hepatic steatosis observed in 
mice consuming olive oil may be protective, as it does not appear to induce the detrimental 
metabolic alterations. This protective antioxidant effect may also explain why mice perinatally 
exposed to Mediterranean diet in this study did not exhibit altered hepatic or metabolic responses 
at 10-months.  
In this entire study, perinatal BPA exposure on a Control diet (Control+BPA) only 
impacted pup Day 3 mortality and body weight in PND10 offspring; no effects were observed in 
dams or 10-month offspring. Perinatal low-dose BPA exposure has been associated with lower 
birth weight in murine models [99]; we observed this decreased body weight at PND10, but only 
among male offspring. Our findings support the previously reported detrimental effect of 
perinatal BPA exposure on reproductive outcomes [71,72,99], but suggest that maternal diet may 
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have a greater impact on offspring health trajectory, than BPA exposure. This is good news from 
a public health standpoint; in general, people have more control over the food they eat than over 
food and beverage packaging. Perinatal BPA exposure may not be sufficient to alter offspring 
health trajectory, an additional postnatal stressor or dietary challenge may be required. A theory 
of developmental “priming” by perinatal EDC exposure has been proposed, suggesting that 
exposure-induced changes in gene methylation may prime the loci for increased transcription in 
response to a later challenge [100]. Two mouse studies that examined perinatal BPA exposure 
followed by a postnatal HFD challenge reported greater hepatic TGs in offspring exposed to both 
the BPA and HFD [40,41], supportive of BPA’s potential priming effect. Thus, perinatal low-
dose BPA exposure may increase offspring susceptibility to hepatic steatosis, but postnatal diet 
may be required to trigger the pathologic response. 
In contrast to the lack of metabolic or hepatic response to the Control+BPA diet, the 
diet*BPA combination diets, especially Western+BPA, significantly impacted organ weights and 
serum hormone levels in a sex-specific manner among 10-month offspring. In 10-month males, 
the predicted aggravation of Western diet by BPA was observed; the effect was not seen in 10-
month females. This is consistent with previous reports of prenatal programming of metabolic 
disease by maternal HFD occurring in male offspring, without effect in females [19,101]. The 
Mediterranean+BPA diet had a distinctly different effect on mice at all ages. Among dams, 
Mediterranean+BPA exposure was similar to Western and Western+BPA effects, and associated 
with increased weight gain and hepatic TGs, but decreased serum insulin. Among PND10 
offspring of both sexes, however, adding BPA to the Mediterranean diet seemed protective 
against adipogenic effects of Mediterranean.  
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Interestingly, perinatal BPA exposure was also protective, when combined with maternal 
over-nutrition in a sheep model of perinatal exposure also [102,103]. We recently reported that 
prenatal exposure to BPA protected overfed sheep offspring from the increased blood pressure 
and greater left ventricle area observed in overfed offspring not exposed to BPA [102]. Gene 
network analysis identified a reversal of overfeeding effects on gene expression, by prenatal 
BPA exposure, at FABP4, A2M, APOD, HLA-C [104], suggestive of greater fatty acid uptake in 
adipocytes, more cytokine transport, and greater circulating high-density lipoproteins. Multiple 
animal models now suggest a diet*BPA interaction, so future perinatal BPA exposure studies 
should include multiple background diets to elucidate this interaction. Human populations are 
simultaneously exposed to BPA and a variety of diets; improved understanding this interaction 
may be critical for interpretation of epidemiologic data on BPA exposure.  
 
Challenges & Limitations 
 Assessing the impact of perinatal exposures across time in offspring can be challenging 
in the same mouse. In order to assess hepatic steatosis in offspring at multiple time points 
(PND10 and 10-months), an invasive biopsy procedure would have been required at PND10, to 
follow the same mouse to 10-months. Although liver tissue regenerates [105], we decided 
against this study design due to the added stress (metabolic and mental) that surgery induces. 
Instead we analyzed sex-matched littermates at PND10 and 10-months to approximate the effects 
over time. Non-invasive tissue samples could be collected at multiple time points from the same 
mouse to avoid the littermate challenge.  
 This study investigated phenotypic outcomes in dams, PND10, and 10-month offspring. 
However, subtle changes could have occurred due to perinatal exposures that would be apparent 
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at a molecular level. Perinatal exposure to both HFDs and BPA has been associated with 
alterations in epigenetic modifications and differential gene expression. Future analyses of 
nucleic acids may reveal changes in metabolic and/or hepatic regulation.  
 
Study Innovation & Future Directions 
 Due to widespread interest in perinatal programming of NAFLD, human birth cohorts 
and animal models are simultaneously exploring the epidemiological factors and molecular 
pathways involved in altering offspring health trajectories. However, most studies focus on 
offspring outcomes and do not explore the impact perinatal exposures can have on the directly 
exposed mothers. Mothers are commonly considered the route of exposure for a developing 
fetus, but the predictive power of maternal phenotype is often overlooked. In this study, dam pre-
gestational weight change and post-partum body weight impacted models predicting PND10 
hepatic TGs. Detailed characterization of maternal metabolic phenotype during pregnancy in 
human birth cohorts could provide additional insight into factors affecting perinatal 
programming. Maternal adaptation to a diet or chemical exposure may be triggering the altered 
health trajectory in offspring, not the exposure itself. For instance, we know maternal pre-
gestational weight increases risk of offspring metabolic dysregulation [8–11], maternal diet may 
be responsible for increased maternal pre-gestational weight, so the impacts attributed to the diet 
exposure, may actually result from the mom’s diet-altered weight status. 
 
 
CONCLUSION 
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In this study, we examined the potential role of perinatal diet and BPA, two common daily 
exposures, on developmental programming of NAFLD, assessed via hepatic TGs and associated 
metabolic outcomes. This is the first study, examining perinatal programming of NAFLD, to 
begin exposures prior to gestation, to provide diet and BPA exposures concurrently, and to 
investigate the potential interaction of BPA with multiple background diets. The differential 
response of dams, PND10 and 10-month offspring to the six experimental diets suggests that 
environmental exposures can exert dissimilar effects at different ages and life stages. The hepatic 
and metabolic effects of these perinatal diets differed not only by mouse age, but also by 
offspring sex and diet composition. The substantial impact of experimental diets on maternal 
phenotype and the subsequent effect of maternal phenotype on PND10 offspring hepatic TGs, 
suggests that detailed characterization of maternal factors would improve our understanding of 
developmental programming. To build on these insights, future studies should consider 
beginning perinatal exposures prior to gestation, continuing to explore diet*EDC interactions, 
including more detailed maternal phenotyping measures, increasing the number of offspring 
evaluations (between PND10 and 10-months), and incorporating molecular analyses with 
phenotypic outcomes.  
 
ACKNOWLEDGEMENTS 
We are grateful to the following individuals for providing their expert opinion and talents to 
make this study possible. Ms. Jessica Flowers at Harlan Teklad (now Envigo, Indianapolis, IN) 
for assistance designing the humanized experimental diets. Mr. Jason Whalen at the Michigan 
Diabetes Research Center (MDRC) Chemistry Lab for multiplexed hormone analysis on 10-
month offspring serum samples.  
  
67  
 
FUNDING INFORMATION 
This work was supported by the University of Michigan (UM) NIEHS/EPA Children’s 
Environmental Health and Disease Prevention Center P01 ES022844/RD83543601, the 
Michigan Lifestage Environmental Exposures and Disease (M-LEEaD) NIEHS Core Center 
(P30 ES017885), and the MDRC Chemistry Lab (P30 DK020572), as well as UM Institutional 
and Individual Training Grants T32 ES007062 (EHM), T32 HD079342 (EHM), and F31 
ES025101 (EHM). 
  
		 6ͺ	 	
Figure	2.1	Experimental	Design	of	Longitudinal	Mouse	Exposure	Study	
 Wild	type	(a/a),	virgin	dams	(8-10	weeks	of	age)	were	randomly	assigned	to	one	of	six	experimental	diets.	They	were	mate-paired	two	weeks	later	with	young	(7.5	week	old),	virile,	Avy/a	males.	Dams	remained	on	their	assigned	experimental	diet	throughout	pregnancy	and	lactation.	Offspring	were	exposed	to	the	diet	in	utero	and	via	mother’s	milk.	All	offspring	were	weaned	onto	the	Control	diet	at	postnatal	day	21	(PND21).	Thus,	10M	offspring	had	not	been	exposed	to	their	perinatal	experimental	diet	for	over	nine	months	at	the	time	of	sacrifice	and	tissue	collection.	Sacrifices	were	performed	at	three	time	points:	(1)	dams:	4	days	post-weaning	(PND25),	(2)	offspring:	at	PND10,	and	(3)	offspring:	at	10M.	
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Table 2.1 Composition of Experimental Diets: Mice Perinatal Exposures 
 
Diet Ingredients 
3 Experimental Mouse Diets 
Control Western  Mediterranean  
MACRONUTRIENTS 
Calories (Kcal/g chow) 3.98 4.72 4.53 
% Calories from Fat 16 40 42 
        PUFA : SFA : MUFA 1 : 0.2 : 0.5 1 : 1.9 : 1.6 1 : 1.3 : 5.6 
Protein (casein) (g/100g chow) 20 19 19 
Carbohydrate Content (g/100g chow)    
        Cornstarch 40 14 23 
        Sucrose 10 25.5 9.2 
        Cellulose 5 2 8 
VITAMINS & MINERALS 
Vitamin A (IU/kg chow) 4000 4000 8000 
Vitamin C (mg/kg chow) 0 0 500 
Vitamin D (IU/kg chow) 1000 400 1000 
Vitamin E (IU/kg chow) 75 25 75 
Folic Acid (mg/kg chow) 2 1 4 
Sodium (mg/kg chow) 1039 7000 1039 
Potassium (mg/kg chow) 3600 3600 8000 
Magnesium (mg/kg chow) 513 513 850 
 
The Control diet is equivalent to AIN-93G, except that corn oil replaced soybean oil as the 
source of fat. The experimental Mediterranean and Western diets were designed to reflect 
the nutrient content of human dietary patterns in Crete and the U.S., respectively. Nutrient 
content of the mouse diets were achieved on a per weight basis.  
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Figure 2.2 Lipid Composition of the Three Experimental Mouse Diets 
 
 
This figure illustrates the difference in lipid sources used to create each of the study’s three 
experimental diets. Corn oil was the sole lipid source in the Control diet. Saturated fats 
composed >60% of the Western diet, contributed largely by butter and palm oil. In the 
Mediterranean diet, olive oil was the main source; fish oil was also added to reflect the 
higher n-3 PUFA content of human Mediterranean diets. 
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Figure	2.2	Lipid	Composition	of	Three	Mouse	Experimental	Diets	
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Table 2.2 Reproductive Outcomes by Perinatal Exposure Group 
 
Reproductive Outcomes 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
Delivery Time (days) 
No 25.29 (10.00) 30.50 (12.04) 26.55 (9.23) 
0.2502 
n.s. Yes 24.62 (5.47) 30.67 (8.33) 28.56 (9.51) 
Litter Size (pups) 
No 7.20 (1.15) 7.43 (1.95) 6.85 (2.37) 
0.6141 n.s. 
Yes 6.52 (1.72) 6.53 (2.53) 7.38 (1.63) 
Dead Pups (pups / litter) 
No 0.73 (0.88) 0.64 (0.84) 1.25 (1.71) 
0.0223 Cont vs. CBPA = 0.0149 
Yes 2.00 (1.76) 1.33 (2.23) 0.38 (0.81) 
Live Pups (pups / litter) 
No 6.47 (0.99) 6.79 (1.76) 5.60 (2.60) 
0.0037 Cont vs. CBPA = 0.0075 
Yes 4.52 (2.66) 5.20 (2.04) 7.00 (1.59) 
Male Pups (% / litter) No 47.71 (19.58) 51.90 (16.12) 53.02 (17.56) 
0.8532 n.s. 
Yes 51.34 (23.20) 45.71 (20.90) 45.71 (20.90) 
Avy/a Offspring (% / litter) No 48.38 (17.10) 50.27 (17.28) 58.38 (17.80) 
0.4245 n.s. 
Yes 57.77 (28.14) 45.94 (27.43) 49.44 (14.32) 
 
*Only significant (p < 0.05) or borderline significant (p < 0.10) comparisons are provided; all others are not significant (p > 
0.10). The definition of the reproductive outcome variables presented in this table are as follows: ‘Delivery Time’ = the number 
of days from mate-pairing to delivery, ‘Litter Size’ = the number of pups initially delivered, ‘Dead Pups’ = the number of pups 
per litter that died within the first 3 days of life, ‘Live Pups’ = the number of pups per litter that were alive from day 3 onwards. 
Dam sample size varied slightly by experimental exposure group: Control = 15, Western = 14, Mediterranean = 20, 
Control+BPA = 21, Western+BPA = 15, Mediterranean+BPA = 16. 
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Figure 2.3 Dam Hepatic Triglyceride Levels, Four Days After Weaning Offspring (25 Days 
Post-Partum) 
 
 
Average hepatic triglycerides (TGs) in dams (n=97), four days after weaning offspring, by 
experimental exposure group. a Denotes the average TGs of Control dams; groups that do 
not differ significantly from Control are also marked with ‘a’. b Denotes exposure groups 
with average TGs that differ significantly (p < 0.05) from Control.   
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Figure 2.4 PND10 Offspring Hepatic Triglyceride Levels by Exposure Group 
 
 
Average hepatic triglycerides (TGs) in PND10 offspring (n = 118), by experimental 
exposure group: Panel A = female PND10 offspring (n = 60), Panel B = male PND10 
offspring (n = 58). a Denotes the average TGs of Control PND10 offspring; groups that do 
not differ significantly from Control are also marked with ‘a’. b Denotes exposure groups 
with average TGs that differ significantly (p < 0.05) from Control.   
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Table 2.3 Correlation of Three Hepatic Steatosis Measures in 10-Month Offspring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Pearson’s 
Correlation 
Hepatic TGs 
(mg/g) 
OilRedO  
(score) 
Vacuolation  
(score) 
Female 10-month Offspring 
Hepatic TGs (mg/g) Coefficient 1.000 0.4130 0.6189 
 p-value --- 0.0006 <0.0001 
OilRedO (score) Coefficient 0.4130 1.000 0.6453 
 p-value 0.0006 --- <0.0001 
Vacuolation (score) Coefficient 0.6189 0.6453 1.000 
 p-value <0.0001 <0.0001 --- 
Male 10-month Offspring 
Hepatic TGs (mg/g) Coefficient 1.000 0.2758 0.4163 
 p-value --- 0.0239 0.0005 
OilRedO (score) Coefficient 0.2758 1.000 0.5826 
 p-value 0.0239 --- <0.0001 
Vacuolation (score) Coefficient 0.4163 0.5826 1.000 
 p-value 0.0005 <0.0001 --- 
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Figure 2.5 Histopathologic Measures of Hepatic Steatosis at 10-Months 
 
 
Hepatic steatosis ranged from negligible to severe (>50% of tissue affected) in liver 
samples from the 10-month offspring. (A) OilRed0 staining, score 0: no visible lipid 
accumulation, (B) OilRedO staining, score 4: severe accumulation, (C) H&E staining, score 
1: minimal (<9% tissue affected), (D) H&E staining, score 4: severe. 
   
Figure	2.4	Histolopathologic	Measures	of	Hepatic	Steatosis	at	10-Months	
A B	
C	 D
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Table 2.4 Impact of Experimental Diet Exposure on Dam Hepatic Liver Triglyceride Levels 
25 Days Post-Partum. 
 
Experimental Diet 
Model 1 Model 2 Model 3 
Change in 
TGs 
p-value 
Change in 
TGs 
p-value 
Change in 
TGs 
p-value 
Western 15.49 0.0058 11.85 0.0343 11.24 0.0009 
Mediterranean 19.98 0.0002 18.65 0.0003 18.02 0.0518 
BPA 5.29 0.2918 6.37 0.1978 6.05 0.2279 
Western*BPA -9.71 0.1891 -8.76 0.2317 -8.63 0.2410 
Mediterranean*BPA -13.58 0.0589 -13.73 0.0503 -13.24 0.0634 
 
Linear mixed effect models with ‘Cohort’ as a random effect were run to assess the impact 
of experimental diet components and their interaction on dam (n=97) hepatic TG levels, 25 
days post-partum. Effect size p-values were bolded if significant (p < 0.05) or borderline 
significant (p < 0.10) to highlight the experimental diet components that contribute to 
model prediction of hepatic TG levels.  
• Model 1: includes only the experimental diet variables, no additional covariates.  
• Model 2: adjusted for dam body weight, 25 days post-partum.  
• Model 3: additionally adjusted for dam pre-gestational body weight change.  
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Table 2.5 Impact of Perinatal Experimental Diet Exposure on Hepatic Liver Triglyceride 
Levels in PND10 Offspring, Sex-Stratified 
 
Experimental Diet 
Model 1 Model 2 Model 3 
% Change 
TGs 
p-value 
% Change 
TGs 
p-value 
% Change 
TGs 
p-value 
Female PND10 Offspring 
Western -1.7 0.6680 -3.60 0.3820 -3.53 0.3926 
Mediterranean 6.7 0.1194 5.48 0.2034 6.14 0.1620 
BPA 2.2 0.6113 2.31 0.5836 3.38 0.4377 
Western*BPA 1.3 0.8214 2.71 0.6479 2.70 0.6489 
Mediterranean*BPA -7.3 0.2367 -6.47 0.2883 -8.02 0.2048 
Male PND10 Offspring 
Western 6.80 0.0265 5.47 0.0586 5.92 0.0543 
Mediterranean 17.75 <0.0001 17.43 <0.0001 18.16 < 0.0001 
BPA 4.53 0.1679 4.84 0.1165 5.29 0.1061 
Western*BPA -6.73 0.1396 -5.78 0.1678 -6.19 0.1539 
Mediterranean*BPA -12.29 0.0145 -11.77 0.0132 -12.73 0.0150 
 
Linear mixed effect models were run to assess the impact of perinatal experimental diet 
components and their interaction on Ln-transformed hepatic TG levels in PND10 offspring. 
Models were sex-stratified (female: n=48, male: n=55), and all included ‘Litter ID’ as a 
random effect. Effect size p-values were bolded if significant (p < 0.05) or borderline 
significant (p < 0.10) to highlight the experimental diet components that contribute to 
model prediction of hepatic TG levels.  
• Model 1 adjusted for litter size.  
• Model 2 additionally adjusted for dam body weight, 25 days post-partum.  
• Model 3 additionally adjusted for dam pre-gestational body weight change. 
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Table 2.6 Impact of Perinatal Experimental Diet Exposure on Hepatic Liver Triglyceride 
Levels in 10-month Offspring, Sex-Stratified 
 
Experimental Diet 
Model 1 Model 2 Model 3 
% Change 
TGs 
p-value 
% Change 
TGs 
p-value 
% Change 
TGs 
p-value 
Female 10-month Offspring 
Western 3.21 0.5067 4.08 0.3914 4.22 0.3765 
Mediterranean 0.69 0.8881 0.64 0.8944 0.59 0.9022 
BPA -4.13 0.4263 -3.66 0.4716 -2.55 0.6281 
Western*BPA 2.36 0.7378 1.74 0.8021 5.85 0.9341 
Mediterranean*BPA 15.28 0.0318 14.71 0.0355 15.21 0.0309 
Male 10-month Offspring 
Western -6.70 0.1430 -6.86 0.1344 -5.00 0.2639 
Mediterranean -1.99 0.6466 -2.09 0.6318 -1.27 0.7635 
BPA 2.39 0.6000 2.13 0.6415 2.32 0.5993 
Western*BPA 1.95 0.7649 1.07 0.8703 1.08 0.8644 
Mediterranean*BPA -5.00 0.4396 -4.75 0.4632 -3.40 0.5878 
 
Linear mixed effect models were run to assess the impact of perinatal experimental diet 
components and their interaction on Ln-transformed hepatic TG levels in 10-month 
offspring. Models were sex-stratified (female: n=65, male: n=67) and all included ‘Cohort’ 
as a random effect. Effect size p-values were bolded if significant (p < 0.05) or borderline 
significant (p < 0.10) to highlight the experimental diet components that contribute to 
model prediction of hepatic TG levels.  
• Model 1 adjusted for litter size.  
• Model 2 additionally adjusted for relative mWAT in 10-month offspring.  
• Model 3 additionally adjusted for the presence of nodular hyperplasia in 10-month 
offspring. 
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Supplemental Information 
 
 
Table S2.1 Complete Composition of Three Experimental Diets 
 
Ingredient  
Experimental Exposure Diets 
Control Western Mediterranean 
Main Ingredients (g/100g food) 
Fat Source 7 20.5* 21.4 
Casein 20 19 19 
Cornstarch 40 14 23 
Dyestrose 13.2 13.2 13.2 
Sucrose 10 25.5 9.2 
Cellulose 5 2 8 
Mineral Mix 3.5 3.8 3.8 
Vitamin Mix 1 1.1 1.1 
Composition of Fat Source (g/100g food) 
Corn Oil 100 29 4 
Butter, anhydrous 0 33 4 
Palm Oil 0 30 0 
Olive Oil 0 8 91 
Menheden (Fish) Oil 0 0 1 
Vitamins (unit/kg food) 
Nicotinic acid (mg) 30 30 30 
Pantothenate (mg) 15 15 15 
Pyridoxine (mg) 6 6 6 
Thiamin (mg) 5 5 5 
Riboflavin (mg) 6 6 6 
Folic acid (mg) 2 1 4 
Biotin (mg) 0.2 0.2 0.2 
Vitamin B12 (ug) 25 10 10 
Vitamin K (ug) 900 900 900 
Vitamin E (IU) 75 25 75 
Vitamin A (IU) 4000 4000 8000 
Vitamin D (IU) 1000 400 1000 
Choline (mg) 1000 1000 1000 
Vitamin C (mg) 0 0 500 
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Table S2.1 Complete Composition of Three Experimental Diets, Continued 
 
Ingredient  
Experimental Exposure Diets 
Control Western Mediterranean 
Minerals (unit/kg food) 
Calcium (mg) 5000 5000 5000 
Phosphorus (mg) 3000 3000 3000 
Magnesium (mg) 513 513 850 
Sodium (mg) 1039 7000 1039 
Potassium (mg) 3600 3600 8000 
Chloride (mg) 1631 1631 1631 
Sulfur (mg) 300 300 300 
Iron (mg) 45 45 45 
Zinc (mg) 38 38 38 
Manganese (mg) 10 10 10 
Copper (mg) 6 6 6 
Iodine (mg) 0.2 0.2 0.2 
Molybdenum (mg) 0.15 0.15 0.15 
Selenium (mg) 0.15 0.15 0.15 
Silicon (mg) 5 5 5 
Chromium (mg) 1 1 1 
Fluoride (mg) 1 1 1 
Nickel (mg) 0.5 0.5 0.5 
Boron (mg) 0.5 0.5 0.5 
Lithium (mg) 0.1 0.1 0.1 
Vanadium (mg) 0.1 0.1 0.1 
 
* Bolded text is used to emphasize nutrients in the Western and Mediterranean diet that 
differ significantly from the Control diet. These differences reflect nutrient differences in 
human Western and Mediterranean dietary intake patterns. 
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Figure S2.1 Pre-Gestational Body Weight Change in Dams by Exposure Group: First Two 
Weeks of Exposure 
 
 
Dams were exposed to one of six experimental diets for two weeks prior to mate-pairing. 
Body weight changed as the dams adjusted to their new diets. This figure illustrates the 
average weight change by exposure group; error bars denote the SEM for each group. a 
Denotes the average TGs of Control PND10 offspring; groups that do not differ significantly 
from Control are also marked with ‘a’. b Denotes exposure groups with average TGs that 
differ significantly (p < 0.05) from Control. c Denotes the exposure group with average TGs 
that differ from Control with borderline significance (p < 0.10). 
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Figure S2.2 Body Weight Change in Dams by Exposure Group: Initial Exposure to Offspring 
Weaning 
 
Dam body weight was measured at three times: (1) start of exposure to experimental diets, 
at 8-10 weeks of age, (2) at mate-pairing, two weeks later, (3) and four days after their 
pups were weaned (PND25). Mean body weight of dams in each exposure group is plotted 
above with the SEM designated by the error brackets.  
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Table S2.2 Dam Metabolic Outcomes  
 
Metabolic Outcomes in Dams 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
Exposure Body Weight (grams) 
No 19.10 (1.15) 18.97 (1.95) 19.22 (2.37) 
0.6141 n.s. 
Yes 18.91 (1.72) 18.64 (2.53) 18.64 (1.63) 
Mate-Pairing Body Weight (grams) 
No 18.55(0.88) 19.63 (0.84) 19.66 (1.71) 
0.0223  
Yes 18.68 (1.76) 19.42 (2.23) 18.74 (0.81) 
Post-Weaning Body Weight (grams) 
No 25.99 (2.54) 27.84 (4.10) 27.17 (1.91) 
0.0960 Cont vs. West = 0.0728 
Yes 25.45 (2.13) 27.25 (2.54) 25.86 (2.46) 
Exposure Weight Change (grams) 
 
No 
 
-0.55 (0.99) 
 
0.66 (0.91) 
 
0.39 (0.86) 
0.0004 
Cont vs. West = 0.0006 
Cont vs. WBPA = 0.0001 
Cont vs Med = 0.0062 
Cont vs. MBPA = 0.0560 
Yes -0.22 (1.14) 0.79 (1.08) 0.15 (1.17) 
Pregnancy Weight Change (grams) 
No 7.46 (1.92) 9.01 (3.35) 7.26 (1.43) 
0.1420 Cont vs. West = 0.0903 
Yes 6.62 (3.01) 7.65 (2.49) 7.07 (1.99) 
Relative Liver Weight  
(liver weight / body weight) 
No 0.054 (0.007) 0.055 (0.007) 0.050 (0.006) 
0.1446 Cont vs. Med = 0.0842 
Yes 0.054 (0.007) 0.051 (0.008) 0.055 (0.009) 
Relative Mesenteric Adipose Weight 
(MAT weight / body weight) 
No 0.025 (0.005) 0.033 (0.008) 0.028 (0.008) 
0.0065 
Cont vs. West = 0.0035 
Cont vs. WBPA = 0.0078 Yes 0.026 (0.007) 0.032 (0.010) 0.025 (0.006) 
Serum Insulin Levels (ng/dL) 
No 2.64 (2.60) 1.33 (0.54) 1.69 (1.28) 
0.1913 
Cont vs. West = 0.0433 
Cont vs. WBPA = 0.0730 
Cont vs. MBPA = 0.0782 
Yes 2.41 (1.46) 1.59 (1.17) 1.59 (1.03) 
Serum Leptin Levels (ng/dL) 
No 5.16 (4.20) 4.54 (2.46) 5.63 (4.34) 
0.9598 n.s. 
Yes 5.93 (4.28) 5.76 (3.99) 5.59 (3.92) 
Hepatic TG levels (mg/g) 
 
No 14.64 (12.11) 29.66 (15.66) 34.98 (16.60) 
0.0030 
Cont vs. West = 0.0077 
Cont vs. WBPA = 0.0410 
Cont vs. Med = 0.0001 
Cont vs. MBPA = 0.0365 
Yes 20.24 (15.00) 25.48 (13.98) 25.74 (13.17) 
 
*Only significant (p < 0.05) or borderline significant (p < 0.10) comparisons are shown; all others are not significant (n.s.). 
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Table S2.3 PND10 Offspring Metabolic Outcomes  
 
Metabolic Outcomes 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
PND10 Female Offspring 
PND10 Body Weight (grams) 
No 5.97 (0.54) 5.71 (0.75) 5.34 (0.95) 
0.5371 Cont vs. Med = 0.0955 
Yes 5.43 (1.14) 5.55 (0.90) 5.89 (1.17) 
Relative Liver Weight  
(liver weight / body weight) 
No 0.030 (0.003) 0.029 (0.005) 0.030 (0.005) 
0.4358 n.s. 
Yes 0.029 (0.005) 0.032 (0.008) 0.027 (0.004) 
Serum Leptin Levels (ng/dL) 
No 3.40 (2.13) 2.15 (1.60) 8.84 (6.77) 
0.0668 Cont vs. Med = 0.0284 
Yes 5.47 (4.38) 7.21 (6.93) 7.48 (6.42) 
Hepatic TG levels (mg/g) 
No 3.68 (2.50) 2.34 (1.23) 5.71 (2.42) 
0.1859 n.s. 
Yes 4.01 (3.26) 4.63 (3.45) 5.04 (2.63) 
PND10 Male Offspring 
PND10 Body Weight (grams) 
No 5.78 (0.67) 5.71 (0.99) 5.59 (0.89) 
0.2075 Cont vs. CBPA = 0.0434 
Yes 4.74 (0.74) 5.98 (1.33) 5.44 (1.59) 
Relative Liver Weight  
(liver weight / body weight) 
No 0.026 (0.004) 0.027 (0.006) 0.031 (0.004) 
0.3109 Cont vs. Med = 0.0691 
Yes 0.026 (0.005) 0.029 (0.005) 0.026 (0.007) 
Serum Leptin Levels (ng/dL) 
No 2.40 (3.23) 4.62 (5.65) 11.55 (7.82) 
0.0063 Cont vs. Med = 0.0011 
Yes 1.66 (1.80) 3.91 (2.71) 5.38 (5.23) 
Hepatic TG levels (mg/g) 
No 1.63 (0.60) 4.56 (5.26) 11.93 (9.17) 
0.0007 
Cont vs. Med < 0.0001 
Cont vs. MBPA = 0.0803 Yes 2.85 (1.38) 2.73 (1.07) 5.09 (2.71) 
 
*Only significant (p < 0.05) or borderline significant (p < 0.10) comparisons are shown; all others are not significant (n.s.).  
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Table S2.4 10-Month Offspring Metabolic Outcomes 
 
Metabolic Outcomes 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
10-month Female Offspring 
Body Weight (grams) 
No 32.92 (8.02) 35.44 (8.23) 36.50 (7.48) 
0.7765 n.s. 
Yes 34.25 (6.94) 32.85 (5.97) 35.46 (4.48) 
Relative Liver Weight  
(liver weight / body weight) 
No 0.031 (0.007) 0.038 (0.006) 0.038 (0.006) 
0.0356 
Cont vs. West = 0.0122,  
Cont vs. WBPA = 0.0166, 
Cont vs. Med = 0.0092 
Yes 0.033 (0.005) 0.037 (0.007) 0.034 (0.007) 
Relative Mesenteric Adipose Weight 
(MAT weight / body weight) 
No 0.040 (0.014) 0.037 (0.011) 0.040 (0.013) 
0.8011 n.s. 
Yes 0.038 (0.008) 0.036 (0.008) 0.043 (0.015) 
Serum Leptin (ng/dL) 
No 8.47 (4.33) 8.90 (5.55) 12.54 (6.26) 
0.3579 n.s. 
Yes 8.62 (3.21) 10.60 (5.20) 11.16 (4.31) 
Serum Insulin (ng/dL) 
No 1.59 (1.58) 2.58 (3.95) 3.22 (2.35) 
0.6845 n.s. 
Yes 1.95 (3.16) 2.98 (2.67) 1.86 (0.88) 
Serum Resistin (ng/dL) 
No 1.99 (9.63) 2.47 (1.29) 2.56 (1.09) 
0.1663 n.s. 
Yes 1.88 (0.55) 2.07 (0.72) 1.63 (0.42) 
Serum PAI-1 (ng/dL) 
No 7.73 (1.91) 6.82 (4.20) 6.13 (2.55) 
0.0020 Cont vs. MBPA = 0.0043 
Yes 7.89 (2.55) 6.73 (2.71) 12.37 (5.59) 
Hepatic Triglycerides (mg/g) 
No 5.79 (4.30) 8.10 (7.11) 7.47 (8.16) 
0.1228 Cont vs. MBPA = 0.0118 
Yes 6.64 (8.72) 7.13 (7.72) 13.62 (5.45) 
 
  
  
86  
Table S2.4 10-Month Offspring Metabolic Outcomes, continued 
 
Metabolic Outcomes 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* 
Control Western Mediterranean 
10-month Male Offspring 
Body Weight (grams) 
No 43.41 (5.49) 44.15 (4.89) 45.69 (5.53) 
0.5703 Cont vs. WBPA = 0.0846 
Yes 44.30 (2.40) 46.78 (4.16) 44.70 (4.77) 
Relative Liver Weight  
(liver weight / body weight) 
No 0.036 (0.009) 0.041 (0.007) 0.043 (0.016) 
0.6172 n.s. 
Yes 0.039 (0.010) 0.039 (0.004) 0.038 (0.009) 
Relative Mesenteric Adipose Weight 
(MAT weight / body weight) 
No 0.034 (0.006) 0.034 (0.010) 0.035 (0.008) 
0.1575 Cont vs. WBPA = 0.0235 
Yes 0.036 (0.010) 0.041 (0.007) 0.033 (0.007) 
Serum Leptin (ng/dL) 
No 10.02 (3.09) 12.74 (4.51) 14.63 (4.51) 
0.0448 
Cont vs. WBPA = 0.0021 
Cont vs. Med = 0.0213 
Cont vs. MBPA = 0.0965 
Yes 11.93 (6.35) 16.13 (4.12) 13.24 (5.11) 
Serum Insulin (ng/dL) 
No 5.02 (3.77) 5.48 (3.04) 6.11 (3.44) 
0.9551 n.s. 
Yes 5.20 (2.62) 6.23 (2.84) 5.91 (5.26) 
Serum Resistin (ng/dL) 
No 1.23 (0.60) 1.64 (0.74) 1.57 (0.55) 
0.0496 Cont vs. WBPA = 0.0046 
Yes 1.25 (0.45) 2.00 (0.78) 1.38 (0.63) 
Serum PAI-1 (ng/dL) 
No 11.40 (6.98) 8.41 (3.48) 8.96 (4.74) 
0.5564 Cont vs. WBPA = 0.0774 
Yes 10.07 (6.01) 7.78 (4.40) 8.98 (2.69) 
Hepatic Triglycerides (mg/g) 
No 9.38 (8.59) 4.85 (4.05) 10.66 (10.37) 
0.1815 n.s. 
Yes 13.52 (10.41) 7.61 (5.96) 6.39 (6.59) 
 
*Only significant (p < 0.05) or borderline significant (p < 0.10) comparisons are shown; all others are not significant (n.s.).  
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Table S2.5 10-Month Offspring Hepatic Lesions Assessed via Histopathology 
Hepatic Lesion 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
10-month Female Offspring 
Continuous Variables: Mean (SD) 
Oil Red O 
No 2.10 (0.57) 1.58 (1.31) 1.91 (1.04) 
0.0591 Cont vs. WBPA = 0.0124 
Yes 1.67 (1.12) 0.91 (0.83) 2.25 (1.22) 
Hepatocellular Vacuolation 
No 1.50 (0.85) 1.25 (1.29) 1.55 (1.37) 
0.0424 Cont vs. MBPA = 0.0258 
Yes 1.56 (1.01) 1.18 (1.25) 2.58 (0.69) 
Hepatocellular Hypertrophy 
No 2.30 (1.70) 1.50 (1.38) 0.91 (1.30) 
0.0231 
Cont vs. WBPA = 0.0096 
Cont vs. Med = 0.0291 Yes 1.33 (1.22) 0.64 (1.03) 2.42 (1.73) 
Proliferative 
No 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
0.0061 
Cont vs. CBPA = 0.0063 
Cont vs. MBPA = 0.0263 Yes 0.44 (0.73) 0.00 (0.00 0.33 (0.49) 
Non-Proliferative 
 
No 4.30 (4.11) 1.58 (2.15) 1.27 (1.10) 
0.0132 
Cont vs. West = 0.0217 
Cont vs. WBPA = 0.0153 
Cont vs. Med = 0.0126 
Cont vs. BPA = 0.0819 
Yes 2.11 (2.57) 1.36 (1.21) 4.33 (3.63) 
Discrete Variables (Presence/Absence): Frequency (%) 
Chi-squared 
p-value 
 
Adenoma  
No 0 0 0 
n.s. n.s. 
Yes 0 0 0 
Nodular Hyperplasia  
No 0/10 (0.00) 0/12 (0.00) 0/11 (0.00) 
0.0122 n.s. 
Yes 2/9 (22.22) 0/11 (0.00) 4/12 (33.33) 
Oval Cell Hyperplasia 
No 5/11 (45.45) 1/12 (8.33) 1/12 (8.33) 
0.0094 n.s. 
Yes 3/11 (27.27) 1/11 (9.09) 8/12 (66.67) 
Kupffer Cell Hyperplasia 
No 5/11 (45.45) 1/12 (8.33) 2/12 (16.67) 
0.0299 n.s. 
Yes 2/11 (18.18) 2/11 (18.18) 8/12 (66.67) 
Cell Infiltrates 
No 8/11 (72.73) 9/12 (75.00) 9/12 (75.00) 
0.7327 n.s. 
Yes 7/11 (63.64) 9/11 (81.82) 11/12 (91.67) 
Eosinophilic Foci 
No 0/11 (0.00) 0/12 (0.00) 0/12 (0.00) 
0.3398 n.s. 
Yes 1/11 (9.09) 0/11 (0.00) 0/12 (0.00) 
Mixed Cell Foci 
No 0 0 0 
n.s. n.s. 
Yes 0 0 0 
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Table S2.5 10-Month Offspring Hepatic Lesions Assessed via Histopathology, continued 
 
Hepatic Lesion 
Perinatal 
BPA 
Exposure 
Experimental Diet: Mean (SD) 
ANOVA 
p-value 
Tukey’s 
p-values* Control Western Mediterranean 
10-month Male Offspring 
Continuous Variables: Mean (SD) 
Oil Red O 
No 1.67 (0.98) 1.40 (0.52) 1.83 (1.19) 
0.7078 n.s. 
Yes 1.90 (1.20) 1.75 (1.06) 2.08 (0.79) 
Hepatocellular Vacuolation 
No 1.50 (1.38) 1.40 (0.97) 1.80 (1.23) 
0.9471 n.s. 
Yes 1.58 (1.00) 1.75 (0.75) 1.75 (1.14) 
Hepatocellular Hypertrophy 
No 2.25 (1.22) 2.30 (1.42) 2.20 (1.55) 
0.3538 Cont vs. WBPA = 0.0478 
Yes 2.75 (1.29) 1.67 (1.07) 2.75 (1.36) 
Proliferative 
No 0.83 (1.27) 0.50 (0.85) 1.10 (1.45) 
0.5303 n.s. 
Yes 1.10 (1.45) 0.75 (1.22) 0.25 (0.62) 
Non-Proliferative 
No 6.33 (5.00) 2.80 (3.65) 4.00 (4.82) 
0.1704 
Cont vs. WBPA = 0.0136 
Cont vs. West = 0.0573 Yes 4.60 (4.06) 1.92 (2.64) 5.00 (4.77) 
Discrete Variables (Presence/Absence): Frequency (%) 
Chi-squared 
p-value 
Tukey’s 
p-values* 
Adenoma  
No 1/12 (8.33) 2/12 (16.67) 2/10 (20.00) 
0.4076 n.s. 
Yes 3/10 (30.00) 3/12 (25.00) 0/12 (0.00) 
Nodular Hyperplasia  
No 7/12 (58.33) 5/12 (41.67) 3/10 (30.00) 
0.2804 n.s. 
Yes 5/10 (50.00) 3/12 (25.00) 2/12 (16.67) 
Oval Cell Hyperplasia 
No 7/12 (58.33) 4/12 (33.33) 2/10 (20.00) 
0.1349 n.s. 
Yes 5/11 (45.45) 6/12 (50.00) 1/12 (8.33) 
Kupffer Cell Hyperplasia 
No 7/12 (58.33) 4/12 (33.33) 2/10 (20.00) 
0.1826 n.s. 
Yes 6/11 (54.55) 6/12 (50.00) 2/12 (16.67) 
Cell Infiltrates 
No 10/12 (83.33) 10/12 (83.33) 9/10 (90.00) 
0.8363 n.s. 
Yes 8/11 (72.73) 10/12 (83.33) 10/12 (83.33) 
Eosinophilic Foci 
No 0/12 (0.00) 1/12 (8.33) 0/10 (0.00) 
0.2093 n.s. 
Yes 2/11 (18.18) 0/12 (0.00) 0/12 (0.00) 
Mixed Cell Foci 
No 0/12 (0.00) 1/12 (8.33) 0/10 (0.00) 
0.6153 n.s. 
Yes 0/11 (0.00) 1/12 (8.33) 1/12 (8.33) 
*Only significant (p < 0.05) or borderline significant (p < 0.10) comparisons are shown; all others are not significant (n.s.). 
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Figure S2.3 Variation in Body Size, Liver Health and Mesenteric Adiposity at 10-Months 
 
A female and male mouse perinatally exposed to the Control+BPA diet had very different 
hepatic responses to the exposure. The female mouse (left) weighed only 25.1g, had a 
relative liver weight of 3.6%, relative MAT weight of 2.1%, and a dark red, healthy liver 
with only minimal vacuolation and hypertrophy. In contrast, the male mouse (right) 
weighed 47.4g, had a relative liver weight of 5.9%, relative MAT weight of 3.3%, and a 
yellowish-pink liver, riddled with masses and moderate to severe hyperplasia. This 
example is indicative of the range of responses observed within the same perinatal 
exposure group, across all study groups. So although many hepatic outcomes did not differ 
by perinatal exposure, there was a wide range of responses among the individual study 
animals. 
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CHAPTER 3 
 
Perinatal High Fat Diets and Bisphenol A Exposure  
Differentially Alters Maternal Metabolic Parameters that  
Affect Metabolic Health and Redox Markers in Postnatal Offspring 
 
 
ABSTRACT 
Metabolic diseases can be developmentally programmed, with exposures during perinatal 
development altering life long disease risk. Perinatal exposure to bisphenol A (BPA), a 
ubiquitous high production volume chemical used in polycarbonate plastics and epoxy resins, 
has been associated with perinatal metabolic programming and alterations in tissue oxidation. 
Maternal high fat diet (HFD) during pregnancy is known to alter offspring metabolic health, but 
the potential for HFD to modify perinatal BPA exposure has not been examined. This study 
investigated whether perinatal exposure to BPA and HFDs altered offspring metabolic health at 
postnatal day 10 (PND10) and 10-months, and whether these alterations were accompanied by 
changes in the hepatic redox environment or markers of lipid peroxidation. Dams were 
randomized to one of six experimental diets from pre-gestation through lactation; a Control diet, 
one of two HFDs, or each of these diets with 50 g BPA/kg diet added. Offspring were weaned 
onto the Control diet and followed to postnatal day 10 (PND10) or 10-months of age. Perinatal 
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exposure to HFD increased body weight and relative mWAT weight in dams and 10-month 
offspring; serum leptin levels were elevated in HFD-exposed offspring at PND10 and 10-
months. This impact of perinatal HFD extended to hepatic lipid peroxidation, with elevated 8-
isoprostane-prostaglandin F2 (8-iso-PGF2) levels observed in offspring perinatally exposed to 
HFDs. Hepatic S-glutathionylation (S-glut), protein-bound glutathione, was highly variable but 
decreased in HFD-exposed dams and 10-month female offspring. Glutathione and cysteine redox 
potentials (EhGSH and EhCys) were not impacted by perinatal HFD, but perinatal BPA exposure 
was associated with more oxidizing EhGSH in PND10 females. Perinatal BPA did not have the 
anticipated detrimental effect on offspring metabolic health or hepatic lipid peroxidation. In this 
study, a human-relevant dose of BPA did not perinatally program alterations in metabolic health, 
hepatic redox environment, or lipid peroxidation; the minimal impact only occurred at PND10, 
while offspring were still exposed to BPA. Perinatal HFD did have programming effects, 
consistently altering metabolic health and hepatic 8-iso-PGF2 at PND10 and 10-months, but 
there was no evidence of diet-modification of BPA effects. Hepatic redox potentials at 10-
months did not differ by perinatal exposure, suggesting the redox environment was not 
perinatally programmed, but likely remains sensitive to ongoing changes in physiologic and 
postprandial states, and environmental stressors. 
 
INTRODUCTION 
 Prevalence of chronic metabolic diseases is increasing worldwide. Metabolic disease 
risk can be elevated due to perinatal exposures [1–3]. This process, known as 
developmental programming, proposes that in utero exposures can alter lifelong offspring 
health trajectory [4,5]. Perinatal exposures to bisphenol A (BPA) and to a maternal high fat 
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diet (HFD) have both been associated with increased risk of offspring metabolic disease.  
Perinatal BPA exposure has been associated with increased body weight, adiposity, 
impaired glucose homeostasis and insulin resistance in offspring [6,7]. Maternal HFD 
during pregnancy has been correlated with altered birth weight, growth trajectory, 
neuroendocrine function, and energy homeostasis [8–10]. Metabolic disease has been 
associated with a classical definition of oxidative stress [11,12], whereby an imbalanced 
redox environment leads to a preponderance of oxidizing equivalents. However, these 
classical oxidative stress biomarkers only provide a qualitative characterization, whereas 
intracellular redox potentials (Eh) are a more sensitive gauge of overall redox environment 
[13–16]. Under normal, healthy conditions, the post-translational modifications of protein 
thiol groups into reduced and oxidized states occurs in stable non-equilibrium [14,17,18].  
As this homeostatic balance shifts towards a more oxidized environment, protein thiol 
groups oxidize, which can alter protein function, thus disrupting cell signaling and redox 
sensing [14,18]. Perinatal programming of Eh has not been investigated.    
Perinatal exposure to bisphenol A (BPA) is associated with altered developmental 
programming of metabolic disease [6,19–23] and with increased classic measures of 
oxidation in adult mice [24–27]. Free BPA can induce reactive oxygen species (ROS) via 
enzymatic (peroxidase/H2O2, CYP450/NADPH) and non-enzymatic (HOCl/-OCL, 
CO2/peroxynitrite) radical generation [28–31]. Levels of other radical species (peroxides, 
superoxides, and hydroxyl radicals) are often observed following BPA exposure, likely due 
to ROS acting on intracellular glutathione or NADPH [29,30]. However these measures do 
not give insight into the redox environment; the impact of BPA exposure on redox 
parameters has never been examined. BPA has been shown to cross the placenta and is 
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measureable in breast milk in both human and murine models [32–35], making it an good 
model exposure to study for potential impact on perinatal programming of tissue oxidation. 
BPA is a synthetic, high-production volume chemical, used in a wide range of consumer 
products including the polycarbonate plastics and epoxy resins used in food packaging 
[36,37]. Therefore, a substantial portion of human BPA exposure occurs via ingestion. 
These combined factors suggest that maternal ingestion of a human-relevant dose of BPA 
during the perinatal period would be an ideal way to test whether developmental 
programming of hepatic redox imbalance and lipid oxidation can occur. 
Maternal diet during pregnancy has also been linked to altered risk of metabolic 
disease in offspring [8,9,38]. Among adult rodents and humans, Western-style HFDs have 
been associated with increased classical oxidative stress measures across a variety of tissue 
types, including liver [39–44].  Western HFDs contain high total and saturated fat, high 
sugar / low fiber, high salt, and low antioxidant content [45–48]. On the other hand, a 
Mediterranean-style HFD has been clinically recommended to prevent, slow or reverse 
progression of metabolic disease [49], due to the associations of Mediterranean diet 
consumption with improved insulin sensitivity, reduction in hepatic steatosis, plasma lipids 
and oxidative stress in adults [50–54]. A Mediterranean HFD contains a comparable 
percent of total fat as Western HFDs, but monounsaturated fat from olive oil is the main 
component not saturated fat; the diet is also characterized by high fiber, low salt, and high 
micronutrient content [55–57]. In human adults, adherence to a Mediterranean diet has 
been associated with decreased oxidative stress, measured by an increased GSH/GSSG ratio 
[58].  However, a complete Mediterranean diet has not been investigated in animal models, 
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so the potentially disparate effect of the two HFDs, on the perinatal programming of 
offspring oxidative outcomes, has not yet been examined.  
 To date, studies analyzing the association between metabolic health and oxidative 
response or examining the response to BPA or HFD exposures have used the classical 
measures of oxidative stress mentioned above. Unfortunately, these measures are usually 
qualitative, characterizing the downstream responses to elevated ROS, without shedding 
light on the redox environment. To address this gap, direct quantification of the redox 
environment based on changes in the GSH/GSSG and Cys/CySS redox couples has been 
proposed [14–16,59]. Intracellular GSH is considered the most reliable indicator of changes 
in intracellular redox state because of its abundance and direct involvement in cellular 
redox biochemistry [60]. Measuring thiol concentrations is critical to understanding the 
redox environment, but levels of these thiols fluctuate considerably over time [61,62]. 
Calculating Eh, from intracellular thiol concentrations, provides a useful measure of steady 
state perturbations, which can trigger altered intracellular signaling, changes in protein 
activity, or transcriptional regulation [14–16]. The redox environment is tightly controlled 
to maintain homeostasis. Rapid response of thiols to oxidative insults is expected, but due 
to their short turnover time, they quickly maintain stable non-equilibrium, which would 
suggest that redox environment could not be perinatally programmed. A recent study 
examining perinatal exposure to phthalates used Eh to examine embryonic alterations 
following perinatal exposure [62], so this study will build on that precedent.  
 A common measure of lipid peroxidation, F2-isoprostane, 8-iso-prostaglandin F2,  
(8-iso-PGF2), has been used to examine oxidative outcomes during pregnancy and birth 
[63–65]. Since prenatal programming was not expected to alter the redox environment, 8-
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iso-PGF2 will also be measured in this study, to determine if this lipid metabolism marker 
can be impacted by perinatal exposures. Urinary and plasma 8-iso-PGF2 have been widely 
used in human epidemiologic studies [11,66]. Despite its widespread use as a marker of 
lipid peroxidation, and its identification by the NIEHS Biomarkers of Oxidative Stress Study 
(BOSS) as an ideal marker [67–69], 8-iso-PGF2 has inaccurately been assumed to be 
exclusively associated with increased reactive oxygen species (ROS) because they are often 
positively correlated, but the direct connection is rarely measured. The half-life of serum 8-
iso-PGF2 is 4-6 minutes in rodents, suggesting that elevated ROS levels would need to be 
maintained for extended periods if the 8-iso-PGF2 were actually formed predominantly 
from the non-enzymatic free radical initiated peroxidation of arachidonic acid [59,70]. 
Recent findings suggest that 8-iso-PGF2 may also result from prolonged inflammation, 
catalyzed by the ROS-independent prostaglandin-endoperoxidase synthetase (PES) [59,70]. 
This inflammation-induced mechanism for lipid peroxidation/lipid metabolism is most 
likely to remain relevant over the longer-term evaluation periods used in this longitudinal 
study design.  
Since prenatal programming has become a concern in the rising prevalence of 
metabolic diseases, it is timely to examine if alterations in redox environment occurred, 
indicating a potential programming of lifelong redox response. To examine whether 
offspring hepatic redox environment or lipid peroxidation could be perinatally 
programmed by maternal diet or BPA, we designed a perinatal exposure study with 
longitudinal offspring follow-up. BPA, a daily exposure for many U.S. women, shares an oral 
route of exposure with maternal diet, so it was incorporated into diet pellets, to examine 
the impact of various diets (Control, Mediterranean, and Western) with and without 
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simultaneous BPA exposure. Hepatic redox environment was assessed by redox potentials 
(EhGSH, EhCys) and S-glutathionylation (S-glut), while hepatic lipid peroxidation was 
measured by 8-isoprostane-prostaglandin F2 (8-iso-PGF2) to determine if redox 
parameters and inflammation-induced lipid peroxidation responded similarly to perinatal 
exposures. This is the first study to examine the potential for perinatal programming of 
redox parameters by two common developmental exposures, BPA and maternal diet. 
Examining oxidative responses in dams and offspring at two time points, postnatal day 10 
(PND10) and 10-months, provided further insight into the impact perinatal exposures can 
have across generations and in offspring across time. This study aimed to explore whether 
perinatal BPA and HFD exposures could: affect the hepatic redox environment of offspring 
postnally, impact hepatic lipid peroxidation in offspring across time, and if changes in 
redox environment or lipid peroxidation were associated with alterations in offspring 
metabolic health. 
 
METHODS 
Experimental Design 
This study used mice from a viable yellow agouti (Avy) mouse colony, maintained for 
over 250 generations. Mating of agouti males (Avy/a) with wild type females (a/a) maintains 
forced heterozygosity of the Avy allele. Agouti mice have been extensively characterized 
previously [71,72]. Briefly, litter composition approximates 50% Avy/a and 50% a/a offspring; 
Avy/a mice, heterozygous for the Avy allele, display a range of coat colors from yellow, mottled, 
to pseudoagouti and develop obesity and diabetes in adulthood. Coat color and disease severity 
vary based on epigenetic marks in the cryptic promoter of the Agouti gene. Wild type a/a mice 
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have black coats and remain lean throughout life [73–76]. This study only followed a/a offspring 
to avoid potential confounding from adult-onset obesity and diabetes in Avy/a mice. Per the 
Institute for Laboratory Animal Research (ILAR) guidelines [77], mice were treated humanely, 
provided enrichment in their polycarbonate-free cages, and given ad libitum access to food and 
water 24 hours a day, in a climate-controlled room with a 12-hour light-dark cycle. The study 
protocol was approved by the University of Michigan’s University Committee on Use and Care 
of Animals (UCUCA) [78]. 
Virgin, 8-10 week old, a/a dams were randomly assigned to one of six experimental 
diets: Control, Control + 50 g BPA/kg diet, Mediterranean, Mediterranean + 50 g BPA/kg, 
Western, or Western + 50 g BPA/kg diet. Dams were mate-paired with young, virile Avy/a 
males (average: 7.5 weeks old) and remained on their assigned experimental diet throughout 
pregnancy and lactation. At postnatal day 21 (PND21), all offspring were weaned onto the 
Control diet with TBHQ (Figure 3.1). Offspring were followed to two static time points of 
analysis. To standardize measurements and normalize diurnal fluctuations, all sacrifices were 
conducted in the afternoon (2-5pm) and 10-month females were sacrificed while in estrus, 
determined by vaginal cytology [79].  
To assess the potential for perinatal exposures to program alterations in hepatic Eh and 
lipid peroxidation in adult offspring, one male and one female a/a pup per litter were followed to 
10-months of age. Agouti mice at 10-months are analogous to middle aged humans [80], 
providing insight into adult offspring health prior to aging-related declines. All other a/a pups 
were sacrificed at postnatal day (PND10). In rodents, serum leptin levels surge at PND10 [81]; 
this surge has been associated with hypothalamic programming, that may alter satiety, food 
intake, and energy homeostasis for the offspring’s lifespan [82,83]. Thus, alterations in leptin 
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levels at PND10 could impact offspring metabolic health into adulthood. PND10 data provides 
insight at an early time point, when young offspring are still exposed to the experimental diets 
via mother’s milk, and provides a comparison for metabolic outcomes among 10-month 
offspring. 
 
Experimental Diet Composition 
 The Control diet was a modification of the standard AIN93G mouse diet [84,85]. Corn oil 
replaced soybean oil in the Control diet to prevent potential developmental programming by 
phytoestrogens in soybean oil (the standard fat source in AIN93G), [86,87]. The Western and 
Mediterranean experimental diets differed from Control in their lipid, carbohydrate, vitamin, and 
mineral compositions, reflecting distinctions in human dietary patterns. Casein was the sole 
source of protein and was consistently provided in all three experimental diets. The Western diet, 
based upon NHANES II dietary intake data [47,48], simulated U.S. dietary intake with high 
saturated fat, sugar, and sodium but low fiber and antioxidant content. In contrast, the 
Mediterranean diet was based on the traditional Cretan diet, which includes high fruit, vegetable, 
and nut intake [56,57,88]. Mouse diets were designed on a nutrient / kg weight basis at the 
University of Michigan and were manufactured by Harlan Teklad (Madison, WI). Additional 
information on diet formulation has been previously reported (Chapter 2).  
A human-relevant, oral dose of BPA was incorporated into the pelleted mouse diets. A 
previous study, using mice from this same agouti colony, reported that 50 g BPA/kg diet 
produced an average 2.02 ng BPA/g liver [89]; this falls within the range of BPA levels assessed 
in human fetal liver samples (< LOQ to 96.8 ng BPA/g liver) [35]. BPA, supplied by the 
National Toxicology Program (NTP, Durham, NC), was mixed into sucrose in glass containers to 
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create a 0.1% BPA/sucrose mixture. Harlan Teklad, incorporated this BPA mixture into three of 
the six experimental diets at 0.05 g/kg, creating in the Control+BPA, Mediterranean+BPA, and 
Western+BPA diets. 
To avoid masking the impact of perinatal BPA and HFD on tissue Eh and lipid 
peroxidation, TBHQ was removed from all six perinatal experimental diets. The preservative 
tert-butylhydroquinone (TBHQ) has potent antioxidant properties that prevent fatty acid 
rancidity in chow, thereby increasing shelf life [84,85]. TBHQ potently activates nuclear factor 
erythroid factor 2 (Nrf2), a redox sensitive transcription factor that binds to antioxidant response 
elements (ARE) in genes involved in responding to oxidative injury and inflammation [90]. Nrf2 
activation by TBHQ has been associated with preserving microvascular endothelial function 
[91], attenuating hypertension and inflammatory response in the paraventricular nucleus [92], 
and decreasing hepatic ischemia-reperfusion injury [93], in murine models. This dissertation was 
designed to investigate the lifelong impact of perinatal exposure to BPA and/or HFD, so the 
exposures ended and TBHQ removal was no longer necessary once offspring transitioned out of 
the perinatal period. 
 
Body Weight and Tissue Collection  
 Dam body weight was recorded at three times: initial exposure (pre-gestation), mate-
pairing (2 weeks after exposure), and sacrifice (4 days post-weaning). Dam pre-gestational 
weight change (initial exposure to mate-pairing) and gestational weight gain (mate-pairing to 
sacrifice) were calculated from the three dam body weight measures. PND10 and 10-month 
offspring body weights were recorded at sacrifice only. Liver and mesenteric white adipose 
tissue (mWAT) were recorded for dams and 10-month offspring. At PND10, mice have 
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negligible mWAT, so only liver weights were recorded. Percent liver and mWAT weights were 
calculated by: absolute organ weight / total body weight * 100%. All body and organ weights 
were measured using a SLF103 balance (Fisher Scientific), to the hundredths digit. 
During necropsy, the liver was dissected and separated by lobe; all analyses were 
conducted on left lobe tissue. A 5-10mg liver aliquot was placed into 300 L of HPLC 
preservation buffer (5% perchloric acid, 0.2M boric acid, and 10M -glutamylglutamate [-EE]) 
[94], to preserve the in vivo oxidation state of the hepatic tissue and to prevent further tissue 
oxidation during storage. Sample aliquots were flash frozen in liquid nitrogen and stored at -
80oC until HPLC processing.  
 
Hepatic Redox Environment via HPLC 
 Reverse-phase HPLC analysis was used to quantify hepatic concentration of soluble 
thiols and protein-bound glutathione, as previously described [94]. Supelcosil LC-NH2 column 
(Sigma-Aldrich, St. Louis, MO) was used to measure thiol concentrations on a Waters 2695 
Alliance Separations Module. HPLC mobile phases were composed of (A) 80% HPLC grade 
methanol (Fisher Scientific) and 20% ddiH20, and (B) 62.5% methanol, 12.5% glacial acetic acid 
(Fisher Scientific), and 214 mg/mL sodium acetate trihydrate (Sigma-Aldrich) in ddiH20 with a 
gradient flow rate of 1.0 mL/min. Peak visualization, via fluorescence detection at 335 and 518 
nm, was performed using a Waters 2474 fluorescence detector. Waters Empower software 
(Waters, Milford, MA) processed and compiled the peak visualization data.  
The area under the curve (AUC) was resolved for each peak to quantify soluble thiol 
concentrations in each sample. AUC was normalized to the sample-specific internal standard, 
cellular volume and protein concentration, assessed via bicinchoninic acid assay (BCA assay, 
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Thermo Fisher) adapted for a microplate reader [95,96]. The soluble thiols measured in this 
study, reduced glutathione (GSH), oxidized glutathione disulfide (GSSG), reduced cysteine 
(Cys), and oxidized (CysS), were reported as intracellular concentrations (M). Eh for 
GSSG:GSH and CysS:Cys were calculated for each redox couple using the Nernst equation. At 
pH 7.4, the E0 = -264 mV and RT/nF = 30, so: Eh = -264 + 30*log([GSSG]/[GSH]
2) and Eh = -
264 + 30*log([CysS/Cys]2).  
Hepatic S-glutathionylation (S-glut), a measure of protein-bound GSH, was quantified 
via further processing of the protein pellet remaining from the first derivation [94], used to 
quantify redox couples above. Briefly, a chloroform:methanol extraction was used to cleave the 
disulfide bonds formed between hepatic proteins and GSH; thus freeing GSH into solution. The 
solution was derivatized via 150 L of 2X HPLC buffer and 150 L of 15.4 mg/mL 
dithiolthreitol (DTT, Sigma-Aldrich). Dansyl chloride was added to 300 L of aqueous layer 
from the derivatized sample. Samples were analyzed via the same reverse-phase HPLC method 
described above. GSH peaks in this second derivative were normalized to internal standard and 
protein concentrations, and reported as nmol/mg liver tissue. 
 
Hepatic Lipid Peroxidation via 8-iso-PGF2 
During necropsy, a 15-20mg liver aliquot was immersed in a microcentrifuge tube filled 
with 0.005% BHT, to prevent oxidation during storage. Serum samples were stored at -80oC 
until all samples could be sent to Cayman Chemical for testing at once. Samples were transferred 
to Cayman Chemical (Ann Arbor, MI, USA) on dry ice and 8-iso-PGF2 analyses were 
conducted via enzyme immunoassay (EIA) kit (No. 516351), with a sensitivity of 2.7 pg/mL and 
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an intra-assay %CV of 9.5%. Hepatic 8-iso-PGF2 measures were adjusted by total protein 
content of the liver, thus adjusting for sample-specific cellular concentration.  
 
Statistical Analyses  
All values were examined for biological plausibility; statistical outliers, defined as values 
1.5 times the interquartile range, were removed prior to further analyses. Variable distribution 
was examined for normality via a Q-Q probability plot of the residuals. EhGSH and EhCys were 
normally distributed, but thiol concentrations (GSH, GSSG, Cys, CysS, S-glut), and 8-iso-PGF2 
distributions were right skewed (Table S1). Skewed variables were ln-transformed for univariate 
analyses. The impact of perinatal BPA and HFD on hepatic 8-iso-PGF2 and redox parameters 
were analyzed by one-way ANOVA, with Tukey’s post hoc analyses, to compare means from all 
six perinatal exposure groups. ANOVAs were conducted cross-sectionally, comparing 
differences between group means among mice of each age: dams, PND10, and 10-months.  
Univariate analyses were conducted via generalized linear models between continuous 
predictor variables (i.e. dam and offspring metabolic parameters) and tissue oxidation measures. 
To examine whether the two measures of hepatic oxidative response (8-iso-PGF2 and redox 
parameters) were correlated, Kendall’s tau correlation matrices were computed. Sexually 
dimorphic responses to perinatal exposures occurred, so cross-sectional comparisons were sex-
stratified for PND10 and 10-month offspring. Significance was pre-determined at p < 0.05. 
Borderline significance (p < 0.10) and suggestive significance (p < 0.20) were also highlighted to 
assess biological patterns that occurred, but may not have reached statistical significance. All 
analyses were conducted in SAS 9.4 (Cary, NC, USA). 
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RESULTS 
Metabolic Characteristics Altered by Perinatal Exposures 
 Perinatal exposure to HFDs, but not BPA, affected the metabolic health of dams and 
offspring. HFD exposure was consistently associated with increased body weight, relative 
mWAT weight, and altered serum hormone levels (Table 3.1) in mice at all three time points. 
Among dams, body weight and relative mWAT weight were higher in the Mediterranean, 
Western, and Western+BPA groups, while relative liver weight was decreased by these diets. 
This supports the theory that greater postpartum maternal body weight is due to increased 
adiposity, not gain in lean mass. Although leptin levels usually increase with gains in adipose 
tissue, no difference was observed in this study; serum leptin levels did not differ by exposure 
group. However, consistent with decreased intracellular fuel needs in individuals on hyper 
caloric diets, postpartum serum insulin levels were lower in dams on the HFDs than Control. 
Gestational BPA exposure did not impact dam metabolic health. 
 Perinatal HFD exposure had a minimal impact on body weight and relative liver weight 
in offspring at PND10. Unlike dams, where HFDs were associated with increased body weight, 
at PND10, body weight tended to be lower among HFD-exposed pups compared to Control 
offspring. PND10 serum leptin levels were affected by perinatal exposure to HFDs, especially 
the Mediterranean diet. PND10 females perinatally exposed to Mediterranean diet had 2.6-fold 
higher leptin levels, while 4.8-fold higher levels were observed in males. High variation among 
the leptin measures in Mediterranean offspring supports tremendous inter-individual variation, 
suggesting individual mice responded differently to the same diet. Although not significant, the 
other HFDs tended to have greater serum leptin levels also in PND10 offspring of both sexes. 
Since the PND10 leptin surge impacts neural circuitry in the hypothalamus, the increased leptin 
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levels following perinatal HFD exposure may alter offspring metabolic health across their 
lifespan. The only PND10 metabolic outcome impacted by perinatal BPA exposure was male 
body weight; Control+BPA males weighed 82% less than Control males, consistent with 
previous reports of low birth weight following perinatal BPA exposure. However, the lack of 
more widespread alterations based on perinatal BPA suggests that the 50 g BPA/kg diet dose 
does not offspring metabolic health, in this mouse model. 
 Perinatal exposure to HFDs, but not BPA, was associated with altered metabolic health 
effects in adult offspring, at 10-months. Mice at 10-months had not been exposed to the 
experimental diets for over 9 months, which suggests altered health outcomes at this age may be 
the result of perinatal programming. Despite the elevated serum leptin levels observed at PND10 
among HFD-exposed offspring, body weight and mWAT weight were not systematically 
elevated at 10-months as would be expected if energy homeostasis had been altered by the 
increased leptin surge. The only perinatal effect on 10-month weights was observed in males 
perinatally exposed to Western+BPA diet, which had an 8% greater body weight and 22% higher 
mWAT weight compared to Controls. This is consistent with previous reports of metabolic 
programming occurring in male offspring, but not females. Of note, perinatal HFD exposure was 
associated with elevated serum leptin levels in offspring at 10-months, just as it was at PND10. 
This tended to be true of serum insulin also, with non-significantly greater insulin levels 
observed in 10-month offspring perinatally exposed to HFDs. Although these findings were not 
statistically consistent at 10-months, the biologic trend of altered metabolic outcomes occurring 
subsequent to perinatal HFD exposure suggests that maternal diet during pregnancy may impact 
offspring health into adulthood. 
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Hepatic Soluble Thiol Concentrations 
 Rapidly changing soluble thiol concentrations play an important role in many cell 
activities, like intracellular signaling, enzyme activity, and transcription factor binding. The 
selective reduction and oxidation of protein thiols for these cellular processes means thiol levels 
vary considerably. This large variation is apparent in the thiols measured in this study (Figure 
3.2), making them challenging to use them as reliable markers of the overall redox environment. 
This natural variation in thiol concentrations may also be masking differences in hepatic 
concentrations based on perinatal exposure group.  
 
Hepatic Redox Potentials 
 Evaluating Eh, instead of variable soluble thiols, provides value as a quantitative measure 
of perturbations to the steady state redox environment (Table 3.2, Figure 3.3). Hepatic EhGSH 
was consistently about -230 mV in PND10 and 10-month offspring perinatally exposed to the 
Control diet: -233.1 + 8.0 mV in PND10 females, -229.6 + 9.5 mV in PND10 males, -229.4 + 
7.4 mV in 10-month females, and -229.3 + 7.8 mV in 10-month males. This EhGSH falls 
between highly reduced cellular proliferation conditions (-240 to -250 mV) and more oxidized 
differentiation conditions (-200 to -220 mV) that have been determined from a large variety of 
different species, cells and tissues. This suggests Control offspring livers are healthy and in a 
natural state of tissue repair and regeneration (Figure S3.1). Hepatic EhGSH and EhCys did not 
differ by perinatal exposure among dams or 10-month offspring. However, in offspring at 
PND10 perinatal exposures did impact hepatic (Eh). 
 Among PND10 females, perinatal BPA exposure was associated with decreased EhGSH: 
Control+BPA (-216.7 + 23.2 mV), Mediterranean+BPA (-208.7 + 36.7 mV), and Western+BPA 
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(-220.8 + 22.1 mV). These levels suggest differentiating redox conditions. At this young age, 
differentiating conditions are not entirely unexpected since the pups are undergoing rapid growth 
and development at PND10. However, the consistent reduction in EhGSH, towards a more 
oxidized environment, only among BPA-exposed offspring, supports the theory that the BPA 
exposure may trigger steady state perturbations that result in more hepatic tissue repair. Of note, 
perinatal BPA exposure did not have the same oxidizing effect in PND10 males. Perinatal 
Mediterranean diet exposure was associated with a decreased EhGSH (-216.8 + 8.8 mV) in 
males. 
 These oxidizing shifts in EhGSH were aligned with metabolic health alterations in male, 
but not female, PND10 offspring. In PND10 females, EhGSH was altered by perinatal BPA 
exposure, but serum leptin levels differed by perinatal HFD exposure, not BPA. However, in 
PND10 males, perinatal Mediterranean diet exposure was associated with a more oxidized 
EhGSH and increased relative liver weight and serum leptin levels. Since these measures were 
collected cross-sectionally, they are not evidence of causation; the association does suggest that 
the Mediterranean diet was able to affect both the redox environment and metabolic outcomes. 
These impacts no longer exist in 10-month offspring, though, so the Mediterranean diet may be 
exerting a direct effect at PND10 that does not continue into adulthood via perinatal 
programming. 
 
Hepatic Protein S-glutathionylation  
 Hepatic S-glut represents a measure of GSH bound to intracellular proteins. Among dams 
and 10-month females, HFDs were associated with decreased S-glut levels. S-glut is thought to 
protect protein thiols from irreversible oxidation, thus maintaining their ability to respond to 
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alterations in redox environment. Thus, decreased S-glut levels could impair a tissue’s redox 
responsiveness, which in turn could alter intracellular signaling and regulatory functions. The 
decreased S-glut observed in 10-month offspring may be an age-related decline in the ability to 
maintain redox homeostasis.  
 
Hepatic 8-iso-PGF2 Levels 
 Under inflammatory conditions, prostaglandin endoperoxide synthase can synthesize 8-
iso-PGF2, resulting in elevated levels. Hepatic 8-iso-PGF2 varied by perinatal diet in mice at all 
time points. Among dams, those exposed to the Western+BPA diet had 1.46-fold greater 8-iso-
PGF2 levels compared to Controls. Perinatal HFD exposure altered 8-iso-PGF2 in offspring at 
both PND10 and 10-months. In PND10 females, Mediterranean diet pups had 1.35-fold higher 8-
iso-PGF2 than Controls; levels were 1.59-fold higher in Western diet pups and 1.57-fold higher 
in Western+BPA pups. Female 10-month offspring also had elevated 8-iso-PGF2 levels, if they 
were perinatally exposed to a HFD, with 1.26- to 1.42-fold greater 8-iso-PGF2 than Controls. In 
contrast, perinatal exposure to the Mediterranean and Mediterranean+BPA diets were associated 
with decreased 8-iso-PGF2 levels (0.66- and 0.70-fold, respectively) in PND10 males. But 
among 10-month males, perinatal HFDs were again associated with increased 8-iso-PGF2 
levels. Perinatal BPA exposure only affected 8-iso-PGF2 levels in 10-month males, who had 
1.41-fold greater levels than Controls. Thus, the metabolic alterations observed in offspring, 
following perinatal HFD exposure, were mirrored by increased hepatic 8-iso-PGF2 levels in 
HFD exposed offspring. It is often posited that metabolic dysfunction is accompanied by 
increased systemic inflammation. The findings in this study are consistent with the theory. 
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Sex-Specific Effects in Metabolic and Oxidative Outcomes 
At PND10, mean hepatic EhGSH and S-glut differ between female and male offspring 
(Table 3.4). PND10 males have a suggestively more reduced EhGSH (-226.8 mV) than females 
(-222.4 mV), but alterations in signaling pathways have not been observed in Eh changes of less 
than 15 mV. So although EhGSH differs significantly by PND10 sex, the difference is unlikely to 
have a biological impact. On the other hand, PND10 females had a significantly greater S-glut, 
with 250.7 + 392.5 nmol/mg liver tissue, compared to males (66.7 + 245.4 nmol/mg). But the 
variance of S-glut within each sex exceeds the group mean, suggesting this measure is highly 
variable at PND10, and the sex difference may be an artifact of measurement timing, not a 
biologically relevant difference. At 10-months, S-glut levels were higher in males (1.1 nmol/mg) 
than females (0.9 nmol/mg). Hepatic 8-iso-PGF2 levels did not differ by offspring sex at 
PND10 or 10-months. 
 At PND10, there were few differences in metabolic parameters by offspring sex, but by 
10-months, every parameter differed (Table 3.4). At PND10, relative liver weight was greater in 
females (2.95%) than in males (2.73%), but body weight and serum leptin did not differ by sex. 
At 10-months, every metabolic outcome differed by sex; males had greater body weight, percent 
liver weight, serum leptin, and serum insulin levels, while females had a greater percent mWAT 
weight than males. Thus, sex-specific results were more apparent and biologically relevant in 
metabolic outcomes than in hepatic redox parameters or lipid peroxidation. 
 
DISCUSSION 
A major objective of this study was to investigate the potential to alter perinatal 
programming of the hepatic redox environment through dietary intervention and 
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environmental (chemical) stimuli.  In offspring at both PND10 and 10-months post partum, 
hepatic 8-iso-PGF2 levels, a biomarker of lipid peroxidation, were more impacted by 
perinatal exposure than were redox parameters, suggestive of a greater susceptibility to 
perinatal programming in 8-iso-PGF2. Multiple dam metabolic and oxidative parameters 
were observed to impact oxidative responses in offspring, emphasizing the critical impact 
the maternal physiologic states could have on developing offspring.  
 The differential response of hepatic 8-iso-PGF2 levels and redox parameters to 
perinatal maternal diet and BPA exposure, suggests that the redox environment itself is not 
altered long term by perinatal exposure, but that mechanisms underlying the regulation of 
8-iso-PGF2 levels may be altered. Isoprostanes are prostaglandin-like molecules, produced 
via free-radical induced auto-oxidation of arachidonic acid, in a cyclooxygenase (COX) free 
process or through a free radical-independent prostaglandin-endoperoxidase synthetase 
pathway [97,98].  Formation of 8-iso-PGF2 is rate-limited by the presence of molecular 
oxygen and free radicals in the tissue [99]; however, dietary intake may also alter 8-iso-
PGF2 levels. Although urinary 8-iso-PGF2 levels were not affected by a 2-day, very low fat 
diet (5%) [100] or the consumption of a fast food meal [101], levels increased following 
elevated consumption of conjugated linoleic acid (CLA) via diet [102] or supplementation 
[103,104]. CLA is a metabolic precursor to arachidonic acid; thus, the increased 8-iso-PGF2 
levels likely reflect an abundance of the parent molecule, arachidonic acid. Despite the 
reported association between elevated 8-iso-PGF2 levels and metabolic diseases [105–
110], 8-iso-PGF2 has a short half life: 16 minutes in humans [111,112], and 4 minutes in 
rodents, with 80% elimination by four hours [113]. Thus, continuous production of 8-iso-
PGF2 due to an excess of dietary precursors or molecular oxygen and free radicals would 
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be necessary to maintain the association between 8-iso-PGF2 and chronic metabolic 
disease over time. Studies reporting the link between metabolic disease and 8-iso-PGF2 do 
not control for dietary intake and since ROS production is not chronically sustained, 
elevated 8-iso-PGF2 over extended periods is likely due to synthesis via inflammation-
induced PES enzymes. 
 Although free radicals and reactive oxygen species alter the intracellular redox 
environment, driving the formation of more oxidizing equivalents, the redox state of thiols 
is tightly controlled by numerous enzymes. For instance, GSH biosynthesis is determined 
by availability of amino acid precursors [114,115] and -glutamate cysteine ligase (GCLc) 
activity [14,114], while GSH conjugate degradation is regulated by -glutamyl 
transpeptidase and GSSG reduction is regulated by glutathione disulfide reductase 
[116,117]. Redox couples and their respective redox potentials play a critical role in 
intracellular signaling and redox sensing [15,18], so are carefully regulated to maintain 
cellular homeostasis [14,17,18]. Numerous studies conducted in monocultured cells and 
tissues from a variety of different species have shown that shifts in redox potential as small 
as +/- 15 mV are sufficient to change cellular functions from proliferation to differentiation 
to apoptosis (Figure S1). Even though measurements in tissues containing multiple cell 
types may exhibit smaller Eh changes, it is likely that redox shifts within individual cell 
types can be significantly greater. Evidence of this homeostatic control was also observed 
in human plasma, where the antioxidant capacity of the GSH:GSSG redox pair was retained 
through age 45, despite linear oxidation of Cys:CysS with age [118]. The 10-month old mice 
in this study are equivalent to human middle age, so their GSH:GSSG antioxidant capacity 
may still be tightly controlled, accounting for the minimal impact of perinatal exposures on 
  
120  
EhGSH. Further supporting the independent signaling role of each redox pair (e.g. 
GSH:GSSG, Cys:CysS), evidence suggests redox pairs are individually affected by oxidative 
changes to the intracellular environment [16,119,120]. In this study, the independent 
response was observed in the different impact of perinatal exposures, dam metabolic and 
oxidative responses on offspring EhGSH and EhCys. At 1.6-2.4 minutes in human plasma 
[121,122], the half-life of GSH is even shorter than that of 8-iso-PGF2, making GSH even 
more acutely responsive to environmental alterations, such as postprandial state, 
xenobiotic stress, and inflammatory cascades. This rapid turnover and tight homeostatic 
control of redox parameters results in a rapid return to baseline, ensuring that intracellular 
signaling continues. 
 Protein S-glut is a reversible post-translational modification that protects cysteine 
residues from irreversible oxidation and may also play a critical role in relaying redox 
signals [123–125]. Preventing oxidation of protein thiols protects their ability to respond 
to changes in redox environment, preserving the capacity for intracellular signaling, 
appropriate protein function, and transcriptional regulation [123–126]. The decreased S-
glut levels observed in dams and 10-month females perinatally exposed to the HFDs in this 
study, suggest that the hepatic GSH reserve might be depleted in these animals. The lack of 
differential impact of perinatal HFD on 10-month males suggests a potential sexually 
dimorphic response; however, a sex-specific analysis did not find a biologically relevant 
difference in S-glut levels among 10-month females and males. Offspring at 10-months had 
not been exposed to the perinatal diets for more than nine months, suggesting that 
differences observed among 10-month female S-glut levels might be perinatally 
programmed. This was the only measure of the redox environment impacted at 10-months; 
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it warrants additional investigation to confirm these findings. HFD exposure has been 
linked to elevations in classical oxidative stress markers [40–43] and was associated with 
increased inflammation-induced lipid peroxidation, thus it is possible that perinatal 
exposure to a HFD could perinatally program post-translational modifications in hepatic 
tissue. However, in this situation, programming would be expected to protect against the 
increased stress presented by the HFD. Instead, the depressed S-glut levels observed in this 
study could reflect an increased lifelong GSH demand, required to maintain redox 
homeostasis in a regularly stressed tissue. Since S-glut levels in PND10 offspring varied 
drastically, no pattern of sex-specific or perinatal exposure-specific differences could be 
identified. The lack of impact on PND10 S-glut by perinatal exposures further suggests that 
the exposures do not alter S-glut regulation directly. 
 Perinatal HFD exposure altered oxidative responses, especially hepatic 8-iso-PGF2, 
in offspring at PND10 and 10-months. Postprandial oxidative stress can result from 
sustained hyperglycemia or hyperlipidemia [127] and may contribute to the differences in 
hepatic 8-iso-PGF2 observed in this study according to perinatal HFD exposure. Dietary 
studies in human adults have reported increased reactive oxygen species following intake 
of glucose [128], cream [129], and a high fat, high carbohydrate meal [130]. Few studies 
have examined the impact of maternal diet during pregnancy on offspring oxidative 
response, but a study in C57BL/6J mice reported that dam HFD intake during gestation was 
associated with increases in serum 8-OHdG and hepatic 3-nitrotyrosine levels in offspring 
at 8 weeks [131]. This is consistent with our findings that the Western and Mediterranean 
HFD increased hepatic 8-iso-PGF2 in offspring at PND10 and 10-months. Perinatal HFD 
exposure had a greater impact on hepatic 8-iso-PGF2 than redox parameters in offspring 
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at PND10 or 10-months. Although perinatal BPA has been linked to altered offspring 
metabolic health [6,19–23], and to increased oxidative outcomes in adult animals [24–27], 
no studies had investigated the potential to impact offspring redox environment. The 
results of this study suggest that perinatal exposure to a human-relevant dose of BPA may 
not induce perinatal programming of oxidative responses later in life.  
 Sexually dimorphic responses to perinatal HFD and BPA occurred in both metabolic 
and oxidative offspring outcomes, but the differences were only biologically relevant in the 
metabolic outcomes among 10-month offspring. In murine models, maternal HFD during 
pregnancy has previously been associated with sex-specific effects in offspring metabolic 
health [132–134]. The differential effect of estrogen sulfotransferase (EST) by sex has been 
associated with altered risk of type 2 diabetes; in females EST ablation improves insulin 
sensitivity, while decreasing hepatic lipogenesis and gluconeogenesis, while in males EST 
ablation was linked to decreased islet -cell mass and glucose-activated insulin secretion, 
aggravating the diabetic phenotype [135]. EST sulfonates and deactivates estrogens, thus 
regulating estrogen homeostasis. Induction of EST can occur by Nrf2 activation following 
hepatic ischemia-reperfusion injuries; in females this induction inhibits estrogen activity, 
whereas in males EST ablation exacerbated the injury [136]. Based on these sexually 
dimorphic effects of EST activity, differences in redox parameters and 8-iso-PGF2 could be 
expected. However, no biologically relevant differences were observed in this study, which 
suggests these results were estrogen-independent. 
 In this study, dam metabolic parameters were consistently associated with oxidative 
response in PND10 and 10-month offspring (Figure 3.4), although the exact changes 
differed by age and offspring sex (Tables 3.4, 3.5, 3.6). The predictive dam metabolic 
  
123  
parameters: gestational weight gain, dam body weight, percent liver weight, and serum 
insulin, have all previously been associated with metabolic alterations in offspring.  
Maternal pre-pregnancy obesity and gestational weight gain have been linked to increased 
risk of childhood obesity and metabolic comorbidities [137–140], but few studies have 
examined their effect on offspring oxidative responses. A human birth cohort study 
reported maternal pre-pregnancy obesity was associated with increased oxidative 
outcomes in newborn umbilical cord plasma, assessed by malondialdehyde and nitric oxide 
levels [141]. These results are supported by our study findings; dam body weight was 
consistently associated with oxidizing changes in dams, PND10, and 10-month offspring in 
this study. 
 Dam oxidative parameters (8-iso-PGF2 and redox parameters) were also associated 
with oxidative response in offspring at both PND10 and 10-months. Together with the 
impact of dam metabolic parameters, this suggests that the maternal physiologic 
environment during pregnancy may be as important if not more important than other 
perinatal exposures (like diet and BPA exposure). Interestingly, despite the fact that dams 
were directly exposed to the six experimental diet groups for a minimum of 8 weeks, the 
exposures had a negligible impact on dam 8-iso-PGF2 and redox parameters. Thus, the 
impact of dam oxidative parameters on offspring oxidative response does not appear to be 
a ‘translation’ of perinatal exposure effect through the dam, but rather a physiologic 
response to the dam’s redox state. 
 Given the high global rates of metabolic disease, this study examined the relevant 
question of whether oxidative response could be perinatally programmed, thus providing a 
potential mechanism for the perinatal programming of metabolic diseases. Although two 
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different markers of oxidative response, hepatic 8-iso-PGF2 and GSH-based redox 
parameters, were measured in this study, further insight could be provided by assessing 
additional markers of oxidative response, including enzyme levels, antioxidant capacity, 
and levels of reactive oxygen and nitrogen species. Although BPA did not have a strong 
impact on offspring oxidative response, in this study, other common chemical exposures 
might induce perinatal programming. Offspring oxidative response was only investigated in 
hepatic tissue, in this study; investigation into the potential for oxidative programming in 
other tissues is warranted. Despite the need to examine these additional avenues before 
complete understanding of perinatal effects on oxidative response, the experimental design 
of this study has multiple strengths. In vivo study of oxidative response is critical due to the 
sensitivity of redox parameters to minute physiologic changes and exocrine cell signaling, 
which cannot be captured by in vitro models. Examining offspring at multiple ages allows 
assessment of changes in response over time, and provides the opportunity to introduce 
post-natal interventions, like diet or chemical challenges. 
 Study limitations include the oral dosing of BPA, the single static time point used to 
assess perinatal programming, and the use of a non-specific biomarker of lipid 
peroxidation, 8-iso-PGF2. The ingested route of BPA exposure was chosen to mimic human 
BPA exposure, which commonly occurs via food packaging. A trade-off of designing a 
human-relevant exposure study is that the exact quantity of BPA ingested by each animal is 
not known, mice ate ad libitum. So although mice in three experimental diet groups had 
access to 50 g BPA/kg diet, their BPA body burden may have differed considerably. This 
may partially account for the lack of altered health effects observed following perinatal 
BPA exposure in this study.  To better assess the potential for perinatal programming, 
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intermediate time points assessing metabolic, redox, and lipid peroxidation outcomes 
would have provided additional insight. Other life periods, such as peripuberty, have been 
identified as sensitive to environmental exposures; measuring offspring health at 
peripuberty and other times prior to 10-months might have illuminated trends or 
demonstrated a consistent impact across time, both of which would be instructive for 
translation to human health outcomes.  
Lastly, although 8-iso-PGF2 has been widely used in human epidemiology studies as 
a marker of classic oxidative stress, the potential for 8-iso-PGF2 to be synthesized via two 
distinct pathways makes mechanistic interpretation difficult. This lack of biomarker 
specificity occurs because 8-iso-PGF2 can be produced via non-enzymatic oxidation of 
arachidonic acid by ROS or via inflammation-induced PES enzymes. However, the time 
course for these two mechanisms differs; ROS generation is a rapid response, whereas 
inflammation-induced changes can occur over a more sustained time frame. In this study, 
since 8-iso-PGF2 levels remained high at 10-months, the biomarker likely reflects the 
prolonged inflammatory response associated with altered metabolic health. Despite these 
limitations, this study advanced understanding of perinatal programming. 
 In conclusion, perinatal exposure to HFDs was associated with increased hepatic 8-
iso-PGF2 in offspring at PND10 and 10-months, but with no changes in redox parameters. 
Exposure to the HFDs had a greater impact than perinatal BPA exposure, supporting the 
importance of maternal diet during pregnancy. Although direct exposure to the HFDs and 
BPA had a negligible effect on dams, dam metabolic and oxidative parameters were 
associated with offspring hepatic 8-iso-PGF2 and redox parameters. Associations were 
sex-specific and age-dependent. Given the inconsistent impact of perinatal exposures on 
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offspring redox parameters, the role of postnatal diet and chemical exposures may have a greater 
effect on redox imbalance. Comparing the influence of perinatal and postnatal exposures on 
metabolic disease risk is a critical next step in understanding the link between oxidative 
responses early in life and metabolic disease development. 
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Figure	3.1	Experimental	Design	of	Mouse	Perinatal	Exposure	Study		
	Primiparous,	wild	type	(a/a)	dams	were	randomly	assigned	to	one	of	six	experimental	diets	at	8-10	weeks	of	age.	The	antioxidant	preservative,	TBHQ,	was	removed	from	all	six	experimental	diets.	Two	weeks	later,	these	dams	were	mate-paired	with	virile,	young	(7.5	week	old),	Avy/a	males.	Dams	had	ad	libitum	access	to	their	assigned	experimental	diet	from	pre-gestation	through	lactation.	At	postnatal	day	21	(PND21),	all	offspring	were	weaned	onto	the	Control	diet	with	TBHQ.	Mice	were	sacrificed	for	examination	of	hepatic	oxidation	measures	at	three	time	points:	(1)	dams	at	PND25:	4	days	after	weaning,	(2)	offspring	at	PND10:	still	exposed	to	mother’s	milk,	and	(3)	offspring	at	10-months:	not	exposed	to	the	experimental	diets	for	nine	months.		
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Table 3.1 Metabolic Characteristics of the Mouse Population  
 
Mouse 
Exposure 
Group 
N 
Body Weight % Liver Weight % mWAT Weight Serum Leptin Serum Insulin 
Mean SD p Mean SD p Mean SD p Mean SD p Mean SD p 
Dams 
ALL GROUPS      0.096d     0.145e     0.007b     0.960     0.191e 
Control 15 25.99 2.54 -- 5.43 0.70 -- 2.47 0.53 -- 5.16 4.20 -- 2.64 2.60 -- 
Con+BPA 19 25.45 2.13 0.572 5.43 0.69 0.994 2.59 0.68 0.628 5.93 4.28 0.599 2.41 1.46 0.697 
Mediterranean 18 27.17 1.91 0.219 4.98 0.01 0.084d 2.84 0.75 0.148e 5.63 4.34 0.746 1.69 1.28 0.111e 
Med+BPA 16 25.86 2.46 0.899 5.52 0.90 0.715 2.53 0.64 0.806 5.59 3.92 0.771 1.59 1.03 0.078d 
Western 14 27.84 4.10 0.073d 5.49 0.72 0.812 3.29 0.81 0.004b 4.54 2.46 0.699 1.33 0.54 0.043c 
West+BPA 15 27.25 3.16 0.212 5.06 0.83 0.177e 3.20 0.98 0.008b 5.76 3.99 0.684 1.59 1.17 0.073d 
Female PND10 Offspring 
ALL GROUPS       0.537     0.436     --     0.067d     -- 
Control 13 5.97 0.54 -- 2.99 0.34 -- -- -- -- 3.40 2.13 -- -- -- -- 
Con+BPA 6 5.43 1.14 0.231 2.92 0.53 0.798 -- -- -- 5.47 4.38 0.492 -- -- -- 
Mediterranean 11 5.34 0.95 0.096d 3.00 0.53 0.963 -- -- -- 8.84 6.77 0.028c -- -- -- 
Med+BPA 11 5.89 1.17 0.831 2.68 0.44 0.155e -- -- -- 7.48 6.42 0.104e -- -- -- 
Western 10 5.71 0.75 0.499 2.92 0.51 0.747 -- -- -- 2.15 1.60 0.622 -- -- -- 
West+BPA 9 5.55 0.90 0.293 3.18 0.75 0.398 -- -- -- 7.21 6.93 0.138e -- -- -- 
Male PND10 Offspring 
ALL GROUPS      0.208     0.319     --     0.006b   -- 
Control 9 5.78 0.67 -- 2.59 0.44 -- -- -- -- 2.40 3.23 . -- -- -- 
Con+BPA 10 4.74 0.74 0.043c 2.63 0.52 0.873 -- -- -- 1.66 1.80 0.754 -- -- -- 
Mediterranean 6 5.59 0.89 0.744 3.13 0.45 0.069d -- -- -- 11.55 7.82 0.001a -- -- -- 
Med+BPA 11 5.44 1.59 0.495 2.56 0.71 0.915 -- -- -- 5.38 5.23 0.209 -- -- -- 
Western 14 5.71 0.99 0.874 2.73 0.56 0.543 -- -- -- 4.62 5.65 0.319 -- -- -- 
West+BPA 8 5.98 1.33 0.713 2.92 0.45 0.220 -- -- -- 3.91 2.71 0.541 -- -- -- 
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Table 3.1 Metabolic Characteristics of the Mouse Population, Continued  
 
Mouse 
Exposure 
Group 
N 
Body Weight % Liver Weight % mWAT Weight Serum Leptin Serum Insulin 
Mean SD 
p-
value 
Mean SD 
p-
value 
Mean SD p-value Mean SD 
p-
value 
Mean SD 
p-
value 
Female 10-month Offspring 
ALL GROUPS     0.777   0.036c   0.801    0.358   0.685 
Control 10 32.92 8.02 -- 3.07 0.71 -- 4.03 1.36 -- 8.47 4.33 -- 1.59 1.58 -- 
Con+BPA 9 34.25 6.94 0.679 3.25 0.47 0.534 3.83 0.83 0.717 8.62 3.21 0.947 1.95 3.16 0.767 
Mediterranean 11 36.50 7.48 0.243 3.80 0.57 0.009b 4.01 1.26 0.970 12.54 6.26 0.071d 3.22 2.35 0.176e 
Med+BPA 12 35.46 4.48 0.395 3.39 0.66 0.237 4.25 1.54 0.671 11.16 4.31 0.220 1.86 0.88 0.816 
Western 12 35.44 8.23 0.399 3.76 0.57 0.012c 3.72 1.09 0.538 8.90 5.55 0.842 2.58 3.95 0.388 
West+BPA 11 32.85 5.97 0.983 3.74 0.69 0.017c 3.59 0.80 0.397 10.60 5.20 0.340 2.98 2.67 0.247 
Male 10-month Offspring 
ALL GROUPS     0.570   0.617   0.158e    0.045c   0.955 
Control 12 43.41 5.49 -- 3.60 0.95 -- 3.37 0.58 -- 10.02 3.09 -- 5.02 3.77 -- 
Con+BPA 10 44.30 2.40 0.659 3.90 1.05 0.489 3.56 1.00 0.570 11.93 6.35 0.344 5.20 2.62 0.906 
Mediterranean 12 45.69 5.53 0.239 4.32 1.62 0.087d 3.52 0.77 0.647 14.63 4.51 0.021c 6.11 3.44 0.475 
Med+BPA 12 44.70 4.77 0.503 3.79 0.90 0.650 3.32 0.72 0.882 13.24 5.11 0.097d 5.91 5.26 0.553 
Western 10 44.15 4.89 0.712 4.08 0.68 0.267 3.39 0.97 0.964 12.74 4.51 0.179e 5.48 3.04 0.768 
West+BPA 12 46.78 4.16 0.085d 3.88 0.37 0.495 4.12 0.73 0.024c 16.13 4.12 0.002b 6.23 2.84 0.417 
 
One-way ANOVAs compared group means of metabolic characteristics by perinatal exposure group. The p-value in the ‘All 
Groups’ rows represents the significance of the ANOVA comparing all six exposures. Subsequent p-values represent the 
significance of each exposure group mean compared to the Control group mean, assessed via Tukey’s post-hoc analysis. 
 
To highlight trends of potential biological importance, a wide range of p-values were annotated in this Table: Significance was 
defined as: a p<0.001, b p<0.01, c p<0.05. Borderline significant p-values were defined as: d p< 0.10. Suggestive p-values were 
defined as: e p<0.20. 
  
  
131  
Table 3.2 Comparison of Hepatic Lipid Peroxidation and Redox Potentials by Perinatal Exposure Group 
 
Perinatal  
Exposure 
N 
8-iso-PGF2  (g/mg) EhGSH (mV) EhCys (mV) S-glut (nmol/mg) 
Mean SD p Mean SD p Mean SD p Mean SD p 
Dams  
All Groups    0.2582    0.9835   0.6218   0.4142 
Control 15 156.81 88.61  -- -223.56 10.57 -- -151.16 32.29 -- 38.95 43.00 -- 
Con+BPA 19 170.51 70.62 0.6734 -221.37 11.62 0.6204 -144.08 18.04 0.4640 27.62 26.45 0.2359 
Mediterranean 18 171.06 54.38 0.6611 -222.68 14.56 0.8458 -157.85 36.66 0.5063 22.03 18.96 0.0815d 
Med+BPA 16 170.66 87.38 0.6783 -222.85 10.12 0.8776 -148.00 18.09 0.7503 32.14 28.85 0.4922 
Western 14 158.43 74.43 0.9633 -223.52 12.48 0.9942 -159.53 24.44 0.4331 22.12 18.89 0.1027e 
West+BPA 16 228.74 145.54 0.0333a -220.61 16.07 0.5275 -151.63 29.08 0.9623 21.31 22.38 0.0820d 
PND10 Females 
All Groups     0.0049b    0.1315e   0.7337   0.6756 
Control 13 193.78 96.64 -- -233.07 7.99 -- -209.68 34.55 -- 118.84 238.13 -- 
Con+BPA 6 196.35 102.69 0.9554 -216.67 23.24 0.1200e -184.52 46.22 0.1998e 447.61 532.13 0.1112e 
Mediterranean 11 261.82 100.61 0.0782d -225.54 10.15 0.3859 -203.55 44.88 0.7046 279.54 350.47 0.3750 
Med+BPA 11 181.76 85.89 0.7522 -208.68 36.72 0.0065b -215.18 38.43 0.7341 194.00 262.84 0.6609 
Western 10 307.67 88.29 0.0050b -225.03 14.85 0.3674 -212.35 36.13 0.8724 256.57 380.35 0.4465 
West+BPA 9 303.27 80.76 0.0085b -220.82 22.13 0.1848e -206.28 38.14 0.8423 315.26 612.36 0.2791 
PND10 Males 
All Groups     0.1270e    0.2901   0.9552   0.8044 
Control 9 287.53 75.17 -- -229.60 9.45 -- -202.96 45.16 -- 110.44 297.73 -- 
Con+BPA 10 252.24 113.59 0.4712 -223.68 20.99 0.3388 -213.49 34.86 0.5900 16.85 23.49 0.4367 
Mediterranean 6 190.67 78.73 0.0883d -216.78 8.78 0.0722d -195.64 43.11 0.7422 3.69 2.17 0.4359 
Med+BPA 11 202.39 56.16 0.0792d -230.01 10.80 0.9465 -207.77 43.92 0.8014 22.08 45.27 0.4627 
Western 14 258.28 150.04 0.5204 -226.59 10.56 0.6009 -205.63 37.16 0.8836 132.92 432.95 0.8412 
West+BPA 8 322.59 96.84 0.4983 -231.65 11.57 0.7535 -197.73 44.46 0.7998 72.61 111.15 0.7649 
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Table 3.2 Comparison of Hepatic Lipid Peroxidation and Redox Potentials by Perinatal Exposure Group, Continued 
 
10-month Females 
All Groups     0.3584    0.9048   0.5521   0.3141 
Control 10 147.86 48.26 -- -229.38 7.40 -- -141.30 22.53 -- 1.14 0.72 -- 
Con+BPA 9 159.22 34.08 0.7488 -227.34 8.05 0.4769 -147.94 18.67 0.4951 0.95 0.41 0.2714 
Mediterranean 11 206.86 113.39 0.0842d -229.52 4.13 0.9609 -145.32 17.45 0.6585 0.82 0.13 0.0739d 
Med+BPA 12 210.07 88.87 0.0637d -229.64 6.77 0.9216 -135.47 10.98 0.5110 0.98 0.23 0.3450 
Western 12 186.97 80.96 0.2395 -230.44 3.73 0.7195 -145.10 22.87 0.7084 0.86 0.22 0.1208e 
West+BPA 11 192.32 55.65 0.1908e -230.45 3.68 0.7169 -152.88 22.74 0.2369 0.75 0.13 0.0368c 
10-month Males 
All Groups     0.0495c    0.9375   0.9079   0.7477 
Control 10 161.48 41.91 -- -229.25 7.77 -- -152.56 27.09 -- 1.22 0.52 -- 
Con+BPA 8 226.99 104.77 0.0349c -229.62 8.48 0.9365 -148.29 33.21 0.7536 0.98 0.31 0.2057 
Mediterranean 10 173.03 57.61 0.6913 -228.33 9.22 0.8373 -152.60 29.00 0.9975 1.07 0.34 0.4008 
Med+BPA 10 233.90 99.21 0.0151c -230.37 5.59 0.8066 -139.99 21.09 0.3573 1.21 0.16 0.9774 
Western 8 218.20 54.13 0.0666d -225.60 16.81 0.4412 -143.53 26.46 0.4910 1.15 0.23 0.7110 
West+BPA 7 171.46 45.57 0.7314 -229.95 8.90 0.8866 -143.43 25.09 0.5223 1.21 0.16 0.9953 
 
The effect of perinatal HFD and BPA on lipid oxidation or redox parameters was analyzed via one-way ANOVA, with Tukey’s 
post-hoc analysis. Means and standard deviations (SDs) presented in this table represent average and distribution by perinatal 
exposure group. The ‘All Groups’ p-values represent the values for the overall ANOVA for each mouse age and sex group. 
Additional p-values represent the comparison between the mean of each perinatal exposure group and the Control group 
mean, as analyzed by Tukey’s post hoc analyses. To highlight trends of potential biological importance, a wide range of p-
values were annotated in this Table: Significance was defined as: a p<0.001, b p<0.01, c p<0.05. Borderline significant p-values 
were defined as: d p< 0.10. Suggestive p-values were defined as: e p<0.20. 
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Figure 3.2 Hepatic Intracellular Thiol Concentrations in Dams and Offspring 
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Figure 3.3 Hepatic Glutathione and Cysteine Redox Potentials in Dams and Offspring  
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Figure 3.4 Hepatic 8-iso-PGF2 Levels in Offspring by Perinatal Exposure Group 
  
 
Perinatal exposure to HFDs impacted offspring hepatic 8-iso-PGF2 levels at both PND10 
and 10-months. This bar chart illustrates differences between group means by perinatal 
exposure group; error bars represent the standard error of the mean (SEM) for each group. 
Average hepatic 8-iso-PGF2 values that differ from the Control mean are marked: * p < 
0.05, ^ p < 0.10. 
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Table 3.3 Summary of Findings: Impact of Perinatal Exposures on Hepatic 8-iso-PGF2 and 
Redox Parameters in Offspring at PND10 and 10-months 
 
Hepatic 
Oxidation 
Measures 
Perinatal Exposure Groups compared to Sex-Specific Controls 
CBPA Med MBPA West WBPA CBPA Med MBPA West WBPA 
PND10 Females PND10 Males 
8-iso --  --   --   -- -- 
Eh GSH  --  --  --  -- -- -- 
    GSH --   -- -- -- -- -- -- -- 
    GSSG -- --  -- -- -- -- -- -- -- 
Eh Cys  -- -- -- -- -- -- -- -- -- 
   Cys -- -- -- -- -- -- --  -- -- 
   CysS -- -- --  -- -- --  -- -- 
S-glut -- -- -- -- -- -- --  -- -- 
 10-month Females 10-month Males 
8-iso --   --   --   -- 
Eh GSH -- -- -- -- -- -- -- -- -- -- 
    GSH  -- -- -- -- -- -- -- -- -- 
    GSSG  -- -- -- -- -- -- -- -- -- 
Eh Cys -- -- -- -- -- -- -- -- -- -- 
   Cys -- -- --  -- -- --  -- -- 
   CysS --   --  -- --  -- -- 
S-glut --  --   -- -- -- -- -- 
 
Data from one-way ANOVAs and Tukey’s post-hoc analyses are summarized here. 
• Group mean was higher among the designated exposure group, compared to the 
Control group:  = p < 0.05,  = p < 0.10,  = p < 0.20. 
• Group mean was lower in the designated exposure group, than in the Control group: 
 = p < 0.05,  = p < 0.10,  = p < 0.20. 
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Table 3.4 Differences in Hepatic Lipid Peroxidation and Redox Potentials by Offspring Sex 
 
PND10 Offspring 
Variable Female (n=60) Male (n=58) T-test 
p-value* 
F-test 
p-value** Category Name Mean SD Mean SD 
Lipid Oxidation Liver 8-iso-PGF2 239.70 103.00 253.10 109.50 0.4966 0.6404 
Redox 
Parameters 
Liver EhGSH -222.40 21.72 -226.80 13.09 0.1815e 0.0002a 
Liver EhCys -207.00 38.53 -204.90 39.50 0.7719 0.8492 
Liver S-glut 250.70 392.50 66.72 245.40 0.0040b 0.0007a 
Metabolic 
Parameters 
Body Weight 5.68 0.90 5.53 1.12 0.4151 0.0943d 
Percent Liver Weight 2.95 0.52 2.73 0.55 0.0284c 0.6109 
Serum Leptin 5.93 5.66 4.59 5.32 0.2072 0.6560 
10-month Offspring 
Variable Female (n=65) Male (n=68) T-test 
p-value* 
F-test 
p-value** Category Name Mean SD Mean SD 
Lipid Oxidation Liver 8-iso-PGF2 185.60 77.25 196.00 74.49 0.4312 0.7673 
Redox 
Parameters 
Liver EhGSH -229.40 5.85 -228.90 9.54 0.7073 0.0005a 
Liver EhCys -144.00 18.94 -147.50 26.36 0.4581 0.0256c 
Liver S-glut 0.93 0.38 1.14 0.38 0.0043b 0.9236 
Metabolic 
Parameters 
Body Weight 34.63 6.81 44.87 4.67 0.0001a 0.0026b 
Percent Liver Weight 3.52 0.66 3.92 1.00 0.0066b 0.0010b 
Percent mWAT Weight 3.91 1.17 3.55 0.82 0.0439c 0.0042b 
Serum Leptin 10.05 4.98 13.14 4.91 0.0006a 0.9195 
Serum Insulin 2.37 2.62 5.67 3.54 0.0001a 0.0180c 
 
*Independent t-tests were used to compare variable means between offspring sexes. 
** Equality of Variance was assessed via F-test, where the null hypothesis is no difference in variance between sexes. 
To highlight trends of potential biological importance, a wide range of p-values were annotated in this Table: Significance was defined as: a 
p<0.001, b p<0.01, c p<0.05. Borderline significant p-values were defined as: d p< 0.10. Suggestive p-values were defined as: e p<0.20. 
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Table 3.5 Non-parametric Correlations between Hepatic Lipid Peroxidation and Redox Potentials in Dams and Offspring 
Measure 
Kendall’s 
Tau 
8-iso-
PGF2 
Eh GSH Eh Cys S-glut 
8-iso-
PGF2 
Eh GSH Eh Cys S-glut 
 Dams (n=97)  
8-iso-PGF2 
Coefficient 1.0000 0.0313 0.0885 0.1425  
p-value n/a 0.6565 0.2250 0.0419 
Eh GSH 
Coefficient 0.0313 1.0000 0.4712 -0.2939 
p-value 0.6565 n/a  <0.0001a <0.0001a 
Eh Cys 
Coefficient 0.0885 0.4712 1.0000 -0.0167 
p-value 0.2250 <0.0001a n/a 0.8154 
S-glut 
Coefficient 0.1425 -0.2939 -0.0167 1.0000 
p-value 0.0419 <0.0001a 0.8154 n/a 
 PND10 Females (n=60) PND10 Males (n=58) 
8-iso-PGF2 
Coefficient 1.0000 0.0961 -0.0418 0.1300 1.0000 0.0790 0.1378 0.0013 
p-value n/a 0.2783 0.6370 0.1612  n/a 0.3857 0.1299e 0.9887 
Eh GSH 
Coefficient 0.0961 1.0000 0.0147 0.1286 0.0790 1.0000 0.2594 -0.3338 
p-value 0.2783  n/a 0.8683 0.1656 0.3857  n/a 0.0044b 0.0003a 
Eh Cys 
Coefficient -0.0418 0.0147 1.0000 0.4168 0.1378 0.2594 1.0000 -0.3701 
p-value 0.6370 0.8683 n/a <0.0001a 0.1299e 0.0044b n/a <0.0001a 
S-glut 
Coefficient 0.1300 0.1286 0.4168 1.0000 0.0013 -0.3338 -0.3701 1.0000 
p-value 0.1612 0.1656 <0.0001a n/a 0.9887 0.0003a <0.0001a n/a 
 10-month Females (n=65) 10-month Males (n=68) 
8-iso-PGF2 
Coefficient 1.0000 -0.0370 0.1631 0.0093 1.0000 0.0564 0.2134 0.0472 
p-value  n/a 0.6897 0.1020e 0.9662  n/a 0.6911 0.1453e 0.6700 
Eh GSH 
Coefficient -0.0370 1.0000 -0.0904 -0.1327 0.0564 1.0000 -0.0109 0.1614 
p-value 0.6897  n/a 0.3646 0.1527 0.6911  n/a 0.9416 0.1057e 
Eh Cys 
Coefficient 0.1631 -0.0904 1.0000 0.1791 0.2134 -0.0109 1.0000 -0.1436 
p-value 0.1020e 0.3646 n/a 0.0726d 0.1453e 0.9416 n/a 0.1499e 
S-glut 
Coefficient 0.0093 -0.1327 0.1791 1.0000 0.0472 0.1614 -0.1436 1.0000 
p-value 0.9662 0.1527 0.0726d n/a 0.6700 0.1057e 0.1499e n/a 
Kendall’s Tau, a non-parametric, rank-based correlation method was used due to the non-normal distributions of hepatic 8-iso and S-glut 
dams and offspring. To highlight trends of potential biological importance, a wide range of p-values were annotated in this Table: 
Significance was defined as: a p<0.001, b p<0.01, c p<0.05. Borderline significant p-values were defined as: d p< 0.10. Suggestive p-values 
were defined as: e p<0.20. 
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Table 3.6 Dam Univariate Analysis of Variables Impacting Hepatic Lipid Peroxidation and Redox Potentials 
 
Variable 
Ln-(8-iso-PGF2) EhGSH EhCys Ln-(S-glut) 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Mediterranean Diet 0.108 0.3934 -0.425 0.8902 -5.592 0.4110 -0.144 0.7198 
Western Diet 0.181 0.1723e 0.320 0.9198 -7.963 0.2598 -0.370 0.3778 
BPA 0.151 0.1538e 1.604 0.5303 8.382 0.1399e -0.086 0.7980 
Litter Size (# of pups) -0.111 0.2888 -0.104 0.3118 -0.102 0.3409 0.152 0.0989d 
Time to Delivery (days) -0.151 0.1464e -0.068 0.5132 -0.130 0.2235 0.014 0.4402 
Percent Male Pups 0.003 0.9790 0.072 0.4840 0.037 0.7268 0.007 0.4518 
Percent Avy/a Pups -0.054 0.6074 -0.154 0.1341e -0.080 0.4537 0.000 0.9666 
Dam Body Weight @ Exposure 0.071 0.4915 0.191 0.0622d 0.175 0.0999d 0.091 0.3697 
Dam Pre-Gestational Weight Change 0.161 0.1183e -0.064 0.5377 -0.004 0.9718 0.153 0.3121 
Dam Body Weight @ Mate-Pairing 0.177 0.0869d 0.144 0.1609e 0.169 0.1122e 0.151 0.1238 
Dam Pregnancy Weight Gain -0.215 0.0378c -0.053 0.6070 -0.032 0.7659 0.013 0.8373 
Dam Body Weight @ Sacrifice -0.084 0.4211 0.040 0.7010 0.071 0.5050 0.067 0.2647 
Dam Percent Liver Weight -0.268 0.0090b -0.242 0.0173c -0.091 0.3960 52.91 0.0171c 
Dam Percent mWAT Weight 0.061 0.5600 0.073 0.4768 0.129 0.2266 9.35 0.6330 
Dam Serum Insulin -0.295 0.0093b 0.100 0.3869 0.015 0.9005 -0.133 0.3108 
Dam Serum Leptin -0.089 0.4114 -0.040 0.7104 0.044 0.6934 0.081 0.0754d 
 
Single linear regression models were performed to assess the univariate association between potential predictive variables 
and outcomes measures of lipid oxidation or redox parameters. To highlight trends of potential biological importance, a wide 
range of p-values were annotated in this Table: Significance was defined as: a p<0.001, b p<0.01, c p<0.05. Borderline 
significant p-values were defined as: d p< 0.10. Suggestive p-values were defined as: e p<0.20. 
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Table 3.7 PND10 Offspring Sex-Stratified Univariate Analysis of Variables Impacting Hepatic Lipid Peroxidation and Redox 
Potentials  
 
Variable 
Ln-(8-iso-PGF2) EhGSH EhCys Ln-(S-glut) 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
FEMALE PND10 OFFSPRING 
Mediterranean Diet 0.106 0.5334 10.784 0.1168e -7.626 0.5352 0.573 0.4584 
Western Diet 0.549 0.0027b 4.858 0.4914 -7.736 0.5437 0.185 0.8148 
BPA -0.156 0.3073 13.542 0.0154c 3.461 0.7335 0.193 0.7592 
Litter Size (# of pups) -0.021 0.8753 -0.265 0.0411c 0.018 0.8891 0.020 0.9305 
Time to Delivery (days) 0.069 0.6027 0.055 0.6752 -0.232 0.0739d -0.070 0.0414c 
PND10 Body Weight @ Sacrifice -0.041 0.7584 -0.381 0.0027b -0.081 0.5400 -0.660 0.0695d 
PND10 Percent Liver Weight 0.072 0.5851 -0.051 0.7000 0.183 0.1628e 70.43 0.2467 
PND10 Serum Leptin 0.083 0.5551 -0.208 0.1344e -0.171 0.2217 -0.093 0.0987d 
Dam Body Weight @ Exposure 0.278 0.0318c -0.027 0.8376 -0.210 0.1079e -0.203 0.3553 
Dam Pre-Gestational Weight Change -0.122 0.3536 -0.146 0.2646 0.016 0.9056 -0.410 0.1145e 
Dam Body Weight @ Mate-Pairing 0.067 0.6134 -0.028 0.8334 -0.365 0.0041b -0.331 0.0049b 
Dam Pregnancy Weight Gain -0.018 0.8895 -0.024 0.8549 -0.286 0.0267c -0.440 0.0021b 
Dam Body Weight @ Sacrifice 0.075 0.5706 -0.086 0.5126 -0.318 0.0132c -0.388 0.0003a 
Dam Percent Liver Weight -0.220 0.0916d 0.014 0.9160 -0.054 0.6824 -49.97 0.2761 
Dam Percent mWAT Weight 0.177 0.1767e 0.060 0.6506 -0.184 0.1586e -90.48 0.0552d 
Dam Serum Insulin -0.263 0.0929d -0.041 0.7954 0.089 0.5762 0.171 0.6563 
Dam Serum Leptin -0.115 0.4080 -0.039 0.7821 -0.237 0.0845d -0.208 0.0157c 
Dam Liver 8-iso-PGF2 0.344 0.0072
b 0.156 0.2346 0.113 0.3881 0.006 0.0254c 
Dam Liver EhGSH (mV) 0.132 0.3131 -0.069 0.6013 -0.177 0.1764e -0.003 0.9181 
Dam Liver EhCys (mV) 0.054 0.6911 -0.073 0.5900 -0.248 0.0632d -0.026 0.0415c 
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Table 3.7 PND10 Offspring Sex-Stratified Univariate Analysis of Variables Impacting Hepatic Lipid Oxidation and Redox 
Parameters, Continued  
 
MALE PND10 OFFSPRING 
Mediterranean Diet -0.264 0.0880d 0.973 0.829 5.321 0.697 -0.234 0.7013 
Western Diet 0.004 0.978 -2.113 0.618 6.052 0.637 0.289 0.6085 
BPA 0.032 0.793 -2.931 0.403 -4.251 0.688 0.300 0.5242 
Litter Size (# of pups) -0.154 0.247 -0.283 0.0330c -0.108 0.425 -0.151 0.3068 
Time to Delivery (days) -0.225 0.0890d -0.112 0.409 -0.172 0.201 0.019 0.4291 
PND10 Body Weight @ Sacrifice -0.105 0.434 -0.031 0.820 -0.011 0.934 0.215 0.3098 
PND10 Percent Liver Weight 0.007 0.957 0.257 0.0535d 0.233 0.0808d -52.44 0.2129 
PND10 Serum Leptin -0.201 0.1412e 0.049 0.721 0.052 0.708 -0.023 0.6233 
Dam Body Weight @ Exposure 0.226 0.0879d 0.164 0.223 -0.055 0.686 -0.002 0.9858 
Dam Pre-Gestational Weight Change -0.403 0.0017b 0.048 0.723 -0.026 0.847 0.119 0.5991 
Dam Body Weight @ Mate-Pairing -0.045 0.736 0.283 0.0328c -0.006 0.965 0.017 0.8804 
Dam Pregnancy Weight Gain -0.314 0.0162c -0.472 0.0002a -0.149 0.269 0.002 0.9732 
Dam Body Weight @ Sacrifice -0.291 0.0268c -0.339 0.0100c -0.173 0.1969e 0.012 0.8603 
Dam Percent Liver Weight -0.178 0.1810e -0.110 0.416 -0.137 0.308 -8.674 0.7350 
Dam Percent mWAT Weight -0.105 0.431 -0.155 0.251 0.027 0.841 12.858 0.6541 
Dam Serum Insulin 0.169 0.290 -0.048 0.768 -0.157 0.335 0.167 0.5128 
Dam Serum Leptin 0.042 0.766 -0.046 0.750 -0.072 0.617 0.012 0.8536 
Dam Liver 8-iso-PGF2 0.371 0.0041b 0.080 0.553 0.170 0.206 -0.004 0.1364 
Dam Liver EhGSH (mV) 0.108 0.419 0.149 0.268 0.194 0.1487e 0.008 0.7628 
Dam Liver EhCys (mV) 0.068 0.630 -0.104 0.464 -0.080 0.574 0.004 0.6899 
 
Single linear regression models were performed to assess the univariate association between potential predictive variables 
and outcomes measures of lipid oxidation or redox parameters. To highlight trends of potential biological importance, a wide 
range of p-values were annotated in this Table: Significance was defined as: a p<0.001, b p<0.01, c p<0.05. Borderline 
significant p-values were defined as: d p< 0.10. Suggestive p-values were defined as: e p<0.20. 
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Table 3.8 10-month Offspring Sex-Stratified Univariate Analysis of Variables Impacting Hepatic Lipid Peroxidation and Redox 
Potentials 
 
Variable 
Ln-(8-iso-PGF2) EhGSH EhCys Ln-(S-glut) 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
Effect 
Estimate 
p-value 
FEMALE 10-month OFFSPRING 
Mediterranean Diet 0.250 0.0246c -1.232 0.518 4.070 0.531 0.007 0.9565 
Western Diet 0.191 0.0842d -2.087 0.308 -5.082 0.477 -0.126 0.3933 
BPA 0.073 0.419 0.604 0.706 -0.427 0.939 0.026 0.8192 
Litter Size (# of pups) -0.147 0.242 -0.069 0.615 0.179 0.224 0.005 0.8876 
Time to Delivery (days) -0.127 0.315 -0.069 0.616 0.013 0.928 -0.002 0.8107 
10M Body Weight @ Sacrifice 0.001 0.995 -0.199 0.1459e 0.209 0.1537e 0.014 0.1087e 
10M Percent Liver Weight 0.121 0.338 0.085 0.538 -0.142 0.335 -5.862 0.4982 
10M Percent mWAT Weight -0.059 0.639 -0.274 0.0427c 0.016 0.912 2.183 0.6511 
10M Serum Leptin 0.087 0.501 -0.218 0.1173e -0.008 0.956 0.000 0.4549 
10M Serum Insulin -0.031 0.810 -0.198 0.1546e -0.149 0.323 0.000 0.9595 
10M Serum Resistin 0.106 0.414 -0.042 0.767 -0.180 0.232 0.000 0.3798 
Dam Body Weight @ Exposure 0.007 0.955 0.243 0.0741d -0.036 0.807 0.062 0.1575e 
Dam Pre-Gestational Weight Change 0.180 0.1512e 0.006 0.965 -0.007 0.961 -0.019 0.7319 
Dam Body Weight @ Mate-Pairing 0.066 0.602 0.212 0.1199e -0.072 0.626 0.012 0.6322 
Dam Pregnancy Weight Gain -0.241 0.0534c -0.138 0.314 0.017 0.910 0.012 0.7118 
Dam Body Weight @ Sacrifice -0.112 0.375 0.037 0.791 -0.010 0.944 0.024 0.3443 
Dam Percent Liver Weight -0.100 0.429 -0.054 0.697 0.182 0.216 9.055 0.2427 
Dam Percent mWAT Weight 0.118 0.350 -0.196 0.1510e 0.025 0.868 3.195 0.6712 
Dam Serum Insulin 0.101 0.455 -0.221 0.1320e 0.192 0.218 0.068 0.0640d 
Dam Serum Leptin 0.136 0.287 -0.010 0.942 -0.095 0.529 -0.013 0.4195 
Dam Liver 8-iso-PGF2 -0.053 0.679 0.055 0.691 -0.014 0.924 -0.001 0.3367 
Dam Liver EhGSH (mV) 0.223 0.0768d 0.137 0.323 -0.090 0.548 -0.002 0.6785 
Dam Liver EhCys (mV) 0.179 0.1646e 0.171 0.226 -0.152 0.320 -0.001 0.6855 
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Table 3.8 10-month Offspring Sex-Stratified Univariate Analysis of Variables Impacting Hepatic Lipid Peroxidation and Redox 
Potentials, Continued 
 
MALE 10-month OFFSPRING 
Mediterranean Diet 0.058 0.569 0.118 0.971 3.395 0.713 0.019 0.8648 
Western Diet 0.039 0.706 1.788 0.600 7.314 0.453 0.110 0.3546 
BPA 0.114 0.1666e -2.120 0.430 6.062 0.438 0.005 0.9557 
Litter Size (# of pups) 0.143 0.244 -0.207 0.1403e 0.127 0.391 -0.024 0.3861 
Time to Delivery (days) -0.205 0.0933d -0.237 0.0908d 0.062 0.675 0.008 0.2183 
10M Body Weight @ Sacrifice -0.070 0.573 -0.026 0.855 -0.043 0.771 0.001 0.9124 
10M Percent Liver Weight 0.036 0.768 0.030 0.833 0.104 0.482 -1.372 0.7533 
10M Percent mWAT Weight 0.122 0.323 -0.142 0.316 -0.182 0.215 1.157 0.8371 
10M Serum Leptin -0.054 0.664 -0.067 0.640 0.030 0.843 -0.000 0.7130 
10M Serum Insulin -0.057 0.645 0.082 0.569 0.000 0.998 -0.000 0.6430 
10M Serum Resistin -0.112 0.366 0.159 0.264 -0.014 0.926 -0.000 0.6040 
Dam Body Weight @ Exposure -0.030 0.810 0.161 0.255 -0.293 0.0432c 0.030 0.2545 
Dam Pre-Gestational Weight Change -0.075 0.544 0.132 0.353 0.144 0.329 -0.003 0.9531 
Dam Body Weight @ Mate-Pairing -0.084 0.497 0.248 0.0761d -0.190 0.1957e 0.005 0.8020 
Dam Pregnancy Weight Gain 0.067 0.587 -0.094 0.509 0.007 0.962 0.048 0.0280c 
Dam Body Weight @ Sacrifice 0.011 0.927 0.091 0.523 -0.135 0.360 0.054 0.0045b 
Dam Percent Liver Weight -0.016 0.895 -0.175 0.214 -0.009 0.952 12.166 0.0966d 
Dam Percent mWAT Weight -0.008 0.949 0.203 0.1495e -0.157 0.286 7.329 0.1549e 
Dam Serum Insulin 0.058 0.665 -0.283 0.0571d 0.238 0.1244e 0.037 0.2003 
Dam Serum Leptin 0.067 0.597 0.205 0.1573e 0.014 0.926 -0.007 0.5937 
Dam Liver 8-iso-PGF2 -0.217 0.0819
d -0.018 0.901 -0.216 0.1549e -0.000 0.1661e 
Dam Liver EhGSH (mV) 0.172 0.1640e 0.294 0.0342c -0.045 0.760 0.003 0.4654 
Dam Liver EhCys (mV) 0.047 0.710 0.310 0.0300c -0.189 0.213 0.000 0.8766 
 
Single linear regression models were performed to assess the univariate association between potential predictive variables 
and outcomes measures of lipid oxidation or redox parameters. To highlight trends of potential biological importance, a wide 
range of p-values were annotated in this Table: Significance was defined as: a p<0.001, b p<0.01, c p<0.05. Borderline 
significant p-values were defined as: d p< 0.10. Suggestive p-values were defined as: e p<0.20. 
		 14Ͷ	 	
Figure	3.ͷ	 Associations	between	Dam	Metabolic	Parameters	and	Oxidative	Outcomes	in	Dams,	PND10,	and	10-month	Offspring		
		Multiple	dam	metabolic	parameters	had	consistent	effects	on	oxidative	outcomes	in	mice	across	generation	and	offspring	age.	Oxidative	outcomes	are	grouped	by	their	general	impact	on	the	redox	environment:	reducing	or	oxidizing.	Arrows	between	the	dam	diagram	(left	column)	and	oxidative	outcome	boxes	represent	general	trends;	it	does	not	imply	that	every	oxidative	response	in	the	box	is	associated	with	the	metabolic	parameter,	just	that	the	impact	of	the	metabolic	parameter	corresponds	to	one	or	more	of	the	outcomes	in	the	box.	For	example,	greater	gestational	weight	gain	(GWG)	is	associated	with	decreased	8-iso	in	dams,	PND10	males,	and	10-month	females;	GWG	is	also	associated	with	decreased	
EhGSH	in	PND10	males,	decreased	EhCys	in	PND10	females,	and	increased	s-glut	in	10-month	males,	all	of	which	result	in	a	reducing	redox	environment.	In	PND10	and	10-month	offspring,	dam	body	weight	is	associated	with	both	reducing	and	oxidizing	outcomes.	
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Supplemental Information 
 
 
Table S3.1 Distributions of Hepatic Lipid Oxidation and Redox Parameters in Dams and 
Offspring 
 
Hepatic Measure N Mean SD Min. 25% 50% 75% Max. 
Dam Levels 
8-iso (pg/mg) 95 176.77 91.73 8.71 123.71 155.23 201.15 575.04 
EhGSH (mV) 95 -222.39 12.43 -250.58 -228.49 -223.94 -217.58 -192.51 
     GSH (uM) 96 3229.60 1987.46 292.88 1793.76 3112.16 4464.68 7742.00 
     GSSG (uM) 95 197.33 118.98 14.49 96.80 203.88 284.29 562.73 
EhCys (mV) 90 -151.49 26.77 -225.15 -165.37 -144.91 -133.68 -107.16 
     Cys (uM) 95 140.54 265.78 0.00 18.56 38.56 132.59 1508.23 
     CysS (uM) 95 29.95 72.78 0.00 6.24 15.04 28.03 639.35 
S-glut (nmol/mg) 97 27.31 27.49 0.32 3.11 25.12 43.78 162.17 
PND10 Offspring Levels 
8-iso (pg/mg) 118 246.27 105.99 14.06 171.92 239.85 308.09 652.75 
EhGSH (mV) 117 -224.56 18.10 -254.44 -235.68 -229.07 -219.10 -114.13 
     GSH (uM) 117 5068.36 3051.27 63.31 2126.61 5645.79 7706.09 9911.53 
     GSSG (uM) 117 468.24 390.03 12.90 104.68 410.62 678.86 2020.42 
EhCys (mV) 117 -205.96 38.85 -269.88 -234.42 -220.36 -171.21 -125.56 
     Cys (uM) 117 1795.93 2040.61 25.35 141.31 1405.59 2221.24 9741.66 
     CysS (uM) 117 80.54 112.59 0.46 26.75 41.43 79.42 675.86 
S-glut (nmol/mg) 111 157.89 338.05 0.38 3.60 6.25 68.79 1833.28 
10-month Offspring Levels 
8-iso (pg/mg) 133 190.96 75.74 84.04 139.36 175.25 214.32 510.79 
EhGSH (mV) 107 -229.15 7.83 -239.62 -233.80 -231.55 -227.36 -188.76 
     GSH (uM) 107 5780.99 2010.15 512.50 4957.41 6120.13 6976.98 9576.17 
     GSSG (uM) 107 452.86 188.78 45.63 380.26 465.75 556.42 1109.45 
EhCys (mV) 96 -145.72 22.90 -213.41 -156.04 -140.13 -129.28 -105.45 
     Cys (uM) 107 66.99 214.78 3.43 14.49 26.05 46.09 2176.87 
     CysS (uM) 107 10.89 12.11 0.00 3.17 7.23 14.43 67.11 
S-glut (nmol/mg) 109 1.03 0.39 0.10 0.80 0.96 1.21 2.89 
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Figure S3.1 Glutathione Redox Potentials of this Mouse Study Population 
 
 
This figure is modified from Hansen & Harris, 2012 [94]. The three boxplots at the bottom: 
dams, PND10, and 10-months, represent the distribution of glutathione redox potentials 
(EhGSH). The box represents the interquartile range (IQR) of each age group’s EhGSH, the 
line in the box represents the median, and the whiskers represent the minimum and 
maximum. This illustrates the median and IQR are similar across all ages. 
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CHAPTER 4 
 
Trimester-Specific Influences of Prenatal Bisphenol A and Mediterranean Diet  
on Metabolic Risk Score and Serum Lipid Oxidation in Human Adolescents 
 
 
ABSTRACT 
Prenatal programming of metabolic syndrome (MetSyn) may contribute to the growing 
prevalence of MetSyn worldwide. Gestational diet and exposure to bisphenol A (BPA) are 
associated with altered MetSyn risk in children. To examine the prenatal programming impact of 
maternal BPA exposure and the potential protective effect adherence to a Mediterranean diet 
(MDS) might have on MetSyn risk in youth, we re-enrolled 250 maternal-child dyads from a 
longitudinal human birth cohort, Early Life Exposure in Mexico to ENvironmental Toxicants 
(ELEMENT). Predictive models analyzed the impact of pregnancy-average and trimester-
specific maternal urinary BPA levels, MDS, and the BPA*MDS interaction on metabolic risk 
score (MRS) and serum lipid oxidation (8-isoprostane, 8-iso) levels in peripubertal youth. 
Pubertal status, urinary BPA, diet, physical activity and other youth characteristics were included 
in linear regression analyses to examine the potential for postnatal alteration of prenatal 
programming effects. In models of all youth, maternal pregnancy average and second trimester 
(T2) urinary BPA were associated with suggestive (p<0.20) decreases in youth MRS (-0.36 and -
0.29, respectively); while the pregnancy average BPA*MDS interaction was associated with a 
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suggestive increase in MRS (0.065, p<0.20). These associations were driven by boys; no 
relationship was observed among exposures and MRS in girls. Maternal MDS did not impact 
youth MRS. Among all youth, maternal pregnancy average and T2 urinary BPA was associated 
with increased serum 8-iso levels (16.8%, p<0.20, and 20.1%, p<0.10, respectively). In this case, 
the associations, between prenatal exposures and youth 8-iso, were driven by girls. Maternal 
pregnancy average and T2 MDS impacted youth serum 8-iso, but in opposite directions by sex; 
MDS was associated with increased 8-iso in girls, but decreased 8-iso in boys. Pregnancy 
average and T2 maternal BPA were suggestive predictors of both youth health outcomes (MRS 
and serum 8-iso), supportive of the second trimester as a critical window in the prenatal 
programming of MetSyn. Although sex-specific differences were observed, maternal MDS only 
impacted youth 8-iso, while the BPA*MDS interaction contributed more to youth MRS. The 
contribution of youth BPA exposure, MDS, vigorous physical activity levels, and pubertal status 
to predictive models of youth MRS and 8-iso supports the theory that healthy lifestyle behaviors 
during peripuberty may alter the effect of prenatal programming. Thus, a child’s health trajectory 
at birth may be modified later in life. 
 
INTRODUCTION 
Prenatal programming of metabolic syndrome (MetSyn) has been reported in 
experimental and epidemiologic studies [1–6]. The maternal metabolic environment during 
pregnancy, including maternal obesity [7,8], under nutrition [9,10], and glucocorticoid levels 
[10,11] has been linked to an increased risk of offspring MetSyn. Perinatal exposure to the 
endocrine disrupting chemical (EDC), bisphenol A (BPA) has also been associated with 
increased MetSyn risk in offspring [12–15]. Youth MetSyn development is known to be 
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impacted by lifestyle behaviors, such as diet, leisure-time physical activity, and parental health 
literacy [16,17], but prenatal programming suggests that disease risk can also be affected before 
birth. This amplified risk of MetSyn at birth can increase lifelong morbidity, thus altering the 
child’s health trajectory. Pediatric MetSyn is associated with greater odds of obesity and poor 
cardiovascular health in childhood [18,19], and with a 2- to 3-fold greater risk of MetSyn, Type 
2 Diabetes (T2DM), and atherosclerosis in adulthood [20]. Improved understanding of 
environmental factors capable of prenatally programming MetSyn is warranted. 
Prenatal BPA exposure has been associated with alterations in early life health outcomes, 
such as decreased birth weight, increased birth length [21], increased blood pressure at 4 years 
[22]. Animal models of perinatal BPA exposure report increased MetSyn development in 
adulthood [23–25], suggestive of the potential for this prenatal programming in humans, also. 
The ability of prenatal BPA to alter offspring metabolism is concerning, because urinary BPA 
levels are measurable in >95% of pregnant mothers in the U.S. [26,27]. BPA crosses the placenta 
[28,29], and reduced fetal expression of BPA-specific biotransformation enzymes (e.g. 
UGT2B15, SULT1A1, and STS) [30], suggests an impaired fetal ability to metabolize BPA. BPA 
is present in food and beverage packaging in the form of epoxy resins and polycarbonate plastics 
[31–33]. Thus, studying the interaction of BPA exposure and maternal diet during pregnancy 
will more accurately model concurrent real-world exposures, rather than investigating BPA or 
diet independently. 
Prenatal programming research often focuses on exposures that increase disease risk, 
such as BPA, but a healthy maternal diet may exert a protective effect on offspring, conferring 
resilience against disease later in life. A Mediterranean-style diet is clinically recommended to 
prevent and reverse progression of metabolic diseases in adults [34]. Mediterranean diet 
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consumption has been associated with better glycemic control [35], improved lipid profiles [36], 
and a decreased risk of metabolic diseases [37–40]. A meta-analysis reported Mediterranean diet 
adherence in adults was protective against many MetSyn factors, including waist circumference, 
systolic and diastolic blood pressure, circulating HDL-C, triglycerides, and glucose [41].  
Despite the overwhelming metabolic health benefits attributed to Mediterranean diet adherence 
in adults, the affect of perinatal Mediterranean diet exposure on offspring MetSyn has not been 
examined. Maternal Mediterranean diet consumption during pregnancy is associated with 
protection against low birth weight (LBW) and low placental weight [42]. LBW has been 
associated with greater risk of coronary heart disease [43] and insulin resistance [44] in 
adulthood.  If maternal Mediterranean diet intake can reduce the incidence of LBW, intake may 
also be associated with decreased metabolic disease later in life. This link, between maternal 
consumption of a Mediterranean diet during pregnancy and offspring metabolic health, has not 
been investigated.   
Diagnosing MetSyn in children is challenging, due to developmental changes in 
anthropometric variables, blood pressure, and serum lipids as children grow [45]. Age-specific 
diagnostic criteria are recommended to define pediatric MetSyn [46]. Pubertal development 
compounds the challenge of diagnosing MetSyn in youth. Pubertal changes include sex-specific 
fat accumulation and distribution, a ~30% decrease in insulin sensitivity, with a concurrent 
increase in insulin secretion [45,47,48]. We used both a Metabolic Risk Score [49] and a 
measure of lipid oxidation, serum 8-isoprostane [50], to analyze MetSyn in this study population. 
Oxidative stress, defined as an imbalance of oxidizing and reducing molecules, has been 
implicated as an underlying risk factor in the pathogenesis of many chronic metabolic diseases, 
including MetSyn [51,52].  
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Among U.S. youth, 12-19 years old, MetSyn prevalence is greatest among Hispanic boys 
(12.9%) and girls (8.2%), compared to non-Hispanic white and black children [53,54]. The 
reason for this disproportionate risk is not well understood. To address the lack of evidence in 
human studies supporting the theory that MetSyn can be prenatally programmed by maternal diet 
and EDC exposure, this study examines the effect of prenatal BPA exposure and Mediterranean 
diet on metabolic risk and serum lipid oxidation levels in Hispanic youth. To assess whether 
current, peripubertal exposures and health characteristics could impact the prenatal 
programming, youth BPA, diet, blood pressure, serum hormone, lipid, and lipid oxidation levels, 
physical activity, and pubertal status data were collected from adolescents participating in the 
Early Life Exposures in Mexico to ENvironmental Toxicants (ELEMENT) human birth cohort in 
Mexico City. A secondary analysis investigated the potential effect modification of prenatal BPA 
on adolescent metabolic health by maternal Mediterranean diet adherence during pregnancy. 
 
METHODS 
Study Population 
The human birth cohort, Early Life Exposures in Mexico to ENvironmental Toxicants 
(ELEMENT) is built on a 23-year collaboration with the Instituto Nacional de Salud Publica 
(INSP) in Mexico. The 250 mother-child dyads included in this study were originally recruited 
from hospitals serving low-to-moderate income populations from 1997–2005 [55–59]. Most 
mothers (n=236) were recruited during their first trimester (T1) prenatal visit; maternal height, 
weight, urine samples, and questionnaires on food intake and demographic data were collected at 
each trimester of pregnancy. The additional 14 mothers were recruited at the time of delivery, so 
pregnancy values are not available.  
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The children have been continuously followed from birth through childhood to 
adolescence. At the adolescent visit, conducted in 2010-2012, experienced study personnel 
collected biological samples, anthropometry, physical activity and food frequency questionnaires 
(Figure 4.1). Youth re-recruitment for this study included 132 girls and 118 boys; MRS was 
calculated for 99% of boys and girls. Serum 8-isoprostane was measured in 97% of boys and 
96% of girls, dependent on serum sample volume.  All participants provided informed consent 
prior to enrollment; the study protocols were approved by the research and ethics committees of 
INSP and the University of Michigan. 
 
Urinary Bisphenol A (BPA) Analysis 
 Spot urine samples from mothers at Trimester 1 (n=119), Trimester 2 (n=200), and 
Trimester 3 (n=225) prenatal clinic visits were analyzed for total (free + glucuronidated) BPA at 
NSF International (Ann Arbor, MI, USA) via isotope dilution-liquid chromatography-tandem 
mass spectrometry (ID-LC-MS/MS) [55]. The NSF protocol was developed based on the Centers 
for Disease Control and Prevention (CDC) Laboratory Procedure Manuals (method no. 6301.01; 
revised: April 13, 2009); thus measurements correspond to urinary BPA levels measured in 
NHANES [60]. Specific gravity (SG) was measured with a digital refractometer (ATAGO, 
Company Ltd, Tokyo, Japan) in all urine samples to adjust for variability in urine output and 
concentration between study participants. Youth urinary BPA levels (n = 242) were assessed at 
NSF International by the same ID-LC-MS/MS method as maternal urinary samples. We have 
previously published additional details of the BPA analysis method [55].  
 
Mediterranean Diet Score (MDS) Adherence 
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Mothers completed an interviewer-administered food frequency questionnaire (FFQ) at 
their prenatal clinic visits in all three trimesters (n=227, 234, 235, respectively). The FFQ used 
for this study was a 116 item, semi-quantitative FFQ, validated among 134 women in Mexico 
City [61], based on the 131-item Harvard FFQ [62]. Study youth (n=250) completed FFQs, 
similar to the FFQs their mothers completed during pregnancy [63]. Youth MDS was calculated 
based on these FFQs, and was added to predictive models to adjust for youth’s current diet. 
Foods were compiled into food groups prior to coding into the MDS. Mediterranean diet 
scoring was first proposed by Trichopoulou [64–66]. This original MDS uses scoring criteria 
from 0-9 points (lowest to highest adherence). One point is given for above-median consumption 
of the five beneficial food categories: fish, legumes, fruits & nuts, vegetables, and cereal 
(assumed to be whole grain), and for below-median consumption of the three detrimental food 
categories: meat, poultry, and dairy (assumed to be whole fat). Individuals received an additional 
point if their daily alcohol consumption was within a moderate range (2-25g/day for women) 
[64].  
Multiple variations on the Trichopoulou MDS have been proposed by other authors, 
including adding categories for high-fat convenience foods, desserts, and sugar sweetened 
beverages [67]. We applied these variations, but the additions did not improve the MDS effect 
size or model fit, assessed by Akaike Information Criterion (AIC).  A 2011 comparison [165] of 
10 Mediterranean diet indices, including the Trichopoulou MDS and the aforementioned 
alterations, found that the Trichopoulou MDS had the highest correlation (r=0.84) with the core 
factors determining ‘adherence to the Mediterranean diet’. Since Trichopoulou MDS best 
characterized core Med diet factors and our models did not improve when adding additional food 
groups, we used the Trichopoulou MDS to assess maternal Med diet adherence, in this study 
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[67].  The only variation we made was to remove the alcohol consumption category, since 
alcohol intake was negligible amongst both pregnant women and adolescents; thus the MDS in 
this study ranges from 0-8 points (Figure S4.1, Table S4.1). 
 
Youth Serum Metabolic Markers 
 Fasting glucose, triglycerides (TG) and HDL-C were measured with a biochemical 
analyzer (Cobas Mira Plus, Roche Diagnostics, Basel, Switzerland) on-site, in Mexico City. 
Following venous blood collection, serum aliquots were frozen at -80oC and shipped from INSP 
in Mexico City to the Michigan Diabetes Research Center (MDRC) Chemistry Lab for analysis. 
Serum leptin was measured via RIA (Millipore), IGF-1 by chemiluminescence immunoassay 
(Immulite 1000). Youth metabolic health was assessed via a Metabolic Risk Score (MRS), 
previously validated for diagnosing MetSyn in youth [49]. Sex-specific z-scores, based on this 
sample, were calculated for four adolescent metabolism variables: waist circumference, fasting 
glucose, fasting lipids (TG/HDL-C), and average blood pressure ((SBP+DBP)/2). The sex-
specific MRSs, calculated by averaging the four z-scores, were normalized to zero. 
 
Youth Serum Lipid Oxidation 
  Quantitation of serum 8-isoprostane was performed to assess oxidative stress in study 
adolescents. Serum samples were stored at -80oC with 0.005% BHT to prevent oxidation during 
storage, then transferred on dry ice to Cayman Chemical (Ann Arbor, MI, USA). The 8-
isoprostane analyses were conducted via a competitive enzyme immunoassay (EIA) kit (No. 
516351), with sensitivity 2.7 pg/mL and intra-assay %CV 9.5%. The NIEHS initiative, 
Biomarkers of Oxidative Stress Study (BOSS) determined that F2-isoprostanes were readily 
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quantifiable markers of lipid peroxidation that relate to disease-relevant measures [68,69]. Other 
recent reviews of oxidative stress measures deemed 8-isoprostane to be a highly accurate 
measure of lipid peroxidation [70–72]. 
 
Model Covariates 
Maternal Characteristics 
Trimester-specific and post-partum maternal height and weight were measured on a 
professional scale (PAME, Puebla) to the nearest 0.1cm and 0.1kg, respectively. Maternal 
Trimester 1 (T1) BMI and gestational weight gain were calculated from these measures. Pre-
pregnancy BMI and gestational weight gain have been positively associated with infant birth 
weight [73], macrosomia, large for gestational age (LGA) [74], and child obesity [75–78]. Thus, 
both of these measures were examined as potential confounders in generalized linear models 
(GLM). 
 At baseline, mothers completed questionnaires on maternal education, length of time in 
Mexico City, and smoking history. In this cohort, maternal education is used as a proxy for 
socio-economic status; the two factors are highly correlated, but maternal education data was 
collected on more mothers. Study personnel recorded maternal age-at-pregnancy, parturition 
status, and delivery type (vaginal or Cesarian section).  
 
Youth Characteristics 
Peripubertal youth returned to the clinic for a single follow-up visit at 8-14 years of age. 
Youth height (to 0.1cm) and weight (to 0.1kg) were measured on a professional scale (PAME, 
Puebla). Waist circumference was measured to the nearest 1mm in a consistent location, guided 
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by sex-specific diagrams of measuring tape placement. All anthropometric data were obtained 
after adolescents removed clothing and shoes, remaining in their undergarments and a hospital 
gown. Seated blood pressure measurements were taken in duplicate and the average systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) levels were used in analyses. Fasting, 
venous blood samples were collected from adolescents and analyzed for serum hormone levels 
(leptin, IGF-1). 
 Youth in this study were peripubertal. A dichotomous puberty variable (Yes/No) was 
added to predictive models of youth MRS and 8-iso. The variable was a composite of physician-
assessed Tanner stages, recorded for all youth (n=250) during the study clinic visit. Tanner 
staging is a five-point scale of physical pubertal development based on pubic hair (boys and 
girls), breast (girls), and genital (boys) development [56,58,79].  
Advancement through Tanner stages during pubertal development is associated with the 
decreased insulin sensitivity of adolescence [80]. Sex-specific changes in circulating leptin levels 
also occur at puberty. Pre-pubertal boys and girls have similar leptin levels that increase with 
age; at puberty, leptin levels rise in girls and fall in boys, mirrored by sex-stratified changes in 
fat mass [81]. Insulin-like growth factor-1 (IGF1) levels also increase at puberty, triggered by 
increased gonadal sex steroid levels [82].  
Physical activity has been associated with decreased risk of MetSyn and insulin 
resistance in youth [83]. At the adolescent visit of this study, youth completed a self-reported 
physical activity questionnaire, previously validated in Mexican youth [84,85]. Responses were 
coded into vigorous (e.g. swimming, running, soccer) or moderate activities (e.g. walking, 
cleaning) and cumulative measures were created by adding the hour per week spent in each type 
of activity. 
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Statistical Analysis 
 Normality of all variables was investigated via Q-Q plots of residuals; right-skewed 
variables were Ln-transformed, including urinary BPA and serum 8-isoprostane. The 
distributions of the prenatal exposures (urinary BPA and MDS) were explored and intraclass 
correlation coefficients (ICCs) were calculated to compare exposure measures across trimesters, 
T1 vs. T2, T1 vs. T3, T2 vs. T3. Independent t-tests were performed on all study variables to 
determine which variables differed by youth sex.  
Generalized linear models (GLMs) were constructed to predict the two youth health 
outcomes of interest, (1) MRS and (2) serum 8-iso. To examine if prenatal timing of 
environmental exposures alters metabolic programming in offspring, trimester-specific models 
were run. For example, these models examined whether maternal Trimester 1 urinary BPA, 
MDS, and BPA*MDS impacted adolescent MRS and allowed comparison to the impact of 
Trimester 3 BPA, MDS, BPA*MDS on MRS. Pregnancy averages of urinary BPA and MDS 
were calculated for each mother, and models using these average exposures were also estimated. 
For instance, this model examined whether average maternal urinary BPA, MDS, and 
BPA*MDS across pregnancy altered adolescent MRS. Analyzing pregnancy average values may 
improve confidence in the associations observed between the prenatal exposures and youth 
metabolic health outcomes; potential variability inherent in spot urine samples is balanced by 
averaging values across pregnancy. Significant results in pregnancy average models, but not 
trimester-specific models, could also suggest that timing of the exposures (BPA & MDS) is less 
critical than the magnitude of exposure across pregnancy. Finally, due to previous studies 
identifying sexually dimorphic effects of BPA, sex-stratified models were run, in addition to 
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models including all adolescents. Predictive models did not differ if the 14 youth whose mother’s 
were recruited at delivery were excluded, thus all 250 mother-child dyads were included in the 
modeling process. 
Unadjusted models included the main prenatal exposure variables: maternal trimester-
specific urinary BPA, MDS, and BPA*MDS interaction, for both youth MRS and serum 8-iso 
outcomes. The BPA*MDS interaction term was added to all models to determine if maternal 
MDS modified the effect of prenatal BPA exposure on youth MRS or serum 8-isoprostane. 
Maternal education, youth puberty status, youth BPA and MDS were added to subsequent 
models as a priori covariates. Additional maternal and youth characteristics were investigated as 
potential model covariates, including: maternal trimester-1 BMI, maternal pregnancy weight 
gain, youth serum leptin and IGF-1, youth vigorous and moderate physical activity. In this study, 
predictive variables were sex specific; maternal T1 BMI contributed significantly in models for 
adolescent girls, while vigorous physical activity of adolescent boys significantly impacted 
models. 
Statistical significance was determined a priori at p < 0.05. Borderline significance (p < 
0.10) and suggestive significance (p < 0.20) were also used to assess data trends in this study. All 
analyses were conducted in SAS 9.4 (Cary, NC, USA). 
 
RESULTS 
Study Population 
 Mother’s age at recruitment into the ELEMENT cohort ranged from 14 – 44 years, 
averaging 26.8 years. A high school education was attained by 86% of the mothers. Maternal 
BMI at the T1 clinic visit averaged 25.9 kg/m2, and mothers gained an average of 2.6 kg during 
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pregnancy. Female adolescents comprised 52.8% of youth in the cohort. Only 34.8% of female 
youth had begun puberty, but 49.2% of males had entered puberty according to physician-
assessed Tanner staging (Table 4.1). 
Few variables differed significantly by youth sex. Maternal T1 urinary BPA was slightly 
greater among girls (1.60 ng/mL) than boys (1.46 ng/mL), but was only borderline significant (p 
= 0.059). BPA did not differ significantly in T2, T3, or youth urinary samples. Maternal 
adherence to the MDS did not differ by sex, at any trimester, nor did any other maternal 
covariates. Adolescent health outcomes of interest (MRS and serum 8-isoprostane) did not differ 
by youth sex, but other youth health measures did. Systolic blood pressure was greater in boys 
than girls (p = 0.016), while serum triglycerides (p < 0.001), serum leptin (p < 0.001), and serum 
IGF-1 levels (p < 0.001) were higher in girls compared to boys (Table S4.2).  
 
Maternal Exposures - Comparison Across Trimesters 
Median, specific-gravity adjusted, BPA measurements ranged from 1.14-1.48 ng/mL in 
maternal urine, but levels did not differ by trimester (Table 4.3). In all trimesters, the distribution 
of maternal urinary BPA was highly variable, illustrated by the large ICCs (Table S4.3, Figure 
S4.2A). The median MDS adherence of mothers did not differ across trimesters (Table 4.3). 
Although the ICCs comparing trimester 1 MDS to trimesters 2 and 3 were low (-0.03 & 0.11, 
respectively), the higher ICC comparing trimesters 2 and 3 (0.44, p < 0.05) suggests that 
maternal diets fluctuated more between T1 and T2, then stabilized in the second two trimesters 
of pregnancy (Table S4.3, Figure S4.2B).  
 
Adolescent Metabolic Risk Score & Serum 8-Isoprostane Levels 
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 Metabolic Risk Score (MRS) was normally distributed amongst the Mexican youth in this 
study. Median MRS amongst all youth was -0.02, with a range from -1.65 to 2.00. Since MRS 
was calculated as a sex-specific z-score, there were no differences by sex. Adolescent serum 8-
isoprostane levels were non-normal; a few children had high serum levels, right-skewing the 
data. Median 8-isoprostane measurements did not differ by youth sex; both boys and girls had 
extreme high values (Figure S4.2).  
 Adolescent MRS differed by youth age at re-enrollment, pubertal status, and serum leptin 
levels (Table 4.2). Among all youth, age was directly associated with increased MRS (p = 
0.036); this relationship was driven by boys (p = 0.044), not girls (p = 0.427). Similarly, youth 
who had entered puberty had significantly greater MRS (p = 0.000) than pre-pubertal youth; this 
was true amongst both girls (p = 0.001) and boys (p = 0.046). Higher serum leptin levels are 
associated with greater MRS in all youth (p = 0.000). Adolescent MRS did not differ by maternal 
age at pregnancy, educational attainment, and Trimester 1 BMI. Serum 8-isoprostane levels in 
youth did not differ by any maternal or adolescent factors (Table S4.4).  
 
Predictive Modeling of Adolescent Metabolic Risk Score 
Among all youth, average maternal urinary BPA and the BPA*MDS interactions across 
pregnancy trimesters tended to predict MRS. Average, Ln-transformed urinary BPA was 
associated with a suggestive decrease in MRS (-0.359, p = 0.132), while the BPA*MDS 
interaction associated with a suggestive increase in MRS (0.065, p = 0.191). Average BPA in T2 
was also associated with a suggestive decrease in MRS (-0.287, p = 0.183) among all youth. The 
relationships did not exist between T1 or T3 BPA and youth MRS. Maternal MDS adherence 
during pregnancy did not impact youth metabolic risk score in any adjusted models (Table 4.4).  
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Among male youth, the average maternal urinary BPA and the BPA*MDS interaction 
across pregnancy did not predict youth MRS, but suggestive changes were observed in trimester-
specific models, adjusted for a priori and predictor covariates. T2 maternal urinary BPA was 
associated with a suggestive decrease in MRS (-0.63, p = 0.147) among males. The BPA*MDS 
interaction had a differential effect on male youth, depending on the trimester. Trimester 1 
BPA*MDS was associated with a suggestive decrease in male MRS (-0.11, p = 0.188); but T2 
BPA*MDS was associated with a suggestive increase in MRS (0.14, p = 0.140) in male youth. 
Neither prenatal BPA, MDS, nor their interaction (BPA*MDS) significantly predicted MRS in 
adjusted models for female youth (Table 4.4).  
Pubertal status and T1 maternal BMI were both positively associated with increased MRS 
in all youth across all trimesters and the pregnancy average model. In models including all youth, 
adolescent MDS and vigorous physical activity were negatively associated with MRS. 
Interestingly, these predictive covariates varied by sex. Adolescent pubertal status and T1 
maternal BMI were significant in female youth; both were associated with increased risk of MRS 
in girls across all three trimesters. Youth MDS and vigorous physical activity were significant 
predictors in male models, but were negatively associated with MRS (Table 4.4). 
 
Predictive Modeling of Adolescent Serum 8-isoprostane 
Maternal average Ln-BPA and T2 Ln-BPA were suggestive of associations with serum 8-
isoprostane in all youth.  In adjusted models for all youth, maternal average Ln-BPA was 
associated with a suggestive 16.8% (p = 0.190) increase in youth serum 8-isoprostane; T2 Ln-
BPA was associated with a borderline 20.1% (p = 0.085) increase. Of note, these are the same 
time periods (pregnancy average and T2) that were predictive of youth MRS; thus, T2 may be a 
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perinatal period that is particularly sensitive to BPA exposure. However, the direction of 
association differs by youth outcome. Greater maternal BPA exposure is associated with higher 
8-isoprostane levels in youth; in contrast, maternal BPA exposure is associated with lower youth 
MRS. Neither maternal MDS nor the interaction of BPA*MDS were predictive of 8-isoprostane 
in models including both boys and girls (Table 4.5).  
Among male youth, only T1 maternal Ln-BPA was a suggestive predictor of serum 8-
isoprostane, with T1 Ln-BPA associated with a suggestive 39.4% increase (p = 0.102). Maternal 
MDS, pregnancy average and T2, was negatively associated with male 8-isoprostane. Maternal 
average MDS was associated with a significant 10.2% decrease (p = 0.008), and T2 MDS with a 
suggestive 5.2% decrease (p = 0.180) in male 8-isoprostane levels. The interaction of BPA*MDS 
did not predict 8-isoprostane levels in male youths (Table 4.5).  
In female youth, pregnancy average and T2 Ln-BPA were suggestive predictors of serum 
8-isoprostane. Pregnancy average Ln-BPA was associated with a suggestive 19.7% increase (p = 
0.182), while T2 Ln-BPA was associated with a borderline 24.0% increase (p = 0.067) in female 
8-isoprostane. Maternal MDS was positively associated with 8-isoprostane levels in female 
youth. Pregnancy average MDS was associated with a suggestive 4.2% increase (p = 0.123), T2 
MDS with a significant 6.5% increase (p = 0.020), and T3 MDS with a suggestive 2.9% increase 
(p = 0.189) in female 8-isoprostane. Of note, this association between maternal MDS and youth 
8-isoprostane is in the opposite direction in male and female youth; these opposing, sex-specific 
relationships are a likely reason no association is observed in models that combine boys and 
girls. T2 BPA*MDS was associated with a borderline 4.4% decrease (p = 0.093) in 8-isoprostane 
among girls. The interaction is not a significant predictor at any other time point (Table 4.5). 
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In the adjusted model of T2 exposures predicting serum 8-isoprostane in all youth, youth 
urinary BPA negatively associated with serum 8-isoprostane. BPA measured in youth urine did 
not significantly contribute to any other models. Including youth MDS improved pregnancy 
average, T1, and T2 models of male 8-isoprostane, but had no impact in models predicting 
female 8-isoprostane levels. Youth vigorous physical activity improved prediction of 8-
isoprostane in males only, in pregnancy average and T3 models. These findings suggest that 
peripubertal exposures (e.g. BPA) and behavior (e.g. diet and physical activity) can impact the 
relationship between prenatal exposures and peripubertal serum 8-isoprostane. Of note, pubertal 
status had no effect on models of youth serum 8-isoprostane, supportive of a peripuberty-
independent variation in lipid oxidation. Pubertal status was still included in these models as an a 
priori covariate, due to the innumerable physiologic changes occurring during this 
developmental transition. 
 
DISCUSSION 
This is the first human study to accomplish a long-term follow up of prenatal BPA and 
dietary exposures, which not only explores the EDC-diet interaction, but also examines the 
impact on multiple measures of metabolic health during the peripubertal transition. We examined 
the potential impact of prenatal BPA and maternal dietary intake on peripubertal metabolic risk 
and serum lipid oxidation (Figure 4.2). Maternal urinary T2 BPA was associated with a 
suggestive decrease in MRS among boys only. Similarly, when male and female youth were 
combined, pregnancy average and T2 BPA were suggestive of decreases in youth MRS. On the 
other hand, pregnancy average and T2 maternal urinary BPA were associated with suggestive 
increases in serum 8-isoprostane among girls and all youth combined. Interestingly, maternal 
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MDS contributed to pregnancy average and T2 models of 8-isoprostane in both boys and girls, 
but the direction of association differed. The interaction of maternal BPA*MDS was associated 
with suggestive increases in MRS in boys and all youth combined, but was associated with a 
borderline decrease in serum 8-isoprostane in girls. Youth characteristics, such as urinary BPA, 
MDS, vigorous physical activity, and pubertal status, improved models of youth MRS and 8-
isoprostane, supporting the theory that prenatal programming may be altered by later life 
exposures and behavior. The peripubertal transition may be a developmental period that is 
particularly sensitive to this potential reprogramming. 
This is the first report of prenatal BPA impacting peripubertal serum lipid peroxidation in 
humans. In another pregnancy cohort, one interquartile range increase in urinary BPA was 
associated with a 8.79% (p = 0.02) increase in urinary 8-isoprostane in the mothers [87]. A 
recent study reported that prenatal BPA exposure was associated with increased levels of a 
different marker of oxidative stress, 3-nitrotyrosine levels, in cord blood samples [86], but did 
not follow children after birth. Precedence for perinatal BPA exposure leading to later life 
oxidative stress has been reported in murine models, where perinatal BPA was correlated with 
higher oxidative stress markers into puberty [88] and adulthood [89], even when BPA exposure 
stopped at weaning. The brief half life of 8-isoprostane, 16 minutes in humans [90], suggests that 
the 8-isoprostane measured in peripubertal youth cannot be the same 8-isoprostane generated 
prenatally. Thus, the positive association between prenatal BPA exposure and youth serum 8-
isoprostane levels may be due to confounding by postnatal characteristics. In this study, the 
association between prenatal exposures and youth serum 8-isoprostane was impacted by 
concurrent youth exposures and behavior, suggestive of a significant impact of postnatal 
confounders. 
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The minimal impact of prenatal BPA on peripubertal MRS was unexpected. Studies in 
human children [91,92] and adults [93,94] have reported increased urinary BPA levels are 
correlated with increased waist circumference and impaired insulin sensitivity. In murine 
models, prenatal low-dose BPA exposure has been associated with a detrimental effect on male 
offspring, including increased body weight, liver weight, abdominal fat mass, serum insulin and 
leptin accompanied by decreased glucose tolerance [23]. On the other hand, the CHAMACOS 
birth cohort reported BPA levels at 9 years were associated with increased adiposity at that age, 
but prenatal BPA exposure was inversely correlated to 9 year old adiposity [95]. These 
conflicting effects support the theory that the timing and life-stage of exposure to BPA are 
critical in determining the health impact [58,96]. Despite our original hypothesis that prenatal 
BPA would be associated with increased peripubertal MRS, a recent study investigating the 
impact of prenatal and concurrent BPA exposure on adolescent lipid profile (total cholesterol, 
triglycerides, HDL-C) in this ELEMENT cohort also found no BPA effect [56]. Trimester 3 BPA 
levels were not correlated to other metabolic outcomes in ELEMENT youth, including: serum 
hormones, pubertal status [57], BMI z-score, and skinfold thickness measures [59]. These 
variable findings in the ELEMENT and CHAMACOS birth cohorts warrant additional 
investigation into the potential of prenatal BPA exposure on offspring metabolic risk in late 
childhood. 
Maternal, specific-gravity adjusted urinary BPA levels in this study were within the range 
of previously reported maternal urinary BPA levels (0.5 – 3.5 ng/mL) [97–99]; the ICC also 
correspond to previously reported ICC for BPA measures across trimesters of pregnancy (0.19-
0.32) [98]. Although spot urine collections have been criticized as an inaccurate method of 
measuring BPA exposure, due to the BPA’s short half-life, maternal urinary BPA was consistent 
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across trimesters when considering the population as a whole. Previous investigation into BPA 
levels within the ELEMENT cohort found no difference in urine samples collected in morning 
compared to afternoon; BPA levels also did not differ by child age, 8-10 vs. 11-13yrs [55]. 
Despite consistent average BPA levels in all three trimesters, predictive effects on youth 8-iso 
were trimester-specific in LMMs. Thus, timing of BPA exposure may be more important than 
the level of BPA exposure when determining the potential impact on offspring oxidation status. 
Across the study population of ELEMENT mothers, average maternal MDS was 
consistent across all three trimesters. Maternal adherence to a Mediterranean diet during 
pregnancy altered lipid oxidation in both boys and girls, but had an opposite direction of effect. 
Surprisingly, maternal MDS during pregnancy did not impact MRS in youth of either sex. The 
interaction term of trimester-specific BPA*MDS had a minimal contribution to predictive 
models of youth MRS or 8-iso. However, among boys only, including youth MDS as a covariate 
in predictive models of MRS and 8-iso improved model fit. This again suggests that postnatal 
confounders can alter the health trajectory of youth after the initial period of prenatal 
programming.  
Longitudinal, observational studies have many strengths, built into their study design. 
Repeated maternal urinary BPA and Med diet adherence measures allowed comparison of 
exposures across all three trimesters of pregnancy. The trimester-specific measures allowed 
evaluation of critical windows of susceptibility to each exposure; this proved insightful, since 
Trimester 1 and 2 BPA exerted a greater effect, while only Trimester 3 MDS was predictive of 
youth health outcomes. All predictive models were adjusted for youth BPA and MDS to account 
for current exposures. The suggestive contribution of youth MDS, especially among boys, to 
youth metabolic health outcomes, supports the theory that postnatal diet may alter youth health 
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risk. Thus, although prenatal programming may alter health trajectory, this study suggests the 
peripubertal period may provide a chance to alter that trajectory again. Examining peripubertal 
health effects in both girls and boys allowed sex-specific comparisons. BPA is known to have 
sexually-dimorphic effects on offspring, so sex-stratified analyses allowed an investigation into 
potential differences in metabolic programming. 
Limitations of this study include the spot sample urine collection for BPA measurement 
and the cross-sectional measure of health outcomes. Urinary BPA concentrations vary by recent 
exposure; thus, a single urine sample may not be representative of a subject’s regular BPA level. 
However, averaging BPA measures across the three trimesters of pregnancy may have reduced 
this potential inaccuracy. The fact that pregnancy average models often reflected the suggestive 
results in T2 models, supports the validity of these findings. Health outcome measures at a single 
time point in adolescence cannot provide insights into possible alterations metabolic health over 
time. Comparison of offspring metabolic health measures from birth through puberty would be 
more instructive for determining if prenatal exposures impact offspring health at specific times, 
or if trajectory of MRS and/or serum 8-iso changes over time based on prenatal BPA exposure.  
Contradictory trends in youth metabolic health suggest the causes, prevention, and 
treatment strategies are complex. Understanding the contribution that the in utero environment 
plays on youth metabolic health is critical to improve future interventions.  Results from this 
study suggest a sexual-dimorphism in the impact of both prenatal BPA and diet exposures.. The 
significant impact of puberty on MRS reinforces the knowledge that the pubertal transition is a 
sensitive period for potential metabolic disease development. This sensitive life stage may be a 
second chance to “reprogram” future health risks. Children whose metabolic disease 
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susceptibility was increased due to perinatal exposures, may be able to lower their risk through 
conscientious health decisions during puberty.  
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Figure	4.1.	Study	Participant	Recruitment	and	Follow-Up	Timeline	
	This	study	followed	250	mother-child	dyads.	Most	(n=236)	of	the	mothers	were	recruited	in	Trimester	1	of	pregnancy,	but	14	mothers	were	recruited	at	delivery.	Thus,	prenatal	exposure	measures	(urinary	BPA	and	diet	intake)	were	not	measured	in	these	14	mothers.	Youth	were	re-recruited	during	the	peripubertal	transition	(8-14	years).	Adolescent	metabolic	health	was	assessed	via	Metabolic	Risk	Score	and	serum	8-isoprostane,	among	132	girls	and	118	boys.	
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Table 4.1 Characteristics of the ELEMENT Study Population (n=250) 
Maternal Characteristics  Adolescent Characteristics 
Variable N %  Variable N % 
Education (years)    Sex   
        < 9 89 35.6          Female 132 52.8 
        10 – 12 126 50.4          Male 118 47.2 
        > 12 35 14.0  Pubertal Status: Females 
Delivery Type            Pre-Pubertal 86 65.2 
        Vaginal Birth 149 59.6          Pubertal 46 34.8 
        C-section 99 39.6  Pubertal Status: Males 
        Missing Data 2           Pre-Pubertal 60 50.8 
Trimester 1 BMI (kg/m2)          Pubertal 58 49.2 
        <18.5 5 2.0  Adolescent BMI (kg/ m2) 
        >18.5 to <25.0 100 40.0          <18.5 118 47.2 
        >25.0 to <30.0 83 33.2          >18.5 to <25.0 114 45.6 
        >30.0 to <35.0 29 11.6          >25.0 to <30.0 15 6.0 
        > 35.0 6 2.4          >30.0 to <35.0 3 1.2 
        Missing Data 27 10.8          > 35.0 0 0.0 
 
Maternal Characteristics 
Variable N Mean SD (Range) 
Age at Recruitment (years) 250 26.82 5.63 (14.00 – 44.00) 
Breastfeeding (weeks) 250 8.10 5.86 (0.00 – 30.00) 
Trimester 1 BMI (kg/m2) 223 25.85 3.95 (17.26 – 40.48) 
Pregnancy Weight Gain (kg) 215 2.59 3.75 (-10.00 – 18.70) 
Adolescent Characteristics 
Variable N Mean SD (Range) 
Age at Clinic Visit (years) 250 10.32 1.67 (8.10 – 14.70) 
Adolescent BMI (kg/m2) 250 19.38 3.60 (13.33 – 33.38) 
Serum Leptin (ng/mL) 248 11.25 8.98 (1.40 – 62.20) 
Serum IGF-1 (ng/mL) 248 257.07 104.54 (92.90 – 606.00) 
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Table 4.2 Distribution of Adolescent Metabolic Risk Score (-2 to 2) across background characteristics of ELEMENT mother-
child dyads. 
 
Variable 
All Youth (n=250) Girls (n=132) Boys (n=118) 
N Mean SD P* N Mean SD P* N Mean SD P* 
Maternal Characteristics 
Age at Pregnancy             
     15-24 years 101 0.005 0.625 0.648 51 0.020 0.594 0.667 50 -0.011 0.661 0.881 
     25-34 years 117 -0.026 0.595  60 -0.044 0.546  57 -0.007 0.646  
     35-44 years 30 0.092 0.692  20 0.088 0.764  10 0.099 0.556  
Education             
     < 10 years 88 0.035 0.645 0.735 50 0.034 0.611 0.847 38 0.036 0.696 0.619 
     10-12 years 125 -0.030 0.596  64 -0.009 0.578  61 -0.051 0.617  
     > 12 years 35 0.025 0.638  17 -0.058 0.670  18 0.103 0.616  
Trimester 1 BMI             
     < 18 1 -0.525 . 0.578 0 . . 0.461 1 -0.525 . 0.352 
     18-24.9 103 -0.052 0.634  48 -0.124 0.537  55 0.012 0.707  
     25 - 29.9 84 0.016 0.632  51 0.099 0.639  33 -0.113 0.608  
     30 - 34.9 25 -0.002 0.551  15 0.047 0.612  10 -0.076 0.464  
     > 35 8 0.287 0.867  3 -0.066 1.397  5 0.499 0.437  
Gestational Weight Gain              
     < 6 kg 48 0.029 0.639 0.622 28 0.063 0.649 0.039 20 -0.020 0.638 0.170 
     6 - 8.5 kg 66 -0.008 0.629  34 -0.195 0.541  32 0.191 0.662  
     >8.5 - 11 kg 55 -0.105 0.549  28 -0.096 0.598  27 -0.114 0.504  
     >11 kg 52 0.050 0.714  27 0.264 0.626  25 -0.181 0.743  
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Table 4.2 Distribution of Adolescent Metabolic Risk Score (-2 to 2) across background characteristics of ELEMENT mother-
child dyads, Continued 
 
Variable 
All Youth (n=250) Girls (n=132) Boys (n=118) 
N Mean SD P* N Mean SD P* N Mean SD P* 
Youth Characteristics 
Age at Re-enrollment             
     8-10 172 -0.050 0.651 0.036 93 -0.021 0.661 0.427 79 -0.083 0.641 0.044 
     11-12 54 0.039 0.528  25 -0.024 0.408  29 0.093 0.616  
     13-14 22 0.303 0.464  13 0.208 0.392  9 0.440 0.546  
Pubertal Status**             
     Prepubertal 144 -0.116 0.617 0.000 85 -0.115 0.632 0.001 59 -0.117 0.601 0.046 
     Pubertal 104 0.162 0.584  46 0.215 0.469  58 0.120 0.663  
Serum Leptin             
     <5 62 -0.512 0.411 0.000 18 -0.700 0.329 0.000 44 -0.435 0.419 0.000 
     5 - 8 64 -0.135 0.495  30 -0.255 0.388  34 -0.030 0.557  
     >8 - 15 60 0.129 0.519  39 0.014 0.509  21 0.343 0.478  
     > 15 62 0.529 0.527  44 0.450 0.503  18 0.722 0.546  
Physical Activity (METS)             
     < 17 62 -0.021 0.723 0.828 35 -0.060 0.676 0.583 27 0.030 0.789 0.993 
     17 - 26 62 -0.045 0.596  38 -0.060 0.623  24 -0.022 0.563  
     >26 - 40 58 0.054 0.628  27 0.122 0.606  31 -0.005 0.651  
     > 40 66 0.018 0.525  31 0.039 0.465  35 -0.001 0.579  
 
*p-values represent significance from the Wald test for linear trend, which uses an ordinal indicator entered into a model as a 
continuous variable. For binary variables, p-value is a measure of significance from an Independent t-test. 
** Sex-specific prepubertal (<1) and pubertal (>1) status was determined by physician-assessed Tanner staging for boys 
(genital or pubic hair development) and girls (breast or pubic hair development). 
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Table 4.3 Distribution of Exposure Variables from Prenatal and Adolescent Exposure Periods  
 
Urinary BPA (ng/mL), specific-gravity adjusted 
Analyte N GM GSD Min. 25% 50% 75% Max. 
Maternal Measures 
Pregnancy Average 229 1.13 2.11 0.00 0.70 1.08 1.80 9.16 
     Trimester 1 198 1.57 2.22 0.23 0.87 1.48 2.76 23.40 
     Trimester 2 200 1.66 2.14 0.24 1.04 1.46 2.50 30.29 
     Trimester 3 225 1.28 1.99 0.31 0.80 1.14 1.83 23.38 
Youth Measures 
8-14 Years 242 1.63 2.16 0.40 0.92 1.40 2.57 27.67 
         
Mediterranean Diet Score (0-8) 
Analyte N Mean SD Min. 25% 50% 75% Max. 
Maternal Measures 
Pregnancy Average 236 4.71 1.15 1.67 4.00 4.67 5.33 7.67 
     Trimester 1 227 4.68 1.54 2 4 5 6 8 
     Trimester 2 234 4.65 1.46 1 4 5 6 8 
     Trimester 3 235 4.77 1.55 0 4 5 6 8 
Youth Measures 
8-14 Years 250 3.76 1.47 0 3 4 5 8 
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Table 4.4 Percent Change in Youth Metabolic Risk Score per 1-Unit Urinary Ln-BPA Increase 
 
Significance:  ap < 0.05, bp < 0.10, cp < 0.20 
Model 1: Adolescent serum 8-isoprostane ~ Maternal, trimester-specific urinary, specific-gravity adjusted BPA  
Model 2: additionally adjusted for: maternal education (grade), youth pubertal status (Yes/No), adolescent urinary BPA and 
Mediterranean diet score adherence (0-8).  
Model 3: Model 2 + additionally adjusted for maternal T1 BMI (kg/m2), and adolescent vigorous physical activity (hours/week).  
Pregnancy 
Timing 
Adolescent Metabolic Risk Score 
Model 1: Unadjusted Model 2: A priori Covariates Model 3: Predictor Covariates 
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
All Youth 
Average 225 -0.376b 0.044 0.066 218 -0.259 0.043 0.041 206 -0.359c 0.041 0.065c 
Trimester 1  196 -0.101 0.000 0.009 189 -0.086 0.000 0.006 185 -0.095 0.001 0.016 
Trimester 2 197 -0.324c -0.013 0.066c 190 -0.324c -0.007 0.062c 182 -0.287c 0.007 0.055 
Trimester 3 222 -0.139 0.032 0.016 215 -0.066 0.031 0.00 206 -0.138 0.025 0.015 
Girls 
Average 119 -0.262 0.071c 0.038 116 -0.181 0.043 0.025 109 -0.215 0.047 0.029 
Trimester 1  106 -0.186 0.011 0.032 103 -0.215 -0.005 0.043 103 -0.221 0.006 0.045 
Trimester 2 107 -0.113 0.047 0.012 104 -0.262 0.007 0.041 98 -0.179 0.033 0.016 
Trimester 3 115 0.278 0.060 -0.058 112 0.391 0.044 -0.080c 107 0.337 0.042 -0.078 
Boys 
Average 106 -0.599c 0.013 0.118c 102 -0.400 0.047 0.066 97 -0.581 0.038 0.109 
Trimester 1  90 0.174 -0.012 -0.059 86 0.436 0.024 -0.132c 85 0.373 0.023 -0.109c 
Trimester 2 90 -0.043 -0.002 0.017c 86 -0.728b -0.025 0.152b 84 -0.629c -0.015 0.136c 
Trimester 3 107 -0.422c 0.006 0.070 103 -0.286 0.032 0.040 99 -0.382 0.024 0.057 
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Table 4.5 Percent Change in Youth Serum 8-isoprostane per 1-Unit Urinary Ln-BPA Increase  
 
Significance:  ap < 0.05, bp < 0.10, cp < 0.20 
Model 1: Adolescent serum 8-isoprostane ~ Maternal, trimester-specific urinary, specific-gravity adjusted BPA  
Model 2: additionally adjusted for: maternal education (grade), youth pubertal status (Yes/No), adolescent urinary BPA and 
Mediterranean diet score adherence (0-8).  
Model 3: Model 2 + additionally adjusted for maternal T1 BMI (kg/m2), and adolescent vigorous physical activity (hours/week).  
Pregnancy 
Timing 
Adolescent Serum 8-isoprostane 
Model 1: Unadjusted Model 2: A priori Covariates Model 3: Predictor Covariates 
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
N 
BPA 
%  
MDS 
%  
BPA*MDS 
%  
All Youth 
Average 219 0.192c 0.000 -0.035c 212 0.157 -0.018 -0.025 200 0.168c -0.011 -0.028 
Trimester 1 192 0.162c -0.002 -0.024 185 0.079 -0.019 -0.004 184 0.080 -0.019 -0.005 
Trimester 2 186 0.114c 0.011 -0.009 185 0.203b 0.009 -0.025 177 0.201b 0.011 -0.023 
Trimester 3 216 0.054 0.010 0.001 209 0.078 -0.001 -0.001 200 0.077 0.004 -0.001 
Girls 
Average 115 0.212c 0.038c -0.043c 112 0.218c 0.034c -0.044c 105 0.197c 0.042c -0.037 
Trimester 1 103 -0.040 0.005 0.008 100 -0.089 0.004 0.019 100 -0.090 0.002 0.019 
Trimester 2 103 0.239b 0.066a -0.048b 100 0.237b 0.064a -0.046b 94 0.240b 0.065a -0.044b 
Trimester 3 111 0.205 0.034b -0.034 108 0.186 0.024 -0.027 103 0.172 0.029c -0.023 
Boys 
Average 104 0.249 -0.055c -0.043 100 0.126 -0.103a -0.008 95 0.150 -0.102a -0.016 
Trimester 1 89 0.544a -0.011 -0.092a 85 0.381c -0.041 -0.052 84 0.394c -0.041 -0.055 
Trimester 2 89 0.084 -0.027 0.009 85 0.228 -0.056c -0.011 83 0.218 -0.052c -0.007 
Trimester 3 105 -0.089c -0.014 0.038 101 -0.034 -0.033 0.029 97 -0.020 -0.033 0.029 
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Figure	4.2	Impact	of	Prenatal	BPA	and	Mediterranean	Diet	Exposure	on	Adolescent	Metabolic	Health	
	This	analysis	investigated	the	potential	for	prenatal	programming	of	adolescent	metabolic	health	within	the	ELEMENT	human	birth	cohort.	Maternal	exposure	to	BPA	and	adherence	to	a	Mediterranean	diet	(MDS)	during	pregnancy	significantly	altered	adolescent	serum	lipid	oxidation,	but	not	Metabolic	Risk	Score.	In	addition	to	diet’s	direct	effect,	maternal	MDS	also	modified	the	effect	of	prenatal	BPA	on	lipid	oxidation.	Maternal	T1	BMI,	youth	puberty	status	and	vigorous	physical	activity	also	impacted	adolescent	metabolic	health	
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Supplemental Information 
 
Table S4.1 Mediterranean Diet Score Calculations 
 
Food Group 
Median Daily Intake (grams) Scoring 
T1 T2 T3 > Median < Median 
Beneficial Foods 
Fish 44.36 44.36 41.04 1 0 
Legumes 131.50 135.07 135.07 1 0 
Fruits & Nuts 1214.80 1350.19 1074.34 1 0 
Vegetables 799.66 722.37 667.86 1 0 
Whole Grains 12.95 15.27 12.95 1 0 
Detrimental Foods 
Meat 218.41 205.96 204.52 0 1 
Poultry 78.57 78.57 78.57 0 1 
Dairy 1102.68 1280.71 1268.00 0 1 
 
To compute the trimester-specific Mediterranean Diet Score (MDS) for each ELEMENT 
mother in this study, the median daily intake (grams) was calculated for each of the eight 
food groups: fish, legumes, fruits & nuts, vegetables, whole grains, meat, poultry, and dairy. 
For beneficial foods, above median consumption was scored as ‘1’; below median intake of 
detrimental foods was scored ‘1’. Thus, MDSs ranged from 0-8 depending on adherence to 
the diet; greater adherence received a higher score, while poor adherence warranted a 
lower score.  
  
		 ͳͻͲ	 	
Figure	S4.1	Mediterranean	Diet	Score	Calculation	Workflow		
	Self-reported	dietary	data	was	collected	via	food	frequency	questionnaire	(FFQ).	Mothers	completed	an	FFQ	at	a	clinic	visit	during	each	trimester	of	pregnancy.	FFQ	responses	corresponded	to	food	intake	in	servings/day	quantities.	Intake	of	each	food	was	then	converted	from	servings/day	to	grams/day.	Gram/day	intake,	of	foods	within	each	food	group,	was	summed	(e.g.	apples,	bananas,	oranges,	etc.	were	added	to	create	a	total	Fruit	intake	value).	Median	gram/day	quantities	were	computed	for	each	of	the	eight	food	groups.	Consumption	of	each	food	group	was	compared	to	the	group	median	and	scored	(0	or	1)	based	on	whether	the	food	was	beneficial	or	detrimental.	Scores	for	all	eight	food	groups	were	summed	to	create	the	Mediterranean	Diet	Score	(MDS).	MDS	values	ranged	from	0	to	8.	
Data	Calculations	
1.  Convert	FFQ	code	to	servings/day	
2.  Convert	servings/day	to	grams/day	
Collect	self-reported	dietary	data:	via	
administration	of	the	Food	Frequency	
Questionnaire	(FFQ)	to	study	subjects	
Data	Collection	
Diet	Score	Creation	
1.  Assign	food	group	score:	
intake	to	median	(0	or	1)	
2.  Add	food	group	scores:	
sum	=	MDS	(0	to	8)	
Fruit     Vege    Meat    Dairy . . . . .  MDS 
    1           0            0           1                    4 
    1           1            1           1                    7 
    0           0            1           0                    2 
    1           1            0           1                    5 
    0           1            0           1                    5 
    1           0            1           1                    6 
    1           0            1           0                    3 
Food	Group	Creation	
1.  Add	foods	(gram/day)	within	same	
food	group	for	total	group	intake	
2.  Calculate	trimester-specific	median	
daily	intake	(grams)	of	food	groups	
Group   Foods in Group 
Fruit   papaya, mango, pineapple, etc. 
Vegetable   squash, spinach, tomatoes, etc. 
Legumes   black, fava, garbanzo beans, etc. 
Dairy   whole milk, oaxaca cheese, etc. 
Meat   beef, pork, chorizo, lamb, etc. 
Group   Foods in Group 
Fruit   papaya, mango, pineapple, etc. 
Vegetable   squash, spinach, tomatoes, etc. 
Legumes   black, fava, garbanzo beans, etc. 
Dairy   whole milk, oaxaca cheese, etc. 
Meat   beef, pork, chorizo, lamb, etc. 
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Table S4.2 Sex-Stratification of Prenatal Exposures, Youth Health Outcomes, and Study Covariates 
 
  
Males Females Between
a  
Sex  
p-value N Median IQR Range N Median IQR Range 
Exposures 
T1_BPA_grav (ng/mL) 92 1.46 0.81 - 2.13 0.23 - 10.47 107 1.60 0.89 - 3.10 0.40 - 23.40 0.059* 
T2_BPA_grav (ng/mL) 91 1.33 0.94 - 2.00 0.24 - 12.21 109 1.57 1.11 - 2.67 0.57 - 17.60 0.111 
T3_BPA_grav (ng/mL) 108 1.00 0.72 - 1.66 0.31 - 12.81 117 1.36 0.92 - 2.14 0.47 - 23.38 0.111 
P20_BPA_grav (ng/mL) 113 1.37 0.90 - 2.43 0.40 - 27.67 129 1.46 0.94 - 2.81 0.42 - 20.44 0.545 
T1_MDS (score: 0-8) 107 4.00 3.00 - 5.00 0.00 - 8.00 120 4.00 2.00 - 5.00 1.00 - 8.00 0.642 
T2_MDS (score: 0-8) 109 4.00 3.00 - 5.00 1.00 - 8.00 125 4.00 3.00 - 5.00 0.00 - 8.00 0.412 
T3_MDS (score: 0-8) 110 4.00 3.00 - 5.00 0.00 - 7.00 125 4.00 3.00 - 5.00 0.00 - 8.00 0.909 
P20_MDS (score: 0-8) 118 4.00 3.00 - 5.00 1.00 - 7.00 132 4.00 3.00 - 5.00 0.00 - 8.00 0.277 
Health Outcomes 
Serum 8-isoprostane (pg/mL) 115 478.91 365.46 - 614.06 202.80 - 1364.78 127 469.26 391.21 - 571.98 203.96 - 1044.43 0.552 
Metabolic Risk Score (-2 to 2) 117 -0.01 -0.41 to 0.34 -1.67 to 1.99 131 -0.03 -0.44 to 0.44 -1.29 to 1.47 0.997 
Maternal Covariates 
Highest Education (years) 118 12.00 9.00 - 12.00 3.00 - 20.00 132 11.00 9.00 - 12.00 2.00 - 21.00 0.256 
Age at Pregnancy (years)  118 26.00 23.00 - 30.00 16.00 - 44.00 132 26.50 23.00 - 31.00 14.00 - 40.00 0.650 
Pre-Pregnancy BMI (kg/m2) 105 24.69 22.82 - 28.34 17.26 - 38.45 118 25.98 23.61 - 27.92 18.00 - 40.48 0.270 
Pregnancy Weight Gain (kg) 102 3.00 0.98 - 5.00 -10.00 to 13.50 113 2.20 0.35 - 4.00 -9.90 to 18.70 0.611 
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Table S4.2 Sex-Stratification of Prenatal Exposures, Youth Health Outcomes, and Study Covariates, Continued 
 
 
Males Females Between
a  
Sex  
p-value N Median IQR Range N Median IQR Range 
Adolescent Covariates 
Age (years) 118 9.95 8.98 - 11.73 8.10 - 14.40 132 9.95 8.80 - 11.88 8.10 - 14.70 0.820 
BMI (kg/m2) 118 18.78 16.79 - 20.87 14.06 - 31.44 132 19.01 16.64 - 22.18 13.33 - 33.38 0.180 
Waist Circumference (cm) 118 68.4 62.19 - 76.49 50.10 - 95.60 132 69.93 64.43 - 79.13 50.50 - 111.00 0.123 
Systolic Blood Pressure (mmHg) 118 104.5 96.75 - 111.00 79.00 - 127.00 132 101 91.00 - 110.00 79.00 - 123.00 0.016** 
Diastolic Blood Pressure (mmHg) 118 67 61.00 - 71.00 49.00 - 83.00 132 67 60.00 - 70.00 44.00 - 82.00 0.847 
Serum Glucose (mg/dL) 117 88 83.00 - 93.50 49.00 - 63.00 131 86 80.00 - 91.00 58.00 - 146.00 0.185 
Serum HDL (mg/dL) 117 60 51.50 - 67.00 33.00 - 98.00 131 57 50.00 - 64.00 31.00 - 104.00 0.118 
Serum Triglycerides (mg/dL) 117 70 53.00 - 90.50 21.00 - 245.00 131 81 65.00 - 121.00 35.00 - 269.00 0.000** 
Serum Leptin (ng/mL) 117 6.5 3.60 - 10.80 1.40 - 34.20 131 10.7 6.30 - 18.50 2.40 - 62.20 0.000** 
Serum IGF-1 117 206 165.50 - 270.00 92.90 - 568.00 131 250 198.00 - 359.00 102.00 - 606.00 0.000** 
   
 a Independent t-tests were used to compare each variable by youth sex.  
   P-values that reflect significant differences by sex are bolded: * p < 0.10, ** p < 0.05 
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Table S4.3 Comparison of Prenatal Exposures (BPA & MDS) Across Trimesters 
 
Intraclass Correlation Coefficient (ICC) between Trimesters 
 Trimester 1 (T1) Trimester 2 (T2) Trimester 3 (T3) 
N Coefficient (95% CI) N Coefficient (95% CI) N Coefficient (95% CI) 
Urinary BPA (ng/mL), 
SG-adjusted 
183 0.24 (0.10-0.37) 196 0.32 (0.19-0.44) 196 0.12 (-0.02-0.26) 
MDS 210 0.11 (-0.03-0.24) 233 0.44 (0.33-0.54) 211 -0.03 (-0.17-0.10) 
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Figure S4.2 Trimester-Specific Distributions of Prenatal Exposures: Urinary BPA Levels and 
Mediterranean Diet Score 
 
 
 	
A	 B	
Maternal	Urinary	BPA	(ng/mL)	 Mediterranean	Diet	Score	(0-8)	
A	 B	
Maternal	Urinary	BPA	(ng/mL)	 Mediterranean	Diet	Score	(0-8)	
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Table S4.4 Distribution of Adolescent Serum 8-isoprostane (pg/mL) across background characteristics of ELEMENT mother-
child dyads. 
 
Variable 
All Youth (n=250) Girls (n=132) Boys (n=118) 
N Mean SD P* N Mean SD P* N Mean SD P* 
Maternal Characteristics 
Age at Pregnancy             
     15-24 years 98 523.7 188.4 0.236 48 500.5 151.3 0.798 50 546.1 217.4 0.191 
     25-34 years 114 492.4 172.7  59 499.3 167.1  55 484.9 179.7  
     35-44 years 30 468.9 140.8  20 473.8 152.2  10 459.1 121.9  
Education             
     < 10 years 85 506.1 198.7 0.514 48 494.4 174.8 0.989 37 521.4 227.5 0.376 
     10-12 years 123 508.4 169.7  63 497.7 153.6  60 519.6 185.8  
     > 12 years 34 469.8 135.7  16 492.1 128.6  18 450.1 142.3  
Trimester 1 BMI             
     < 18 1 444.7 . 0.987 0 . . 0.937 1 444.7 . 0.976 
     18-24.9 100 503.6 198.4  47 496.3 159.2  53 510.1 229.0  
     25 - 29.9 81 509.4 170.5  48 506.1 174.8  33 514.3 166.6  
     30 - 34.9 25 489.7 135.0  15 490.3 125.0  10 488.9 155.7  
     > 35 8 472.5 166.6  3 501.1 200.8  5 455.4 165.6  
Gestational Weight Gain              
     < 6 kg 48 495.4 159.0 0.534 28 486.7 125.5 0.677 20 507.7 199.6 0.176 
     6 - 8.5 kg 63 517.1 180.9  32 479.9 157.4  31 555.6 197.6  
     >8.5 - 11 kg 53 524.5 219.2  27 528.8 203.0  26 520.1 239.0  
     >11 kg 51 469.4 145.5  26 508.4 154.7  25 428.8 125.8  
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Table S4.4 Distribution of Adolescent Serum 8-isoprostane (pg/mL) across background characteristics of ELEMENT mother-
child dyads, Continued 
 
Variable 
All Youth (n=250) Girls (n=132) Boys (n=118) 
N Mean SD P* N Mean SD P* N Mean SD P* 
Youth Characteristics 
Age at Re-enrollment             
     8-10 168 501.3 181.4 0.312 90 498.6 157.9 0.277 78 504.4 206.2 0.794 
     11-12 53 523.8 167.9  25 517.1 165.5  28 529.7 172.9  
     13-14 21 454.5 149.0  12 429.7 137.3  9 487.5 165.7  
Pubertal Status**             
     Prepubertal 141 503.2 191.9 0.913 84 500.3 165.5 0.651 57 507.4 226.7 0.921 
     Pubertal 100 500.7 152.4  43 486.8 143.7  58 511.1 159.0  
Serum Leptin             
     <5 59 483.7 169.5 0.284 17 475.7 183.2 0.411 42 486.9 165.8 0.641 
     5 - 8 64 534.8 200.9  30 524.1 144.3  34 544.3 242.0  
     >8 - 15 60 480.5 166.1  39 466.9 143.7  21 505.6 202.8  
     > 15 59 507.4 162.1  41 510.7 169.4  18 499.7 148.2  
Physical Activity (METS)             
     < 17 60 518.8 167.2 0.742 34 548.6 176.4 0.150 26 479.8 148.6 0.726 
     17 - 26 60 494.1 198.9  36 482.5 161.4  24 511.6 247.5  
     >26 - 40 57 510.2 181.9  26 476.4 131.4  31 538.7 213.4  
     > 40 65 487.1 158.3  31 469.3 146.5  34 503.3 168.9  
 
*p-values represent significance from the Wald test for linear trend, which uses an ordinal indicator entered into a model as a 
continuous variable. For binary variables, p-value is a measure of significance from an Independent t-test. 
** Sex-specific prepubertal (<1) and pubertal (>1) status was determined by physician-assessed Tanner staging for boys 
(genital or pubic hair development) and girls (breast or pubic hair development). 
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CHAPTER 5 
 
Discussion 
 
Significance of Research Findings  
Global disease burden from chronic metabolic diseases, like NAFLD, continues to rise. 
NAFLD is now the most common liver disease amongst children and adults in the U.S., with 
incidence rising concomitantly with obesity. In the U.S., recommendations to prevent and 
decrease prevalence of childhood obesity have traditionally focused on altering personal 
behaviors, (e.g. poor diet quality, hypercaloric intake, physical inactivity) and more recently on 
altering the socio-political environment (e.g. safe access to healthy food, places to exercise, 
affordable healthcare, healthy default options) [1–3]. Despite initial publication more than 50 
years ago, the influence of the in utero environment on offspring metabolic health has still not 
been incorporated into medical or policy recommendations. First identified following World War 
II, via natural experiments in free-living human populations (e.g. the Seige of Leningrad [4] and 
the Dutch Hunger Winter [5,6]), the potential for maternal exposures to affect offspring 
metabolic health was later codified into the Barker Hypothesis [7]. Over the past decade, popular 
media has raised awareness regarding the potential for perinatal exposures to increase 
susceptibility to chronic diseases later in life. However, an incomplete understanding of the 
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mechanism underlying this perinatal programming and a lack of clearly/proven beneficial 
interventions has hindered adoption of recommendations.  
Over the past decade, BPA has become a substance of concern [8–13], garnering 
increased media and societal attention. Concern regarding the potential health effects of BPA 
stem from studies reporting obesogenic [14–16], diabetogenic [17], reproductive [18] effects, 
adipogenic proliferation [19] and oxidative stress [20]. Conflicting results, such as lean 
phenotype [21,22] vs. obesogenic agent, have muddled overarching conclusions about BPA’s 
potential threat to human health [23,24]. Despite acknowledging that infants and children are 
exposed to the highest BPA levels, the FDA’s 2008 report concluded that health risks associated 
with BPA exposure were only of negligible to some concern [25]. However, Health Canada’s 
determination of BPA as a “dangerous substance” [26,27] led to the voluntary removal of BPA 
from many infant products in the U.S., including infant formula packaging and baby bottles 
[28,29]. In the U.S., no government regulations on safe consumption levels have been passed 
since 1982, when the NTP determined the lowest adverse effect level (LOAEL) of BPA to be 50 
mg BPA/kg body weight/day [30]. In 2014 the FDA re-reviewed BPA literature and again 
concluded that it is a chemical of minimal concern [31]. Without a commitment to discontinue 
the manufacture and use of BPA in consumer products, complete elimination of exposure is 
challenging on an individual level.  
BPA was detectable in the plasma of all pregnant women (0.5-22.3 ng/mL) assessed in 
Southeast Michigan in 2006 [32]. Documentation of BPA crossing the placenta [33,34] and 
transferring in breast milk [35], combined with lower levels of BPA metabolizing enzymes in 
fetal livers [36] emphasize potential increased risk of BPA exposure during fetal and infant 
development. To address mothers’ challenge to avoid BPA during pregnancy, this dissertation 
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aimed to investigate maternal diet as a potential method for mitigating the detrimental 
developmental effects previously reported from perinatal BPA exposure. If maternal diet could 
help prevent the detrimental health effects, the unavoidable exposure might be of less concern. 
Thereby providing an inexpensive, generally accessible ‘treatment’ to the general public, for a 
difficult-to-avoid exposure.  
The main goal of this dissertation was to examine if perinatal BPA exposure could 
perinatally program NAFLD in offspring and whether this relationship could be modified by 
maternal pregnancy diet. This research revealed that perinatal HFD had a greater impact on 
hepatic steatosis in mouse offspring at PND10 and 10M than did perinatal BPA exposure (Figure 
5.1, Figure 5.2). Interestingly, perinatal HFD was predictive of PND10 hepatic 8-isoprostane 
also, but by 10M, perinatal BPA exposure was the main predictor of hepatic 8-isoprostane. When 
analogous outcomes were investigated in the human birth cohort, ELEMENT, a similar trend 
was observed. Prenatal BPA was a significant contributor in models predicting adolescent serum 
8-isoprostane, with trimester specific impact of maternal MDS adherence. These findings were 
more pronounced in male youth, compared to females. However, the opposite trend was 
observed when predicting youth Metabolic Risk score; then T2 BPA was predictive of risk only 
in female youth, not males. Again, trimester specific maternal MDS adherence improved models, 
supporting a critical role for the inclusion of diet as a co-exposure in future toxiciology studies, 
especially investigating chemicals that share the main route of exposure to the body as food: 
ingestion. 
The impact of perinatal BPA exposure on hepatic steatosis was not as pronounced as we 
expected. During necropsy, 26.6% of all 10M offspring were observed to have some level of 
hepatic masses, visible to the naked eye, of those with gross masses, 26.5% of the offspring were 
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in the Control group. Hepatic histology results for nodular hyperplasia, as read by a certified 
doctor of veterinary medicine, followed a similar trend; 15.6% of all 10M offspring presented 
with moderate to severe hyperplasia, 20% of these were Control mice. The steatotic effect of our 
Control diet was unexpected. To avoid the potential epigenetic programming effect of 
phytoestrogens in soybean oil [37], the default lipid source in standard mouse chow, we 
substituted corn oil  Corn oil consumption in rats and mice has previously been reported to 
induce hepatic steatosis [38,39]. Thus, our Control lipid may have been more steatotic than either 
experimental HFD for the study mice. This would help to explain the high prevalence of hepatic 
hyperplasia in all exposure groups, including offspring perinatally exposed to the Con and CBPA 
diets.  
Perinatal BPA exposure had a greater impact on offspring 8-iso than on the metabolic 
outcomes: liver triglycerides or MRS in mice and humans, respectively. Diet did not modify the 
effect of BPA on 8-iso, liver TGs, or MRS in mice or humans. However, perinatal HFD 
exposures in mice were independently significant predictors of metabolic parameters and redox 
potentials in dams and PND10 offspring. This suggests that perinatal diet may exert a larger 
impact on offspring lifelong health than perinatal BPA exposure. Another recent study also 
reported no effect of 50 g BPA/kg/day on hepatic or serum triglyceride levels compared to 
Controls, in adult male Wistar rats exposed for 35 weeks [40]. Some researchers have questioned 
if the concern over BPA exposure is overblown [23], the findings of this mouse study imply that 
efforts focused on improving maternal diet may be more critical than eliminating BPA exposure 
during pregnancy.  
Most toxicology studies investigating the health effects of BPA exposure do not account 
for the diet consumed during exposure. The liver is the main site of xenobiotic and nutrient 
  
209  
metabolism; thus the liver is an ideal tissue in which to examine the potential interaction between 
EDC exposure and dietary intake. The wide variation in human dietary consumption patterns and 
differing response to diet between mouse and rat strains may explain some of the previously 
reported conflicting study results. This project examined the potential importance of BPA and 
diet interactions during pregnancy by providing three different background diets to mouse moms 
(dams) and by rating adherence to a Med diet in ELEMENT mothers. Results from this project 
suggest that maternal pregnancy diet did not modify of the relationship between BPA and 
offspring health outcomes in either mice or humans. In fact, perinatal diet altered offspring 
metabolic health and oxidation status more than perinatal BPA exposure.  
In order to scientifically isolate the impact of exposures during the perinatal period, 
offspring were not exposed to BPA or HFDs after weaning. This study design differs from many 
other studies that use a later life challenge following perinatal exposure [45–47], to determine if 
exposed offspring react differently to stressors compared to their non-exposed colony-mates. 
This experimental difference in timing (concurrent vs. delayed HFD exposure) may underscore 
the dissimilarity in findings in this thesis from previous studies. Metabolic and redox 
homeostasis are basic cellular functions required for species survival. Both outcomes have many, 
overlapping regulatory pathways to help ensure homeostasis is maintained; if an environmental 
exposure or stressor affects a usual metabolic pathway, another, redundant pathway can be 
upregulated. Without these compensatory mechanisms, mammals would not have survived and 
adapted to as many habitats and climate alterations as we have. A distinct difference in our 
evolutionary environment and the modern world is the frequency with which environmental 
stressors occur today. Humans and most mammals evolved to respond to one or two stressors at 
a time with a significant recovery time between stressors when the body was able to return to 
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metabolic and redox homeostasis. The constant bombardment of chemical, dietary, and physical 
stressors we face on a daily basis now likely overwhelms our system, mimicking a state of 
repeated and often overlapping challenges (like the HFD challenge following perinatal BPA 
exposure). Oxidative stress and metabolic disturbances may be unfairly blamed for the 
development of chronic diseases, when they are actually the body’s natural, physiologic attempt 
to return to homeostasis in a world where the natural system cannot keep pace.  
 
Study Strengths and Limitation 
 This dissertation had many strengths that set it apart from traditional environmental 
health sciences research. Cross-species comparisons were built into the study design of both the 
mouse and human studies, which increased translatability of our findings (Table 5.1). Murine 
and human birth cohort studies are often conducted by separate research teams with different 
measurement or analysis methods. Planning to correlate both studies from the beginning allowed 
us to select a lipid peroxidation measure, 8-isoprostane, which could be used on both mouse and 
human biological specimens. Creating the Mediterranean and Western HFDs for mice based on 
human dietary consumption patterns was a further attempt to make the mouse and human studies 
comparable.  
A unique component of this mouse study was the addition of maternal diet as a potential 
modifier of the perinatal BPA exposure. Traditional toxicology studies take one of two forms: 
(1) dose-range finding studies, or (2) physiology-based pharmacokinetic (PBPK) studies. Dose-
range finding studies aim to identify the level of toxicant at which adverse health effects occur; 
PBPK studies aim to understand how the toxicant works once inside the body. While it is critical 
to understand the level of toxic effects and modes of absorption, digestion, metabolism and 
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excretion for individual toxicants, these studies rarely account for dietary intake. People eat 
every day, so understanding nutrient toxicant interactions will be critical for realistic PBPK 
models. For lipophilic compounds, like BPA, the quantity and type of dietary fat consumed may 
alter the amount of BPA required to elicit a toxic response. Quantity and type of dietary fat likely 
also impacts the absorption and metabolism of BPA. This study was one of the first to begin 
investigating these critical nutrient-toxicant interactions. 
However, during the experimental study design phase of planning this thesis project, 
considerations and concessions were made in order to make this study as translatable to human 
cohort studies as possible. For example, we examined both the directly exposed dams and the 
indirectly exposed pups, thus mimicking a human birth cohort study design. Instead of altering 
one dietary component at a time, as is often done in mouse studies, we developed new mouse 
diets to match the macronutrient and vitamin content to human Western and Mediterranean 
HFDs as closely as possible. The dose of BPA falls within the average human exposure range. 
Physiologic measures commonly collected in human birth cohorts, like maternal pre-pregnancy 
weight, weight gain during pregnancy, early life child weight were recorded in this study also. 
Although findings from the longitudinal mouse exposure study did not translate exactly 
to findings in the human birth cohort, mice provide several experimental benefits. They have a 
shorter lifespan, thus making longitudinal studies more time-efficient; they also have 100% 
dietary compliance, removing the variability and uncertainty found in human diet and toxicology 
studies. It is also easier to study tissues of interest, e.g. liver and adipose, in mice, because all 
tissues are available following IACUC-approved sacrifice; whereas, in human birth cohorts, 
these same tissues would require invasive biopsy sampling. Although protein-coding regions of 
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mice and human genomes are 85% genetically homologous, there are species-specific 
differences not only in sequence but in regulatory control [43,44].  
However, results from the ELEMENT cohort did not find Med diet adherence to be a 
strong predictor of offspring MRS or serum 8-iso. A different type of dietary analysis in human 
birth cohorts might reveal an increased importance of diet on youth health outcomes. We also 
only examined health outcomes during the pubertal transition, at which time many changes in 
metabolic and oxidative health are naturally occurring, which may have masked effects of both 
prenatal BPA and/or diet. Investigations into the impact of maternal pregnancy diet on 
prepubertal children or young adults after the pubertal transition may yield a greater magnitude 
of effect.  
Unexpected results in my study findings highlight the importance of carefully thinking 
through physiological differences between species. Although we share the vast majority of our 
genome with other mammals, like mice, we evolved to inhabit different ecological niches (thus 
evolved with different ideal diets and environmental conditions). These evolutionary adaptations 
can lead to differences in metabolism of certain nutrients, like mono-unsaturated fatty acids 
(MUFA). The unexpected detrimental effect of perinatal Med diet exposure observed in the 
perinatal mouse exposure study may result from a species-specific difference in metabolizing 
enzymes. Mice are not as efficient at metabolizing monounsaturated fatty acids (MUFAs) as 
humans [41,42]. Oleic acid, the main lipid component of olive oil, comprised 89% of the 
humanized Med diet we developed for the mice. The increase in hepatic liver triglycerides 
observed in both male and female mice perinatally exposed to Med HFD may be the result of 
their inability to metabolize the lipid, not because of a broader hepatotoxic effect that would 
translate to human pathology in NAFLD.  
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 Sample sizes in mouse exposure subgroups posed a limitation for some statistical 
comparisons. Although group sample sizes in the longitudinal mouse exposure study was based 
on power calculations from previous longitudinal phenotyping experiments on agouti mice in the 
Dolinoy Lab, larger sample sizes per group would have improved the ability to identify 
significant correlations. Since prenatal programming is known to have sexually dimorphic 
effects, many analyses were sex-stratified; further stratification by perinatal exposure group left 
group totals at 10-12 mice. Future studies would benefit from increasing the number of mice in 
each subgroup to improve power. An additional challenge of these studies is the redundancy of 
metabolic pathways. Metabolism on a cellular level is comprised of very ancient, largely 
conserved pathways; metabolism is a basis, evolutionarily necessary function, so nature created 
multiple backup paths. This means that observing phenotypic changes in mice or even basic 
physiologic measures (like liver triglycerides or 8-isoprostane quantification) may not accurately 
portray the scale of metabolic disruption on a cellular level, if another redundant pathway is able 
to adapt to include the inactive pathway. 
 
Future Directions and Applications 
Further Research Directions 
Although epigenetic modifications have been identified as a mechanism of 
developmental programming, the data has not yet become clinically useful, nor applied to human 
health risk assessments. Current challenges hampering the application of epigenetic data include 
(1) many studies evaluate a single type of epigenetic modification (e.g. DNA methylation), but 
integration of all epigenetic changes will be necessary to fully understand the relevance to human 
health outcomes [48,49]. (2) Variability between tissues, species, study paradigms can be 
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considerable, so epigenetic data should be confirmed across multiple types of studies to ensure 
findings from experimental models translate to human physiologic responses and health 
outcomes of interest [50]. (3) Inconsistencies in epigenetic response to environmental exposure 
between experimental animal model strain, sex, life stage, and inter-individual variation are well-
documented, thus studies will need to cover a range of these factors to make data useful [49]. (4) 
Much of the current epigenetic data is associative, with studies reporting a correlation between 
an exposure or disease state and an alteration in an epigenetic mark. Designing studies to assess 
causality of the would strengthen support for the connection between epigenetic modifications 
and pathogenesis of disease; for example, “pharmacologically blocking a specific epigenetic 
modification to eliminate or decrease the detrimental health. 
 Over the past decade, the integral role of the intestinal microbiome in obesity and its 
related metabolic conditions has been elucidated; NAFLD is no exception [59–61]. High fat, 
high fructose foods have been implicated in gut microbiome alterations and breakdown of the 
intestinal barrier, resulting in metabolic endotoxemia and low-grade systemic inflammation [62–
66]. These diet-induced alterations are associated with increased risk of obesity and NAFLD. 
Animal models suggest the intestinal microbiome can contribute to NAFLD pathogenesis in 
multiple ways, by impacting energy homeostasis [67–71], choline metabolism [72,73], and the 
endocannabinoid system [74,75]. Regulation of energy homeostasis is altered due to increased 
carbohydrate fermentation into short chain fatty acids (SCFAs), which stimulates hepatic de 
novo lipogenesis (DNL), resulting in greater hepatic triglyceride accumulation (simple steatosis) 
[67–71]. Choline is required to synthesize very-low-density lipoproteins (VLDLs), which are the 
transport vesicles responsible for lipid export from the liver [72,73]. Intestinal endocannabinoids 
help regulate inflammation (inflammatory signaling cascades) and maintain integrity of the gut 
  
215  
barrier [74,75]. Administration of probiotics (mainly Lactobacilius and Bifidobacterium) have 
demonstrated beneficial impacts in animal models of NAFLD, improving hepatic steatosis, 
insulin resistance & sensitivity, hepatic inflammation [76–80]. A recent meta-analyses found that 
pre-biotic and probiotic consumption were associated with decreased BMI, body weight, and fat 
mass, suggesting this may be an additional therapeutic avenue for metabolic diseases, including 
NAFLD [81,82]. More work is needed to identify optimal probiotic strains for therapeutic use in 
NAFLD, but results are encouraging and suggest addition of probiotic therapy to diet and 
exercise interventions could enhance NAFLD treatment. 
In addition to impacting the development of NAFLD, intestinal microbiota are sensitive 
to ingested environmental exposures, including. A recent study examined the impact of 10-weeks 
of oral BPA exposure on the intestinal microbiome of adult male CD-1 mice. Microbial species 
diversity decreased in BPA-exposed mice, similar to the mice exposed to a HFD, with increased 
growth of Proteobacteria, Helicobacteraceae, and reduced populations of Firmicutes and 
Clostridia; these patterns are representative of microbial dysbiosis and have been associated with 
obesity and T2DM [84]. Although this study was small in sample size (only 4 mice per exposure 
group), the effects were significant and warrant additional investigation. In another study, 
perinatal exposure to 50ug/kg body weight/day of C3H/HeN mice was associated with greater E. 
coli colony formation, and decreased Bifidobacertium spp. and Clostridium species, in the 
Firmicutes phylum among offspring at postnatal day 45 [85]. These alterations in intestinal 
microbiome preceded insulin resistance, which was not observed until PND160 and M1 
macrophage inflammation, not observed until PND170 [85], supportive of microbiome dysbiosis 
as an early marker of later metabolic alterations. 
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Public Health Relevance 
The rise in U.S. NAFLD prevalence poses a challenge due to the potential increase in 
young people affected by serious co-morbidities, decreased quality of life, and increased life-
long medical bills. Studies are just beginning to explore the healthcare and quality of life costs 
associated with NAFLD [53]. Health-related quality of life is lower amongst NAFLD patients 
than those with other liver conditions, such as alcoholic liver disease, autoimmune or viral 
hepatitis (HBV & HCV), and cholestatic liver disease [55,56]. NAFLD patients had impairments 
in general health, physical functioning, bodily pain, vitality, role performance, and mental health; 
detriments were more pronounced in female patients, compared to males [56]. Physical health 
component scores (PCS) decreased with NAFLD severity; patients with cirrhosis had the lowest 
PCS, followed by non-alcoholic steatoheptitis patients, while those with simple steatosis had the 
least physical impairment. Interestingly, the mental component score did not differ by disease 
severity [57]. Compared to the general population, NAFLD patients have decreased lifespan 
largely attributable to cardiovascular disease and hepatocellular carcinoma [51].  
The growing economic burden of NAFLD in the U.S. is apparent in a study of Medicare 
beneficiaries. The study found that in a five-year period, the number of outpatient visits doubled 
and expenses increased by 38%, although Medicare payments only increased by 12%, leaving 
NAFLD patients responsible for an increasing percentage of their growing health care costs. A 
cost of care model analyzing the projected health care costs by major practice category, 
estimated that per-capita costs of liver-related conditions would increase from 2% in 2000 to 
11% in 2050, due to aging of the Baby Boomer generation [54]. NAFLD is associated with many 
cardio-metabolic comorbidities, which also contributed to the overall increase in per capita 
healthcare costs due to aging: heart & vascular conditions (44%), kidney disorders (55%), 
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gastrointestinal conditions (21%), endocrine conditions (20%) [54]. The studies above only 
account for medical costs associated with adult NAFLD, but growing childhood NAFLD rates 
are concerning due to the long period of medical dependence and thus much larger lifetime 
healthcare expense.  
The need for liver transplants has been dropping in the U.S. due to decreases in hepatitis 
C, alcoholic fatty liver, autoimmune conditions, primary biliary cholangitis, and primary 
sclerosing cholangitis, transplant need due to NAFLD-induced cirrhosis is rising and is likely 
under-diagnosed [52]. Within the last 10 years, the supply of healthy livers available for donor 
transplant has decreased. This supply and demand discrepancy led to trials of “non-ideal” donor 
options. Unfortunately, hepatic steatosis is now present in 37-51% of donated livers; this is 
associated with a 3.7-fold increased risk of poor initial graft function and elevated risk of graft 
failure, decreasing chances of the recipient surviving [52].  
Expanding the public health relevance of NAFLD to the global arena, rates of NAFLD 
are rapidly increasing in East Asian countries. The greatest population growth is predicted to 
occur in this region over the next decade and with some of the highest rates of NAFLD increase 
globally [58], the East Asian region is at risk for epidemic proportions of NAFLD. Improved 
understanding of the early, reversible stages of NALFD (steatosis and steatohepatitis) will 
support the creation of better non-invasive biomarkers that can help clinically diagnose NAFLD 
earlier in the disease course. Deeper characterization of the molecular pathways involved in these 
early stages will hopefully lead to new therapies that assist in the reversal or prevention of 
disease progression. 
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Table 5.1 Cross-Species Comparisons: Strengths and Limitations 
 
Species Comparison 
Mice Humans 
Strengths 
▪ Genetically identical background 
▪ Controlled laboratory environment 
▪ Short lifespan facilitates 
longitudinal study 
▪ Access to internal tissue samples 
▪ BPA & diet exposure during 
perinatal period only 
▪ Creation of humanized diets for 
mice 
▪ Discrete, consistent level of 
exposures 
▪ Repeated maternal exposure 
measures in each trimester of 
pregnancy 
▪ Species of interest – insights could 
be translated for clinical use 
 
Limitations 
▪ Lipid metabolism differs from 
humans 
▪ NAFLD disease progression also 
differs 
▪ Genetic heterogeneity 
▪ BPA & diet exposures continue after 
prenatal period 
▪ Exposure levels vary over time and 
between individuals 
▪ Limited to bioavailable tissue 
specimens 
Combined 
Benefits 
▪ Ability to compare genetically identical background to heterogeneity inherent in 
human populations – helps to identify role of environment on health outcomes 
▪ Limiting exposure to perinatal period in mice clarifies potential fetal 
programming outcomes, which may be more difficult to discern in humans with 
continuous exposure 
▪ Measurement of BPA & diet during all three trimesters of pregnancy provides 
insight into trimester-specific effects that may occur with different prenatal 
exposures 
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Figure 5.1 Translation of Study Findings from Longitudinal Mouse Study to Human Birth 
Cohort 
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Figure 5.2 Summary of Dissertation Findings 
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